apnea has been researched along with Infant, Premature, Diseases in 703 studies
Apnea: A transient absence of spontaneous respiration.
Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized controlled trial including preterm infants < 32 weeks' gestation, prophylactic (in the first 72 h of life) versus therapeutic (only if apnea exists or infant requires mechanical ventilation) decision of caffeine was compared." | 9.51 | Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. ( Elmowafi, M; Mohsen, N; Nasef, N; Nour, I, 2022) |
| " Caffeine is widely used to prevent and treat apnea (temporal cessation of breathing) associated with prematurity and facilitate extubation." | 9.41 | Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. ( Brattström, P; Bruschettini, M; Davis, PG; Onland, W; Russo, C; Soll, R, 2023) |
| "There is sufficient evidence to support use of caffeine therapy for apnea of prematurity, but practices vary widely when it comes to discontinuing therapy." | 9.41 | Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial. ( Jain, N; Nair, PMC; Nandakumar, A; Pournami, F; Prabhakar, J; Prakash, R, 2021) |
| "To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants." | 9.34 | [Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial]. ( Ding, Y; Gan, JM; He, T; Li, W; Liao, ZC; Wang, MJ; Yue, SJ, 2020) |
| "Caffeine is effective in the treatment of apnea of prematurity." | 9.27 | Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Mürner-Lavanchy, IM; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2018) |
| "Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight." | 9.24 | Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017) |
| "To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity." | 9.24 | Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial. ( Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 9.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| " Caffeine is used not only for the treatment of apnea in prematurity, but also for the prevention of BPD." | 9.22 | Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved. ( Dong, W; Lei, X; Yang, Y; Yuan, Y, 2022) |
| "Apnea of prematurity (AOP) is one of the common diseases in preterm infants." | 9.22 | [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022) |
| "Apnea is a frequent occurrence in prematurity and its prevalence in the most severely preterm population is indicative of an immature respiratory neural control system." | 9.22 | Apnea of prematurity and sudden infant death syndrome. ( MacFarlane, PM; Martin, RJ; Mitchell, LJ, 2022) |
| "Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity." | 9.22 | Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022) |
| "The study aimed to systematically review and analyze the impact of nasal intermittent positive pressure ventilation (NIPPV) versus continuous positive airway pressure (CPAP) on apnea of prematurity (AOP) in preterm neonates." | 9.22 | Nasal Intermittent Positive Pressure Ventilation versus Continuous Positive Airway Pressure and Apnea of Prematurity: A Systematic Review and Meta-Analysis. ( Banfield, L; Harrison, A; Mukerji, A; Sabsabi, B, 2022) |
| " It remains unclear, however, whether Bi-NCPAP or Re-NCPAP is more effective for reducing apnea of prematurity (AOP)." | 9.22 | Effects of infant flow Bi-NCPAP on apnea of prematurity. ( Ibara, S; Ishihara, C; Kato, E; Kuwahara, T; Maede, Y; Minakami, H; Ohsone, Y; Tokuhisa, T; Yamamoto, Y, 2016) |
| "To evaluate the effectiveness and safety of different doses of caffeine in treatment of primary apnea in preterm infants." | 9.22 | [Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants]. ( Liu, G; Tian, X; Zhao, Y, 2016) |
| "It seems that preventative effects of caffeine on apnea become apparent by using the drug in very premature infants." | 9.22 | Caffeine Administration to Prevent Apnea in Very Premature Infants. ( Armanian, AM; Faghihian, E; Iranpour, R; Salehimehr, N, 2016) |
| " This low-cost neuromodulatory procedure has the potential to provide a non-invasive intervention to reduce apnea, bradycardia and intermittent hypoxia in premature neonates." | 9.22 | Neuromodulation of Limb Proprioceptive Afferents Decreases Apnea of Prematurity and Accompanying Intermittent Hypoxia and Bradycardia. ( Benharash, P; Cordero, DM; Frank, P; Harper, RM; Kesavan, K, 2016) |
| "Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants." | 9.22 | Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial. ( Benard, M; Boutroy, MJ; Casper, C; Greze, E; Haddad, FE; Hamon, I; Hascoët, JM, 2016) |
| "• Caffeine therapy for treatment of apnea of prematurity has been well established over the past few years." | 9.20 | High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. ( Abdel-Hady, H; Mohammed, S; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2015) |
| "To evaluate the effect of stochastic resonance (SR) stimulation on preterm infant oxygen desaturation, bradycardia, and apnea events." | 9.20 | Stochastic Resonance Effects on Apnea, Bradycardia, and Oxygenation: A Randomized Controlled Trial. ( Cakert, K; Kelty-Stephen, D; Mao, W; Osborne, J; Paydarfar, D; Qureshi Ahmad, M; Smith, VC, 2015) |
| "Apnea of prematurity is a common complication in premature newborns and caffeine is a widespread medication used to treat this complication." | 9.19 | The effects of caffeine on heart rate variability in newborns with apnea of prematurity. ( Blazer, S; Haleluya, NS; Ulanovsky, I; Weissman, A, 2014) |
| "Apnea of prematurity is a common condition that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences on the central nervous system." | 9.19 | Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. ( Asztalos, E; Bhattacharjee, R; Biggs, SN; Bradford, R; Cheshire, M; Costantini, L; D'ilario, J; Davey, M; Dix, J; Doyle, LW; Gibbons, J; Horne, RS; Marcus, CL; Meltzer, LJ; Narang, I; Nixon, GM; Opie, G; Roberts, RS; Schmidt, B; Traylor, J, 2014) |
| "To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring." | 9.14 | Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009) |
| "To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial." | 9.14 | Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. ( Asztalos, E; Davis, PG; Doyle, LW; Haslam, R; Roberts, RS; Schmidt, B; Sinha, S; Tin, W, 2010) |
| "8% CO(2) in preterm infants decreases the duration and rate of apnea as effectively as or better than theophylline with fewer adverse side effects." | 9.13 | A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity. ( Al-Saif, S; Alvaro, R; Cates, D; Kwiatkowski, K; Manfreda, J; Qurashi, M; Rigatto, H, 2008) |
| " This immaturity presents as prolonged apneas with associated bradycardia or desaturation, or brief respiratory pauses, periodic breathing, and intermittent hypoxia." | 9.12 | Immature control of breathing and apnea of prematurity: the known and unknown. ( Dobson, NR; Erickson, G; Hunt, CE, 2021) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed." | 9.12 | Caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2006) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 9.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| " Because these issues may be operative in apnea of prematurity (AOP), we hypothesized that CS reduces episodes of hypoxemia and bradycardia in infants with AOP." | 9.11 | Randomized, controlled trial of oral creatine supplementation (not effective) for apnea of prematurity. ( Bohnhorst, B; Dördelmann, M; Geuting, T; Peter, CS; Poets, CF; Wilken, B, 2004) |
| "Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator." | 9.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| "A relationship between gastroesophageal reflux (GER) and apnea of prematurity (AOP) has long been suspected but is difficult to prove because most GER in this age group is nonacidic and thus undetectable by pH monitoring, the current standard for GER detection." | 9.10 | Gastroesophageal reflux and apnea of prematurity: no temporal relationship. ( Bohnhorst, B; Peter, CS; Poets, CF; Silny, J; Sprodowski, N, 2002) |
| "In this blinded, randomized, placebo-controlled study, we found that infants who received supplemental carnitine did not demonstrate any reduction in apnea of prematurity, ventilator or nasal continuous positive airway pressure days, or the need for supplemental oxygen therapy." | 9.10 | Role of L-carnitine in apnea of prematurity: a randomized, controlled trial. ( Barrington, KJ; Barshop, BA; Finer, NN; O'Donnell, J; Rich, W, 2002) |
| "Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 9.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| "Apnea of prematurity (AOP) is frequently managed with nasal continuous positive airway pressure (NCPAP)." | 9.09 | High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. ( Hudson-Mason, A; Lemke, RP; Osiovich, H; Sreenan, C, 2001) |
| " Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia." | 9.08 | Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995) |
| "This study determined the effect of modifying a single aspect of the intermediate care environment on the incidence of apnea and rate of weight gain in convalescent preterm infants." | 9.08 | Effect of standard rest periods on apnea and weight gain in preterm infants. ( D'Auria, J; Holditch-Davis, D; O'Hale, A; Torres, C, 1997) |
| "The efficacy of nasal intermittent positive pressure ventilation (NIPPV) in treating apnea of prematurity was evaluated." | 9.08 | Efficacy of nasal intermittent positive pressure ventilation in treating apnea of prematurity. ( Lin, CH; Lin, YJ; Wang, ST; Yeh, TF, 1998) |
| "Placing preterm infants suffering idiopathic apnea of prematurity on the VPS had an effect on the infants' respiratory effort and achieved a reduction in the number of apneic episodes secondary to central and mixed apnea." | 9.07 | The effect of vertical pulsating stimulation on apnea of prematurity. ( Jirapaet, K, 1993) |
| "To assess if there was any advantage in the prophylactic use of theophylline to prevent apnea in preterms, we treated 56 preterms (Group A) < 34 weeks gestation with theophylline infusion and compared these with 25 age and weight matched preterms (Group B) who received no therapy." | 9.07 | Prophylactic theophylline infusion for prevention of apnea of prematurity. ( Ashavaid, TF; Merchant, RH; Sakhalkar, VS, 1992) |
| " The frequency and extent of apnea and bradycardia during a 6-hour period in a patient receiving nasal continuous positive airway pressure were compared with a similar crossover period of nasal intermittent positive-pressure ventilation." | 9.06 | Nasal intermittent positive-pressure ventilation offers no advantages over nasal continuous positive airway pressure in apnea of prematurity. ( Finer, NN; Peters, KL; Ryan, CA, 1989) |
| "To investigate claims that oscillating mattresses reduce apnea of prematurity and improve growth and neurobehavioural development, we performed a randomized clinical trial using a predetermined sample size." | 9.06 | Randomized clinical trial of an oscillating air mattress in preterm infants: effect on apnea, growth, and development. ( Campbell, D; Saigal, S; Watts, J, 1986) |
| " The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs." | 9.05 | Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020) |
| "Apnea of prematurity affects the majority of infants born before 34 weeks of complete gestation." | 9.05 | [APNEA OF PREMATURITY - PATHOPHYSIOLOGY, TREATMENT & PROGNOSIS]. ( Erlichman, I; Eventov-Friedman, S; Gileles-Hillel, A; Reiter, J, 2020) |
| "19 infants admitted with a diagnosis of infantile apnea who were found to have periodic breathing were given oral theophylline to determine its effect." | 9.05 | An evaluation of theophylline for idiopathic apnea of infancy. ( Coward, JH; Duffley, LM; Finer, NN; Peters, KL, 1984) |
| "This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant." | 9.05 | The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981) |
| "Theophylline is commonly used to treat apnea of prematurity." | 9.05 | Limitations of theophylline in the treatment of apnea of prematurity. ( Cabal, L; Rambhatla, S; Sims, ME; Wu, PY; Yau, G, 1985) |
| "A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity." | 9.05 | Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study. ( Alpan, G; Arad, I; Dgani, Y; Eyal, F; Glick, B; Peleg, O; Sagi, E, 1985) |
| "The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants." | 9.05 | Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985) |
| "The pharmacokinetics of theophylline were examined in eight low-birth-weight infants (gestation: 26-32 weeks: birth-weight: 887-1,480 gm), who received the drug for treatment of primary apnea." | 9.04 | Theophylline pharmacokinetics in premature infants with apnea. ( Giacoia, G; Jusko, WJ; Koup, JR; Menke, J, 1976) |
| "It has been suggested that idiopathic apnea of prematurity is related to hypoxia from pulmonary instability or an immaturity of central respiratory control mechanisms." | 9.04 | Apnea of prematurity. Comparative therapeutic effects of cutaneous stimulation and nasal continuous positive airway pressure. ( Fanaroff, AA; Katona, PG; Kattwinkel, J; Klaus, MH; Nearman, HS, 1975) |
| " After one week the ventilation weaning, the child presented episodes of cyanosis associated with sudden oxygen desaturation, skin pallor, apnea, and bradycardia." | 9.01 | Apnea events in neonatal age: A case report and literature review. ( Catanzaro, S; Cimino, C; Corsello, G; Falsaperla, R; Vitaliti, G, 2019) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 8.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g." | 8.90 | Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014) |
| " It is thanks to the efforts of Barbara Schmidt and the Caffeine for Apnea of Prematurity (CAP) Trial Group that we now have high-quality and reliable data not only on short-term but also long-term outcomes of caffeine use for apnea of prematurity." | 8.90 | Caffeine for apnea of prematurity: a neonatal success story. ( Bassler, D; Kreutzer, K, 2014) |
| "Central apnea, defined as cessation of breathing for ≥20s, is frequent in premature infants born at <34 weeks׳ gestation but uncommon among healthy late preterm (34(0/7)-36(6/7) weeks׳ gestation) and term (≥37 weeks׳ gestation) infants, where it is usually a clinical manifestation of a neurological or metabolic problem." | 8.90 | Apnea in acute bilirubin encephalopathy. ( Amin, SB; Bhutani, VK; Watchko, JF, 2014) |
| " Respiratory instability characterized by apnea and periodic breathing occurs in premature infants because of immature development of the respiratory network." | 8.89 | Apnea of prematurity--perfect storm. ( Di Fiore, JM; Gauda, EB; Martin, RJ, 2013) |
| "Apnea of prematurity is a common disorder of respiratory control among preterm infants, with potentially serious adverse consequences on infant development." | 8.89 | Forecasting respiratory collapse: theory and practice for averting life-threatening infant apneas. ( Bliss, DW; Paydarfar, D; Williamson, JR, 2013) |
| "Apnea of prematurity and gastroesophageal reflux (GER) are both common occurrences in preterm infants and widely perceived to be causally related." | 8.89 | Neonatal apnea and gastroesophageal reflux (GER): is there a problem? ( Abu Jawdeh, EG; Martin, RJ, 2013) |
| " Most preterm infants exhibit recurrent apnea, resulting in repetitive oscillations in O(2) saturation (intermittent hypoxia, IH)." | 8.89 | Carotid chemoreceptor development and neonatal apnea. ( MacFarlane, PM; Martin, RJ; Ribeiro, AP, 2013) |
| " The carotid body senses dynamic changes in arterial oxygen and carbon dioxide tension and reflexly alters ventilation and plays an essential role in terminating apnea." | 8.89 | Inflammation in the carotid body during development and its contribution to apnea of prematurity. ( Chavez-Valdez, R; Gauda, EB; Kostuk, EW; Mason, A; Pichard, LE; Shirahata, M, 2013) |
| "Apnea of prematurity is a significant problem due to immaturity of the central neural control circuitry responsible for integrating afferent input and central rhythm." | 8.88 | Apnea of prematurity. ( Martin, RJ; Wilson, CG, 2012) |
| "Apnea of prematurity (AOP) is a significant clinical problem manifested by an unstable respiratory rhythm reflecting the immaturity of respiratory control systems." | 8.87 | Apnea of prematurity: pathogenesis and management strategies. ( Mathew, OP, 2011) |
| "Prematurity apnea remains a major clinical problem that requires treatment choices which are sometimes difficult." | 8.86 | [Apnea of prematurity: what's new?]. ( El Ayoubi, M; Lescure, S; Lopez, E; Moriette, G, 2010) |
| "To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea." | 8.86 | Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010) |
| "Although there is a large body of literature describing infants who experience apnea of prematurity and apparent life-threatening events, there is no consensus regarding the use of home monitoring." | 8.85 | Indications for home apnea monitoring (or not). ( Silvestri, JM, 2009) |
| "Apnea of prematurity (AOP) remains a major clinical problem in present day neonatology that warrants frequent evaluations and imposes challenges in therapeutic strategies." | 8.84 | Neonatal apnea: what's new? ( Abu-Shaweesh, JM; Martin, RJ, 2008) |
| "Idiopathic apneas of prematurity remain an alarming problem in neonatology." | 8.84 | [Sensory stimulations for the treatment of idiopathic apneas of prematurity]. ( Gaugler, C; Marlier, L; Messer, J, 2007) |
| "Gastroesophageal reflux and apnea of prematurity are both common occurrences in premature infants." | 8.84 | Infant apnea and gastroesophageal reflux: a critical review and framework for further investigation. ( Hibbs, AM; Martin, RJ; Orenstein, SR; Slocum, C, 2007) |
| "Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence especially in preterm neonates." | 8.84 | Apnea in the newborn. ( Agarwal, R; Aggarwal, R; Deorari, AK; Jeevasankar, M; Mishra, S; Paul, VK, 2008) |
| "To determine the role of carnitine supplementation in premature infants on apnea of prematurity, length of ventilation and duration of hospital stay." | 8.82 | Role of carnitine supplementation in apnea of prematurity: a systematic review. ( Kabra, NS; Kumar, M; Paes, B, 2004) |
| "To determine whether treatment with carnitine will reduce the frequency of apnea, the duration of ventilation and the duration of hospital stay in preterm infants with recurrent apnea." | 8.82 | Carnitine supplementation for preterm infants with recurrent apnea. ( Kabra, NS; Kumar, M; Paes, B, 2004) |
| "Gastroesophageal reflux (GER) and apnea are both common occurrences in premature infants but their relationship is controversial." | 8.82 | Does gastroesophageal reflux cause apnea in preterm infants? ( Di Fiore, JM; Martin, RJ; Molloy, EJ, 2005) |
| " A clear picture is, therefore, emerging of the physiological mechanisms that underlie apnea of prematurity." | 8.82 | Control of breathing and neonatal apnea. ( Abu-Shaweesh, JM; Martin, RJ, 2005) |
| "Apnea, the cessation of respiratory airflow, can begin in many preterm infants in the first week of life and can last until the day of discharge or beyond." | 8.82 | A primer on Apnea of prematurity. ( Stokowski, LA, 2005) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 8.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| "All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 8.81 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001) |
| "The main objective was to determine in preterm infants with recurrent apnea, if treatment with CPAP compared with treatment with theophylline leads to a clinically important reduction in apnea or use of mechanical ventilation, without clinically important side effects." | 8.81 | Continuous positive airway pressure versus theophylline for apnea in preterm infants. ( Davis, PG; Henderson-Smart, DJ; Subramaniam, P, 2001) |
| "Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence in sick neonates." | 8.81 | Apnea in the newborn. ( Aggarwal, R; Deorari, AK; Paul, VK; Singhal, A, 2001) |
| "Apnea of prematurity is almost universal in infants who are born before 34 weeks gestation." | 8.81 | Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity. ( Davis, PG; de Paoli, AG; Lemyre, B, 2002) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 8.81 | Kinesthetic stimulation for preventing apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2002) |
| "In preterm infants with recurrent apnea, how does treatment with doxapram compare with treatment with theophylline in leading to a clinically important reduction in apnea and use of mechanical ventilation, without clinically important side effects." | 8.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 8.80 | Kinesthetic stimulation for preventing apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2000) |
| "Main question: in preterm infants with apnea, does the use of kinesthetic stimulation lead to clinically important reductions in clinical apnea and bradycardia (>50% reduction in number of episodes), use of mechanical ventilation (IPPV) or continuous positive airways pressure (CPAP), and neurodevelopmental disability, without clinically important side effects." | 8.80 | Kinesthetic stimulation for treating apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2000) |
| "A single small study of 20 infants (Saigal 1986) demonstrated a significant benefit to the infants receiving theophylline compared to those on an oscillating water bed in terms of mean rates of clinically important apnea (apnea > 14 seconds and bradycardia < 100, and cyanosis or receiving stimulation)." | 8.80 | Kinesthetic stimulation versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2000) |
| "The main objective was to determine in preterm infants with recurrent apnea, if treatment with CPAP compared with treatment with theophylline leads to a clinically important reduction in apnea or use of mechanical ventilation, without clinically important side effects." | 8.80 | Continuous positive airway pressure versus theophylline for apnea in preterm infants. ( Davis, PG; Henderson-Smart, DJ; Subramanian, P, 2000) |
| "All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 8.80 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 8.80 | Prophylactic methylxanthine for preventing of apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 8.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| "Apnea of prematurity is almost universal in infants who are born before 34 weeks gestation." | 8.80 | Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity. ( Davis, PG; De Paoli, AG; Lemyre, B, 2000) |
| " theophylline, aminophylline or caffeine) for the treatment of apnea in preterm infants." | 8.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea is a disorder of respiratory control commonly seen in premature infants." | 8.80 | Apnea of prematurity: diagnosis, implications for care, and pharmacologic management. ( Albanna, S; Botwinski, C; McWilliam, P; Theobald, K, 2000) |
| "Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation." | 8.80 | Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000) |
| "Apnea of prematurity is one of the most common problems in the neonatal intensive care unit." | 8.79 | Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996) |
| "The neurodevelopmental outcome of term infants with acute life-threatening events (ALTE) and preterm infants with persistent apnea of prematurity were compared to matched control populations." | 8.78 | Neurodevelopmental outcome in infants with apnea. ( Koons, AH, 1992) |
| "Apnea is a common, treatable disorder of respiration in premature infants, which usually resolves over time." | 8.78 | Apnea of prematurity. ( Martin, RJ; Miller, MJ, 1992) |
| "The incidence and proposed mechanisms of apnea of infancy and apnea of prematurity are briefly reviewed, and the use of methylxanthines in managing these conditions is discussed." | 8.77 | Management of apnea in infants. ( Blanchard, J; Kriter, KE, 1989) |
| "Episodic apnea leading to asphyxia is a relatively common disorder of young children." | 8.77 | Sleep apnea in infancy and childhood. ( Thach, BT, 1985) |
| "Caffeine and theophylline are effective in the treatment of apnea in the newborn infant." | 8.76 | Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979) |
| "Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity." | 8.12 | Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport. ( Andersen, L; Ariagno, S; Collura, C; Thorvilson, M, 2022) |
| "Apnea of prematurity (AOP) is a critical condition for preterm infants which can lead to several adverse outcomes." | 8.12 | The effect of apnea length on vital parameters in apnea of prematurity - Hybrid observations from clinical data and simulation in a mathematical model. ( Andriessen, P; Bovendeerd, P; Kommers, D; Lensen, I; van Pul, C; Varisco, G, 2022) |
| "The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity." | 8.12 | The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022) |
| "Caffeine citrate is a commonly used methylxanthine for pharmacologic treatment of apnea of prematurity." | 7.96 | Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ( Di, X; Fan, J; Guo, A; Hu, X; Huang, L; Xie, H; Xue, J; Zhao, P; Zhu, Z, 2020) |
| " Although those patients experience frequent apneas and sleep-wake disturbances during their hospital stay, clinicians still rely on clinical scales to assess pain and stress burden." | 7.91 | The implementation of an apnea-based perinatal stress calculator. ( Bollen, B; Caicedo, A; Deviaene, M; Jansen, K; Lavanga, M; Moeyersons, J; Naulaers, G; Ortibus, E; Van Huffel, S; Varon, C; Wel, O, 2019) |
| "The factors affecting the safety and efficacy of aminophylline use in the treatment of apnea of prematurity (AOP) in the neonatal intensive care unit (NICU) are not clear." | 7.91 | Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit. ( Dong, Z; Lu, X; Lyu, Q; Mao, Y; Miao, C; Ye, C; Yu, L; Zhang, J, 2019) |
| "Apnea of prematurity (AOP) can affect even 85-100% of premature newborns and is related to lack of full maturity of organs." | 7.85 | [Apnea of prematurity - characteristic and treatment]. ( Dołęgowska, B; Goryniak, A; Śleboda, D; Szczęśniak, A, 2017) |
| "Apnea of prematurity is one of the most common diagnoses in the NICU." | 7.83 | Apnea of Prematurity. ( Eichenwald, EC, 2016) |
| "Apnea, bradycardia, and oxygen desaturation events are a common in neonatal intensive care units, with relevant literature to date largely focusing on very low birth weight and extremely low birth weight infants." | 7.83 | Diagnostic Evaluation and Home Monitor Use in Late Preterm to Term Infants With Apnea, Bradycardia, and Desaturations. ( Amberson, M; Freiberger, C; Montenegro, B; Mukhopadhyay, S; Rhein, LM; Veit, L, 2016) |
| "Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)." | 7.83 | Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016) |
| "This study aimed to evaluate predictive factors involved in efficacy and safety in Japanese infants who received theophylline therapy to prevent apnea of prematurity (AOP) after weaning from mechanical ventilation." | 7.83 | Predictive Factors for Efficacy and Safety of Prophylactic Theophylline for Extubation in Infants with Apnea of Prematurity. ( Douchi, T; Irie, T; Irikura, M; Ishitsuka, Y; Kondo, T; Kondo, Y; Mitarai, F; Orita, Y; Shimodozono, Y; Takeda, Y, 2016) |
| " Those in the center of the co-existent knowledge map of Chinses keywords were "preterm infants", "apnea", "primary apnea", "naloxone" and "aminophylline"; while "apnea", "preterm infants" and "caffeine" located in the central place of the co-existent knowledge map of English keywords." | 7.83 | [Current research status of drug therapy for apnea of prematurity]. ( Chen, C; Mu, DZ; Shi, J; Shu, XX; Tang, J; Yang, XY, 2016) |
| "The possible pathophysiology of the relationship between gastro-esophageal reflux disease and apnea of prematurity has been widely investigated." | 7.81 | Gaviscon and domperidon responsive apnea episodes associated with gastro-esophageal reflux disease in twins. ( Bilgin, H; Eren, A; Kara, S, 2015) |
| "In 2006 the apnea of prematurity (AOP) consensus group identified inaccurate counting of apnea episodes as a major barrier to progress in AOP research." | 7.80 | Accurate automated apnea analysis in preterm infants. ( Clark, MT; Delos, JB; Fairchild, KD; Guin, LE; Kattwinkel, J; Lake, DE; Lee, H; Moorman, R; Paget-Brown, AO; Rusin, CG; Smoot, TJ; Vergales, BD, 2014) |
| " We prospectively compared the safety profile of ECC and LP in preterm infants with apnea of prematurity." | 7.80 | Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity. ( Arand, J; Engel, C; Poets, CF; Vatlach, S, 2014) |
| "Apnea of prematurity is very frequent in premature newborns (PNB)." | 7.80 | Instrumentation for the detection and interruption of apnea episodes for premature newborn. ( Camargo, VC; Freitas de Amorim, M; Honorato da Silva, S; Nohama, P, 2014) |
| "It is common practice for premature infants undergoing elective inguinal hernia (IH) repair to be hospitalized for postoperative apnea monitoring." | 7.79 | Postoperative apnea after inguinal hernia repair in formerly premature infants: impacts of gestational age, postconceptional age and comorbidities. ( Arıkan, A; Ozdemir, T, 2013) |
| " Indications for caffeine use in that study were predominantly for treatment of apnea and facilitation of extubation rather than prophylaxis." | 7.79 | Methylxanthine use for apnea of prematurity among an international cohort of neonatologists. ( Abu Jawdeh, EG; Argus, BM; Bandyopadhyay, A; Davis, PG; Limrungsikul, A; Martin, RJ; Nakad, PE; O'Riordan, M; Supapannachart, S; Yunis, KA, 2013) |
| "To investigate for any association between episodes of apnea, desaturation and bradycardia and necrotizing enterocolitis (NEC)." | 7.79 | Episodes of apnea, desaturation and bradycardia and the development of necrotizing enterocolitis in preterm infants: a case-control study. ( Ali, N; Bensouda, B; Mandel, R; Sant'Anna, GM; Tarazi, SE, 2013) |
| "Apnea of prematurity (AOP) occurs frequently in preterm infants and a variable proportion of AOP can be induced by gastroesophageal reflux (GER)." | 7.79 | A thickened formula does not reduce apneas related to gastroesophageal reflux in preterm infants. ( Aceti, A; Battistini, B; Corvaglia, L; Faldella, G; Legnani, E; Mariani, E; Martini, S; Spizzichino, M, 2013) |
| "To compare apnea events recorded by bedside cardiorespiratory monitor and nursing documentation with those detected by visual inspection of continuous electronic cardiorespiratory waveform." | 7.79 | Monitoring apnea of prematurity: validity of nursing documentation and bedside cardiorespiratory monitor. ( Amin, SB; Burnell, E, 2013) |
| "To investigate the usefulness of Multichannel intraluminal impedance-pH (MII-pH) monitoring as compared with conventional pH monitoring for detecting Gastroesophageal reflux (GER) episodes and apnea-related symptom association in preterm infants and neonates." | 7.78 | Impedance-pH monitoring and conventional pH monitoring are complementary methods to detect association between gastroesophageal reflux and apnea-related symptoms in preterm infants and neonates. ( Choi, JH; Kim, HS; Ko, JS; Moon, JS; Seo, JK; Shim, JO; Shin, MS, 2012) |
| "To determine the cost-effectiveness of treatment with caffeine compared with placebo for apnea of prematurity in infants with birth weights less than 1250 g, from birth through 18 to 21 months' corrected age." | 7.77 | Economic evaluation of caffeine for apnea of prematurity. ( Doyle, LW; Dukhovny, D; Kamholz, KL; Kok, JH; Lorch, SA; Mao, W; Roberts, RS; Schmidt, B; Wang, N; Zupancic, JA, 2011) |
| "Apnea of prematurity is one of the most common diagnoses in the NICU." | 7.77 | Variation in diagnosis of apnea in moderately preterm infants predicts length of stay. ( Eichenwald, EC; Escobar, GJ; Mao, WY; McCormick, MC; Richardson, DK; Zupancic, JA, 2011) |
| "This study evaluated the optimal timing for repair, incarceration risk, and postoperative apnea rate in premature infants with inguinal hernias." | 7.77 | A critical review of premature infants with inguinal hernias: optimal timing of repair, incarceration risk, and postoperative apnea. ( Gleason, JM; Lee, SL; Sydorak, RM, 2011) |
| "We examined associations of daily ambient air pollution concentrations with central apnea (prolonged pauses in breathing) and bradycardia (low heart rate) events among infants prescribed home cardiorespiratory monitors." | 7.77 | Ambient air pollution and apnea and bradycardia in high-risk infants on home monitors. ( Flanders, WD; Freed, G; Klein, M; Mulholland, JA; Peel, JL; Tolbert, PE, 2011) |
| "To measure the success rate or the percentage of infants who have no additional events of various apnea- or bradycardia-free intervals after correcting for gestational age, postmenstrual age of the last apnea or bradycardia event, and the severity of the event." | 7.77 | Epidemiology of apnea and bradycardia resolution in premature infants. ( Escobar, GJ; Lorch, SA; Srinivasan, L, 2011) |
| "Apnea of prematurity (AOP) is a disturbance in respiratory rhythm defined by idiopathic pauses in breathing that reduce blood oxygen levels and/or heart rate." | 7.76 | Heritability of apnea of prematurity: a retrospective twin study. ( Bednarek, F; Bloch-Salisbury, E; Boyd, T; Hall, MH; Paydarfar, D; Sharma, P, 2010) |
| "Clinically relevant apneas, which are common in preterm infants, may adversely affect later neuropsychological condition in this group of patients." | 7.75 | Differential diagnosis of apneas in preterm infants. ( Dittrichová, J; Melichar, J; Miletín, J; Paul, K, 2009) |
| "To characterize esophageal motility during episodes of prolonged apnea in premature infants." | 7.75 | Apnea-associated reduction in lower esophageal sphincter tone in premature infants. ( Omari, TI, 2009) |
| " We aimed to measure objectively the effects of feeding on GER, apnea, bradycardia and desaturations." | 7.75 | Apnea, bradycardia and desaturation in preterm infants before and after feeding. ( Arko, M; Di Fiore, J; Hibbs, AM; Martin, RJ; Slocum, C, 2009) |
| "Apnea and bradycardia of prematurity (ABP) are possible risks towards damage of the developing brain." | 7.74 | Factors influencing apnea and bradycardia of prematurity - implications for neurodevelopment. ( Hermann, C; Keller, T; Kribs, A; Pillekamp, F; Roth, B; von Gontard, A, 2007) |
| "Postoperative apneas are reported in up to 49% of premature infants undergoing anesthesia for inguinal hernia repair." | 7.74 | The frequency of apneas in premature infants after inguinal hernia repair: do they need overnight monitoring in the intensive care unit? ( Ansermino, M; Milner, R; Murphy, JJ; Swanson, T, 2008) |
| "Apnea of prematurity (AoP) is, in part, a reflection of brainstem-mediated respiratory control system maturation." | 7.73 | Transient bilirubin encephalopathy and apnea of prematurity in 28 to 32 weeks gestational age infants. ( Amin, SB; Charafeddine, L; Guillet, R, 2005) |
| "To examine the temporal relationship between apnea and gastroesophageal reflux (GER) and to assess the effect of GER on apnea duration." | 7.73 | Apnea is not prolonged by acid gastroesophageal reflux in preterm infants. ( Arko, M; Di Fiore, JM; Kimball, A; Martin, RJ; Whitehouse, M, 2005) |
| "Apnea of prematurity (AOP) is found in >50% of premature infants and is almost universal in infants who are <1000 g at birth." | 7.73 | Summary proceedings from the apnea-of-prematurity group. ( Finer, NN; Higgins, R; Kattwinkel, J; Martin, RJ, 2006) |
| "Adverse cardiorespiratory events including apnea, bradycardia, and desaturations have been described following administration of the first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B (DTP-IPV-Hib) immunization to preterm infants." | 7.73 | Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants. ( Lee, J; Robinson, JL; Spady, DW, 2006) |
| "Caffeine citrate is commonly used for prophylaxis and treatment of apnea in preterm babies." | 7.73 | [Caffeine citrate utilization for treatment of apnea in French neonatal units]. ( Baudon, JJ; Biran-Mucignat, V; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| "Apnea of prematurity develop during the first days of life and usually resolve by the time the infant reaches 36-37 weeks postmenstrual age." | 7.73 | [Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate]. ( Baudon, JJ; Biran-Mucignat, V; Boelle, PY; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| "Young infants with bronchiolitis are at risk for apnea." | 7.73 | Identifying hospitalized infants who have bronchiolitis and are at high risk for apnea. ( Greenes, DS; Harper, MB; Willwerth, BM, 2006) |
| "It is standard practice to defer discharge of premature infants until they have achieved a set number of days without experiencing apnea." | 7.72 | Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity. ( Eichenwald, EC; O'Brien, BJ; Richardson, DK; Weinstein, MC; Zupancic, JA, 2003) |
| " In this statement, the most recent research information concerning extreme limits for a prolonged course of apnea of prematurity is reviewed." | 7.72 | Apnea, sudden infant death syndrome, and home monitoring. ( , 2003) |
| " Apnea of prematurity is defined as the cessation of breathing for longer than 20 seconds or that of any duration if accompanied by cyanosis and sinus bradycardia, for infants born before 37 weeks of gestation." | 7.72 | Consanguinity and apnea of prematurity. ( Beydoun, H; Khogali, M; Melki, I; Tamim, H; Yunis, K, 2003) |
| "To determine whether apnea in preterm infants is associated with abnormal neurodevelopmental outcome." | 7.72 | Apnea is associated with neurodevelopmental impairment in very low birth weight infants. ( Barrington, KJ; Cormier, C; Janvier, A; Khairy, M; Kokkotis, A; Messmer, D, 2004) |
| "An approximate 80% reduction in the frequency of apnea was found with only minimal side effects following low-dose doxapram." | 7.71 | Low-dose doxapram therapy for idiopathic apnea of prematurity. ( Fujimura, M; Itahashi, K; Kajiwara, M; Yamazaki, T, 2001) |
| " This study evaluates the effect of caffeine on oxygen consumption and metabolic rate in premature infants with idiopathic apnea." | 7.71 | Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. ( Bauer, J; Hentschel, R; Linderkamp, O; Maier, K, 2001) |
| "Apnea of prematurity is common and none of the treatments being used are fully effective and free of significant adverse side effects." | 7.71 | Inhalation of low (0.5%-1.5%) CO2 as a potential treatment for apnea of prematurity. ( Al-Aif, S; Alvaro, R; Cates, D; Kwiatkowski, K; Manfreda, J; Rigatto, H, 2001) |
| "Premature infants need to attain both medical stability and maturational milestones (specifically, independent thermoregulation, resolution of apnea of prematurity, and the ability to feed by mouth) before safe discharge to home." | 7.71 | Inter-neonatal intensive care unit variation in discharge timing: influence of apnea and feeding management. ( Blackwell, M; Eichenwald, EC; Lloyd, JS; Richardson, DK; Tran, T; Wilker, RE, 2001) |
| "Episodes of apnea, desaturation, and bradycardia are common in preterm infants." | 7.71 | Cardiorespiratory events in preterm infants referred for apnea monitoring studies. ( Arko, MK; Betkerur, A; Di Fiore, JM; Kenney, SR; Krauss, A; Martin, RJ; Miller, MJ; Zadell, A, 2001) |
| " Apneas of greater than 10 seconds were recorded, as well as the occurrence of bradycardia or desaturation." | 7.71 | Apnea at discharge and gastro-esophageal reflux in the preterm infant. ( Barrington, KJ; Rich, W; Tan, K, 2002) |
| " Fifteen of the 20 preterm infants demonstrated a tendency to have short apneas (2 to 5 seconds) on squeezing, 88% of which were central in origin." | 7.70 | A possible role for the Hering-Breuer deflation reflex in apnea of prematurity. ( Hannam, S; Ingram, DM; Milner, AD, 1998) |
| "Continuous monitoring of premature infants with apnea is mandatory in order to define the pathophysiology and the type of apnea, and to assess the efficacy and tolerance of the treatment." | 7.70 | [Treatment of apnea in prematurity]. ( Boutroy, MJ; Hascoët, JM, 1998) |
| "To determine whether predischarge event recording (PDER) can accurately identify preterm infants with resolving apnea of prematurity (AOP) at risk for postdischarge complications." | 7.70 | Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity. ( DeCristofaro, JD; Katz, S; Subhani, M, 2000) |
| " The study population consist of 5 preterms (26 to 30 weeks of gestational age), in the second week of postnatal age, affected by apnea of prematurity." | 7.70 | [Evaluation of cerebral oxygenation in newborns with prematurity apnea: new frequency domain NIR oximeter]. ( Donzelli, G; Pratesi, S, 2000) |
| "To elucidate risk factors for apnea in preterm infants discharged from the hospital and in full-term healthy infants." | 7.69 | Infant apnea detection after herniorrhaphy. ( Bell, C; Dubose, R; Hughes, CW; Mooney, S; O'Connor, TZ; Oh, TH; Rosen, C; Seashore, J; Touloukian, R, 1995) |
| "Administration of 100% O2 to preterm infants induces an apnea that is usually central." | 7.69 | Induction of mixed apneas by inhalation of 100% oxygen in preterm infants. ( Alvarez, J; Alvaro, R; Cates, D; Kwiatkowski, K; Rigatto, H, 1994) |
| "Methylxanthine use in the treatment of apnea of prematurity is well documented." | 7.69 | Impact of theophylline use in Wolff-Parkinson-White syndrome. ( Abedin, M; Agwunobi, J; Beeram, M; Sinkford, S; Young, M, 1996) |
| "We have shown previously that administration of 100% O2 to preterm infants induces an apnea which in about 20% of cases has an obstructive component." | 7.69 | Low baseline oxygenation predisposes preterm infants to mixed apneas during inhalation of 100% oxygen. ( Al-Saedi, S; Alvaro, R; Cates, D; Kwiatkowski, K; Rigatto, H; Zia Haider, A, 1996) |
| "Apnea of prematurity remains among the most commonly diagnosed conditions in the Newborn Intensive Care Unit and may prolong hospital stays in some infants." | 7.69 | Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. ( Aina, A; Eichenwald, EC; Stark, AR, 1997) |
| "Most neonatologists include an apnea-free period in the criteria for the discharge of preterm infants." | 7.69 | Margin of safety for discharge after apnea in preterm infants. ( Darnall, RA; Kattwinkel, J; Nattie, C; Robinson, M, 1997) |
| "The neurodevelopmental outcome of premature infants with persistent apnea of prematurity (AOP) is reported." | 7.68 | Neurodevelopmental outcome of infants with apnea of infancy. ( Hegyi, T; Hiatt, M; Jadeja, N; Koons, AH; Mojica, N; Ostfeld, B, 1993) |
| "Apnea of prematurity is a common problem in neonatal intensive care nurseries." | 7.68 | Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity. ( Hindmarsh, KW; Kalapurackal, M; Sankaran, K; Tan, L, 1993) |
| "We tested the hypotheses that (1) preterm infants with bronchopulmonary dysplasia (BPD) have an increased incidence of obstructive apneas as compared to those without BPD (control) and (2) the respiratory pattern during obstructive apneas may be associated with more pronounced hypoventilation." | 7.68 | The incidence of obstructive apneas in preterm infants with and without bronchopulmonary dysplasia. ( Alvarez, J; Fajardo, C; Kwiatkowski, K; Rigatto, H; Wong, A, 1993) |
| "Preterm and ex-preterm infants are at risk for life-threatening apnea after general anesthesia." | 7.68 | Are all preterm infants younger than 60 weeks postconceptual age at risk for postanesthetic apnea? ( Lerman, J; Malviya, S; Swartz, J, 1993) |
| "14 kg; gestation, 29 weeks) on 80 occasions, to determine the time course of the response and its relationship with spontaneous apnea occurrence." | 7.68 | Response to external obstruction in preterm infants with apnea. ( Milner, AD; Stokes, GM; Upton, CJ, 1992) |
| " Apnea has been reported following caregiving during peak hours of activity in a neonatal intensive care unit (NICU)." | 7.68 | Reducing the hypoxemia, bradycardia, and apnea associated with suctioning in low birthweight infants. ( Evans, JC, 1992) |
| "The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated." | 7.68 | Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992) |
| "In order to analyze the effects of maturity and apnea frequency on the respiratory control of preterm infants, we studied their responses to tube breathing using tubes equivalent to two anatomical dead spaces." | 7.68 | Response to tube breathing in preterm infants with apnea. ( Milner, AD; Stokes, GM; Upton, CJ, 1992) |
| "The ventilatory effects of doxapram in the initial pharmacotherapy for apnea in the newborn were evaluated in 8 premature infants with idiopathic apnea." | 7.68 | Doxapram for the initial treatment of idiopathic apnea of prematurity. ( Bairam, A; Faulon, M; Monin, P; Vert, P, 1992) |
| " Nursing documentation failed to detect 11 infants with prolonged apnea and bradycardia." | 7.68 | Undetected apnea and bradycardia in infants. ( Graff, M; Hegyi, T; Hiatt, IM; Rovell, K; Soriano, C, 1991) |
| "From a group of 50 premature newborns with central and mixed apnea, 34 received a loading dose of 4." | 7.68 | [Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ( Belmont-Gómez, A; Calderón-Mandujano, B; González-Treviño, J; Juárez-Olguín, H; Prado-Serrano, A; Rodríguez-Palomares, C; Udaeta-Mora, E, 1991) |
| "We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects." | 7.68 | Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991) |
| "The occurrence of central apnea of 15 seconds or longer, transient episodes of bradycardia (TEB), and periodic breathing were studied in 66 healthy premature infants when at least 1 week old and between 32 and 36 weeks postconceptual age." | 7.68 | Apnea, transient episodes of bradycardia, and periodic breathing in preterm infants. ( Cabal, LA; Gonzalez, F; Hodgman, JE; Hoppenbrouwers, T, 1990) |
| "Recordings of breathing movements and heart rate (pneumograms) were obtained prospectively in 89 preterm infants at 0-28 days of age to determine if those who develop apnea and/or bradycardia with cyanosis (Group 1) differ from those who do not (Group 2)." | 7.68 | Prospective pneumogram recordings in preterm infants with and without clinical apnea and bradycardia. ( Kelly, DH; McCulloch, KM, 1990) |
| "It has been suggested that apnea of prematurity may be caused by "immaturity" of central control of breathing." | 7.67 | Apnea of prematurity: I. Lung function and regulation of breathing. ( Bancalari, E; Gerhardt, T, 1984) |
| "Medical records of 261 hospitalized patients less than 1 year old with documented respiratory syncytial virus (RSV) infection were reviewed to determine the incidence of RSV-associated apnea and the accompanying risk of subsequent apnea or death." | 7.67 | Respiratory syncytial virus-related apnea in infants. Demographics and outcome. ( Anas, NG; Brooks, JG; Church, NR; Hall, CB, 1984) |
| "Airway obstruction is a cause of apnea in preterm infants." | 7.67 | Apnea of prematurity: II. Respiratory reflexes. ( Bancalari, E; Gerhardt, T, 1984) |
| "Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2." | 7.67 | Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986) |
| "Eighteen infants with idiopathic apnea of prematurity refractory to therapeutic levels of aminophylline were treated with incremental doses of doxapram beginning at 0." | 7.67 | Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, G, 1987) |
| "Upper gastrointestinal examinations with simultaneous cardiorespiratory monitoring were performed in 39 older premature infants with persistent apnea." | 7.67 | Upper GI examinations in older premature infants with persistent apnea: correlation with simultaneous cardiorespiratory monitoring. ( Fujioka, M; Itani, Y; Niitsu, N; Nishimura, G; Oono, T, 1988) |
| "In an effort to establish the minimum effective dose of theophylline in the treatment of idiopathic apnea of prematurity, a prospective trial of 22 infants with at least 0." | 7.67 | The dose response of theophylline in the treatment of apnea of prematurity. ( Finer, NN; Muttitt, SC; Tierney, AJ, 1988) |
| " We elicited a previously described upper airway reflex in 10 sleeping preterm infants with apnea of prematurity by instilling physiologic saline into the oropharynx and recording respiration, heart rate, and swallowing." | 7.67 | Prolonged apnea associated with upper airway protective reflexes in apnea of prematurity. ( Pickens, DL; Schefft, G; Thach, BT, 1988) |
| "We prospectively studied the stress perception of ten mothers of preterm infants on apnea monitors (birth weight, 1255 +/- 295 g) and ten mothers of term infants on monitors (3156 +/- 700 g) and compared them with 15 mothers of preterm infants (1450 +/- 305 g) and 15 mothers of term infants (3360 +/- 595 g) not on monitors." | 7.67 | Mothers of preterm and full-term infants on home apnea monitors. ( Chen, A; Garcia Coll, C; Oh, W; Vohr, BR, 1988) |
| "Apnea, bradycardia, and neuromuscular hyperirritability have been associated with magnesium (Mg) deficiency in young human infants and weanling animals." | 7.67 | Magnesium therapy in premature neonates with apnea neonatorum. ( Caddell, JL, 1988) |
| "Pharmacokinetics of doxapram were determined in 13 infants with idiopathic apnea of prematurity uncontrolled by aminophylline and caffeine." | 7.67 | Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ( Beaudry, MA; Bradley, JM; Gramlich, LM; LeGatt, D, 1988) |
| "Theophylline and caffeine are two xanthine-derivated drugs frequently administered for their stimulating effects on the respiratory center in premature babies presenting with "idiopathic apnea"." | 7.67 | [Xanthines in apnea of premature infants. Influence on gastroesophageal reflux]. ( Sacré, L; Vandenplas, Y, 1987) |
| "We measured the frequency distribution and the ventilatory correlates of the various types of apneas 3 to 15 s long during sleep in eight term infants (birth weight 3." | 7.67 | A developmental study on types and frequency distribution of short apneas (3 to 15 seconds) in term and preterm infants. ( Caces, R; Cates, D; Kwiatkowski, K; Lee, D; Rigatto, H, 1987) |
| "This review provides an understanding of current problems related to apnea of infancy." | 7.67 | Infant apnea. ( Fox, WW; Spitzer, AR, 1986) |
| " If no cause is found, the diagnosis of idiopathic infantile apnea is made." | 7.67 | Infantile apnea. ( McCulloch, K; Vidyasagar, D, 1986) |
| " The revealing sign was the occurrence, at age 11 days, of frequent apneas with bradycardia, needing mechanical ventilation associated with adapted antibiotic therapy for 14 days." | 7.67 | [Apnea disclosing Chlamydia trachomatis infection in a premature infant]. ( Dehan, M; Gabilan, JC; Magny, JF; Ropert, JC; Saby, MA; Zouari, A, 1986) |
| "Apnea in preterm infants has been classified as obstructive, central (nonobstructive), and mixed, based on the presence or absence of upper airway obstruction." | 7.67 | Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants. ( Carlo, WA; Martin, RJ; Miller, MJ, 1985) |
| "Idiopathic apnea in preterm infants, more than 30 weeks of gestation, after the first week of life is uncommon and poorly understood." | 7.67 | Ventilatory control and carbon dioxide response in preterm infants with idiopathic apnea. ( Barberis, C; Cabal, LA; Durand, M; Georgie, S; Gonzalez, F; Hodgman, JE; Hoppenbrouwers, T, 1985) |
| "A 2750-g female infant was born at 36 weeks' gestation to a 40-year-old woman treated with clonazepam throughout her pregnancy." | 7.67 | Neonatal apnea associated with maternal clonazepam therapy: a case report. ( Coleman, JM; Edgren, BE; Fisher, JB; Mammel, MC, 1985) |
| "The effect of episodes of apnea with bradycardia on cerebral circulation was studied during 101 episodes in 15 premature infants." | 7.67 | Episodes of apnea and bradycardia in the preterm newborn: impact on cerebral circulation. ( Perlman, JM; Volpe, JJ, 1985) |
| "Twelve-hour urinary excretion of 4-hydroxy-3-methoxymandelic acid (VMA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) was studied in 20 premature infants, 8 without apnea and 12 with apnea." | 7.66 | Study of neurotransmitters in premature infants with or without apnea of prematurity. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1982) |
| "Urinary excretion of various catecholamine metabolites (4-hydroxy-3-methoxymandelic acid, homovanillic acid, 3-methoxy-4-hydroxphenylglycol) was studied in preterm infants with idiopathic apnea treated with theophylline." | 7.66 | Effect of theophylline on neurotransmitters in preterm infants with apnea. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1983) |
| "The interactive effect of caffeine and continuous distending airway pressure was evaluated in two premature neonates with apnea." | 7.66 | Interaction of caffeine and continuous distending airway pressure in neonatal apnea. ( Aranda, JV; Outerbridge, EW; Trippenbach, T, 1983) |
| "We assessed the relation between clinical apnea and brain-stem neuronal function in 58 preterm babies." | 7.66 | Clinical apnea and brain-stem neural function in preterm infants. ( Campbell, DJ; Henderson-Smart, DJ; Pettigrew, AG, 1983) |
| "Fourteen preterm infants with apnea (body weight, 1052 +/- 44 g; gestational age, 30." | 7.66 | Effects of aminophylline on respiratory center and reflex activity in premature infants with apnea. ( Bancalari, E; Gerhardt, T; McCarthy, J, 1983) |
| "An acoustic monitor to detect apnea in infants has been developed." | 7.66 | Apnea monitoring by acoustic detection of airflow. ( DiBenedetto, J; Krasner, J; Stark, AR; Werthammer, J, 1983) |
| " We suggest that idiopathic apnea of prematurity is not associated with depletion of catecholamine stores in the central nervous system." | 7.66 | Cerebrospinal fluid concentration of biogenic amine metabolites in idiopathic apnea of prematurity. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1983) |
| "Three cases of hernia repair and simultaneous resolution of prolonged neonatal apnea are reported." | 7.66 | Resolution of prolonged neonatal apnea with hernia repair. ( Mellish, RW; Yeaton, HL, 1983) |
| " Despite apnea monitoring systems, 136/203 (67%) apneic episodes greater than or equal to 20 seconds in duration, including 19 episodes greater than or equal to 50 seconds in duration, were not recorded by nursing staff." | 7.66 | Undetected episodes of prolonged apnea and severe bradycardia in preterm infants. ( Alexander, JR; Farndon, PA; Jones, RA; Kong, C; Levitt, GA; Richards, JM; Southall, DP; Wilson, AJ, 1983) |
| "Cardiorespirographic studies were performed in 11 prematures with episodes of apnea and bradycardia (gestational age: x = 31 weeks, birth weight: x = 1390g)." | 7.66 | [Cardiorespirographic studies in prematures with apnea and bradycardia during spontaneous breathing and CPAP-therapy (author's transl)]. ( Hürter, P; Larsen, H; Pörksen, C, 1980) |
| " A series of 10 newborn infants weighing 1 200 g or less, and requiring nasal IPPV for 5 to 14 days because of intractable apnea has been reported." | 7.66 | Prolonged intermittent positive pressure ventilation by nasal prongs in intractable apnea of prematurity. ( Agostino, R; Bucci, G; Colarizi, P; Marzetti, G; Mendicini, M; Moretti, C; Panero, A; Picece-Bucci, S, 1981) |
| "The site of upper airway obstruction during mixed and obstructive apnea was investigated in nine preterm infants with clinical apnea." | 7.66 | Pharyngeal airway obstruction in preterm infants during mixed and obstructive apnea. ( Mathew, OP; Roberts, JL; Thach, BT, 1982) |
| "The relation between plasma concentration of theophylline and number of apnea preterm infants was studied in six patients." | 7.66 | Plasma concentration-effect relationship of theophylline in treatment of apnea in preterm infants. ( Lagercrantz, H; Rane, A; Tunell, R, 1980) |
| "Theophylline disposition was examined in 17 premature neonates (birth weight 760--1,480 g) at cessation of therapy for primary apnea Mean +/- SD of clearance (22." | 7.66 | Factors affecting theophylline pharmacokinetics in premature infants with apnea. ( Giacoia, G; Hilligoss, DM; Jusko, WJ; Koup, JR, 1980) |
| "We studied the changes in PO2 during 72 isolated episodes of apnea of prematurity in 20 low-birth-weight infants." | 7.66 | Continuous monitoring of PO2 during apnea of prematurity. ( Dangman, BC; Hegyi, T; Hiatt, IM; Indyk, L; James, LS, 1981) |
| "495 kg) with apnea due to periodic breathing (apneic interval = 5 to 10 seconds) or with "serious apnea" (greater than or equal to 20 seconds) were studied before and after the administration of theophylline." | 7.66 | Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. ( Davi, MJ; Rigatto, H; Sankaran, K; Seshia, MM; Simons, FE; Simons, KJ, 1978) |
| "In summary, apnea of prematurity is both a primary and a secondary disorder--a reflection of CNS immaturity as well as a response to an underlying problem." | 7.66 | Apnea in the premature infant: an overview of causes and treatment. ( Messerly, AM; Sham, B, 1978) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 7.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| "The pharmacokinetic profile of caffeine was studied in 32 premature newborn infants with apnea: 12 following a single intravenous dose; 3 after a single oral dose; 7 during treatment with an initial empirical (high) maintenance dose schedule; and 10 during treatment with a revised (lower) dose schedule." | 7.66 | Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ( Aldridge, A; Aranda, JV; Collinge, JM; Cook, CE; Gorman, W; Loughnan, PM; Neims, AH; Outerbridge, EW, 1979) |
| " This polygraphic study was designed to test and extend our previous finding that gently oscillating water beds reduce apnea in premature infants." | 7.66 | Reduction of sleep apnea and bradycardia in preterm infants on oscillating water beds: a controlled polygraphic study. ( Baldwin, RB; Guilleminault, C; Korner, AF; Van den Hoed, J, 1978) |
| "The influence of short-term aminophylline treatment on sleep behaviour was studied in six preterms infants with recurrent apnea." | 7.66 | Sleep and aminophylline treatment of apnea in preterm infants. ( Albani, M; Gabriel, M; Witolla, C, 1978) |
| " Theophylline treatment was not efficient in the prevention of apnea when a serious underlying disease was present." | 7.66 | Kinetics and efficacy of theophylline in the treatment of apnea in the premature newborn. ( Assael, BM; Bonati, M; Caccamo, ML; Gerna, M; Latini, R; Mandelli, M; Marini, A; Sereni, F; Tognoni, G, 1978) |
| "To the well known methods for prevention of neonatal apnea like stimulation, CPAP, and mechanical ventilation the treatment with theophylline has been added recently." | 7.66 | [Prevention of neonatal apnea with theophylline (author's transl)]. ( Frisch, H; Irnberger, E; Müller, W, 1978) |
| "The effect of aminophylline on lung function was studied in 14 premature infants with apnea (gestational age, 30." | 7.66 | Aminophylline therapy for idiopathic apnea in premature infants: effects on lung function. ( Bancalari, E; Gerhardt, T; McCarthy, J, 1978) |
| "The sleep state characteristics of infant sleep apnea were studied in 36 twins examined by polygraphy at 40, 44, and 52 weeks after conception." | 7.65 | The sleep state characteristics of apnea during infancy. ( Fineberg, N; Gould, JB; James, O; Lee, AF; Sander, L; Teager, H, 1977) |
| " No over-all pattern relating sleep state to frequency of apnea could be detected for individual infants." | 7.65 | Sleep state, apnea and bradycardia in pre-term infants. ( Auld, PA; Krauss, AN; Solomon, GE, 1977) |
| "Polygraphic recordings were performed in seven preterm infants who had been given phenobarbital (phenobarbitone) to evaluate its effect on neonatal sleep behavior and on the incidence of neurogenic apnea and/or bradycardia." | 7.65 | Rapid eye movement sleep, apnea, and cardiac slowing influenced by phenobarbital administration in the neonate. ( Albani, M; Gabriel, M, 1977) |
| "The efficacy of theophylline in preventing severe apnea was evaluated in 17 low-birthweight infants (mean weight, 1,400 gm)." | 7.65 | Prevention of apnea and bradycardia in low-birthweight infants. ( Gotay, F; Moylan, FM; Rogers, MC; Shannon, DC; Stein, IM; Todres, ID, 1975) |
| "Five premature infants experiencing frequent episodes of apnea and bradycardia were treated with continuous positive airway pressure delivered by nasopharyngeal tube." | 7.65 | Prolonged apnea of prematurity: Treatment with continuous airway distending pressure delivered by nasopharyngeal tube. ( Boros, SJ; Reynolds, JW, 1976) |
| "4%) demonstrated apnea in association with RSV infection." | 7.65 | Apnea associated with respiratory syncytial virus infection in young infants. ( Bruhn, FW; McIntosh, K; Mokrohisky, ST, 1977) |
| " From the neurophysiological point of view, a review is also made of various therapeutical approaches for the prevention or reduction of apneas." | 7.65 | [Factors causing apneas in otherwise healthy newborns: a neurophysiological Concept (author's transl)]. ( Gabriel, M, 1977) |
| "The effectiveness of aminophylline in the treatment of apnea of prematurity was evaluated in 13 premature infants (mean birthweight, 1." | 7.65 | Treatment of apnea of prematurity with aminophylline. ( Bednarek, FJ; Roloff, DW, 1976) |
| "Respirations and apnea were recorded through an arterial catheter and observed simultaneously in 13 premature infants." | 7.65 | Apnea in premature infants: recording by arterial catheter. ( Belgaumkar, TK; Scott, KE, 1976) |
| "Twelve premature infants with primary apnea were treated with theophylline as an alternative to mechanical ventilation." | 7.65 | Treatment of severe apnea in prematures with orally administered theophylline. ( Shapiro, DL; Smith, B; Uauy, R; Warshaw, JB, 1975) |
| " Fifteen of these infants had idiopathic apnea." | 7.65 | Urinary biogenic amines in idiopathic apnea of prematurity. ( Fanaroff, AA; Kattwinkel, J; Klaus, MH; Mars, H, 1976) |
| "In a randomized controlled trial including preterm infants < 32 weeks' gestation, prophylactic (in the first 72 h of life) versus therapeutic (only if apnea exists or infant requires mechanical ventilation) decision of caffeine was compared." | 5.51 | Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. ( Elmowafi, M; Mohsen, N; Nasef, N; Nour, I, 2022) |
| " Caffeine is widely used to prevent and treat apnea (temporal cessation of breathing) associated with prematurity and facilitate extubation." | 5.41 | Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. ( Brattström, P; Bruschettini, M; Davis, PG; Onland, W; Russo, C; Soll, R, 2023) |
| "There is sufficient evidence to support use of caffeine therapy for apnea of prematurity, but practices vary widely when it comes to discontinuing therapy." | 5.41 | Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial. ( Jain, N; Nair, PMC; Nandakumar, A; Pournami, F; Prabhakar, J; Prakash, R, 2021) |
| "To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants." | 5.34 | [Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial]. ( Ding, Y; Gan, JM; He, T; Li, W; Liao, ZC; Wang, MJ; Yue, SJ, 2020) |
| " There were fewer instances of apnea of prematurity and shorter assisted ventilation times for infants in the caffeine group compared to the placebo group (p < 0." | 5.34 | Early application of caffeine improves white matter development in very preterm infants. ( Liu, S; Liu, Y; Wang, X; Xu, F; Yang, L; Yuan, X; Zhang, R; Zhang, X; Zhu, C, 2020) |
| "The study was performed using information on echocardiography measurements from preterm neonates recruited for apnea of prematurity (75 of 240) and preventing extubation failure (113 of 156) studies." | 5.30 | Acute hemodynamic effects of methylxanthine therapy in preterm neonates: Effect of variations in subgroups. ( Kamath, A; Lewis, LES; M, S; Nayak, K; Purkayastha, J, 2019) |
| "Caffeine is effective in the treatment of apnea of prematurity." | 5.27 | Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Mürner-Lavanchy, IM; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2018) |
| " Other pharmacokinetic indices, although variable, did not exhibit binomial distribution." | 5.27 | Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, GA, 1988) |
| "Caffeine half-life was greatly increased in two infants who had cholestatic hepatitis secondary to prolonged parenteral alimentation and one infant who was breast-fed exclusively." | 5.27 | Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. ( Billon, B; Le Guennec, JC; Paré, C, 1985) |
| " The mean plasma half-live of theophylline was 22." | 5.26 | [Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981) |
| "Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight." | 5.24 | Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017) |
| "To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity." | 5.24 | Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial. ( Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 5.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| " Caffeine is used not only for the treatment of apnea in prematurity, but also for the prevention of BPD." | 5.22 | Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved. ( Dong, W; Lei, X; Yang, Y; Yuan, Y, 2022) |
| "Apnea of prematurity is a developmental disorder affecting most extremely preterm infants." | 5.22 | Caffeine: Some of the Evidence behind Its Use and Abuse in the Preterm Infant. ( Bancalari, E; Chavez, L, 2022) |
| "Apnea of prematurity (AOP) is one of the common diseases in preterm infants." | 5.22 | [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022) |
| "Apnea is a frequent occurrence in prematurity and its prevalence in the most severely preterm population is indicative of an immature respiratory neural control system." | 5.22 | Apnea of prematurity and sudden infant death syndrome. ( MacFarlane, PM; Martin, RJ; Mitchell, LJ, 2022) |
| "Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity." | 5.22 | Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022) |
| "The study aimed to systematically review and analyze the impact of nasal intermittent positive pressure ventilation (NIPPV) versus continuous positive airway pressure (CPAP) on apnea of prematurity (AOP) in preterm neonates." | 5.22 | Nasal Intermittent Positive Pressure Ventilation versus Continuous Positive Airway Pressure and Apnea of Prematurity: A Systematic Review and Meta-Analysis. ( Banfield, L; Harrison, A; Mukerji, A; Sabsabi, B, 2022) |
| " It remains unclear, however, whether Bi-NCPAP or Re-NCPAP is more effective for reducing apnea of prematurity (AOP)." | 5.22 | Effects of infant flow Bi-NCPAP on apnea of prematurity. ( Ibara, S; Ishihara, C; Kato, E; Kuwahara, T; Maede, Y; Minakami, H; Ohsone, Y; Tokuhisa, T; Yamamoto, Y, 2016) |
| "To evaluate the effectiveness and safety of different doses of caffeine in treatment of primary apnea in preterm infants." | 5.22 | [Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants]. ( Liu, G; Tian, X; Zhao, Y, 2016) |
| "It seems that preventative effects of caffeine on apnea become apparent by using the drug in very premature infants." | 5.22 | Caffeine Administration to Prevent Apnea in Very Premature Infants. ( Armanian, AM; Faghihian, E; Iranpour, R; Salehimehr, N, 2016) |
| " This low-cost neuromodulatory procedure has the potential to provide a non-invasive intervention to reduce apnea, bradycardia and intermittent hypoxia in premature neonates." | 5.22 | Neuromodulation of Limb Proprioceptive Afferents Decreases Apnea of Prematurity and Accompanying Intermittent Hypoxia and Bradycardia. ( Benharash, P; Cordero, DM; Frank, P; Harper, RM; Kesavan, K, 2016) |
| "Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants." | 5.22 | Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial. ( Benard, M; Boutroy, MJ; Casper, C; Greze, E; Haddad, FE; Hamon, I; Hascoët, JM, 2016) |
| "• Caffeine therapy for treatment of apnea of prematurity has been well established over the past few years." | 5.20 | High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. ( Abdel-Hady, H; Mohammed, S; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2015) |
| "To evaluate the effect of stochastic resonance (SR) stimulation on preterm infant oxygen desaturation, bradycardia, and apnea events." | 5.20 | Stochastic Resonance Effects on Apnea, Bradycardia, and Oxygenation: A Randomized Controlled Trial. ( Cakert, K; Kelty-Stephen, D; Mao, W; Osborne, J; Paydarfar, D; Qureshi Ahmad, M; Smith, VC, 2015) |
| "Apnea of prematurity is a common complication in premature newborns and caffeine is a widespread medication used to treat this complication." | 5.19 | The effects of caffeine on heart rate variability in newborns with apnea of prematurity. ( Blazer, S; Haleluya, NS; Ulanovsky, I; Weissman, A, 2014) |
| "Apnea of prematurity is a common condition that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences on the central nervous system." | 5.19 | Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. ( Asztalos, E; Bhattacharjee, R; Biggs, SN; Bradford, R; Cheshire, M; Costantini, L; D'ilario, J; Davey, M; Dix, J; Doyle, LW; Gibbons, J; Horne, RS; Marcus, CL; Meltzer, LJ; Narang, I; Nixon, GM; Opie, G; Roberts, RS; Schmidt, B; Traylor, J, 2014) |
| "Preterm infants experience frequent cardiorespiratory events (CREs) including multiple episodes of apnea and bradycardia per day." | 5.16 | Exposure to biological maternal sounds improves cardiorespiratory regulation in extremely preterm infants. ( Doheny, L; Hurwitz, S; Insoft, R; Lahav, A; Ringer, S, 2012) |
| "To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring." | 5.14 | Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009) |
| "To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial." | 5.14 | Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. ( Asztalos, E; Davis, PG; Doyle, LW; Haslam, R; Roberts, RS; Schmidt, B; Sinha, S; Tin, W, 2010) |
| "8% CO(2) in preterm infants decreases the duration and rate of apnea as effectively as or better than theophylline with fewer adverse side effects." | 5.13 | A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity. ( Al-Saif, S; Alvaro, R; Cates, D; Kwiatkowski, K; Manfreda, J; Qurashi, M; Rigatto, H, 2008) |
| " This immaturity presents as prolonged apneas with associated bradycardia or desaturation, or brief respiratory pauses, periodic breathing, and intermittent hypoxia." | 5.12 | Immature control of breathing and apnea of prematurity: the known and unknown. ( Dobson, NR; Erickson, G; Hunt, CE, 2021) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed." | 5.12 | Caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2006) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 5.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| " Because these issues may be operative in apnea of prematurity (AOP), we hypothesized that CS reduces episodes of hypoxemia and bradycardia in infants with AOP." | 5.11 | Randomized, controlled trial of oral creatine supplementation (not effective) for apnea of prematurity. ( Bohnhorst, B; Dördelmann, M; Geuting, T; Peter, CS; Poets, CF; Wilken, B, 2004) |
| "The present work aimed to estimate the theophylline pharmacokinetic parameters (TH-PKP) in preterm neonates with apnea during the first month of life in order to optimize its dosage regimen." | 5.11 | Pharmacokinetics of theophylline in preterm neonates during the first month of life. ( Ali, AS; Fida, NM; Islam, SI; Sheikh, AA, 2004) |
| "Doxapram is used to treat apnea of prematurity when there is an insufficient response to methylxanthine treatment." | 5.11 | Effect of doxapram on cerebral blood flow velocity in preterm infants. ( Horsch, S; Roll, C, 2004) |
| "Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator." | 5.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| " Infants in the restrictive-transfusion group were more likely to have intraparenchymal brain hemorrhage or periventricular leukomalacia, and they had more frequent episodes of apnea, including both mild and severe episodes." | 5.11 | Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. ( Bell, EF; Cress, GA; Johnson, KJ; Kromer, IJ; Mahoney, LT; Mock, DM; Seward, VJ; Strauss, RG; Widness, JA; Zimmerman, MB, 2005) |
| "A relationship between gastroesophageal reflux (GER) and apnea of prematurity (AOP) has long been suspected but is difficult to prove because most GER in this age group is nonacidic and thus undetectable by pH monitoring, the current standard for GER detection." | 5.10 | Gastroesophageal reflux and apnea of prematurity: no temporal relationship. ( Bohnhorst, B; Peter, CS; Poets, CF; Silny, J; Sprodowski, N, 2002) |
| "In this blinded, randomized, placebo-controlled study, we found that infants who received supplemental carnitine did not demonstrate any reduction in apnea of prematurity, ventilator or nasal continuous positive airway pressure days, or the need for supplemental oxygen therapy." | 5.10 | Role of L-carnitine in apnea of prematurity: a randomized, controlled trial. ( Barrington, KJ; Barshop, BA; Finer, NN; O'Donnell, J; Rich, W, 2002) |
| "Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 5.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| "Preterm infants with a gestational age of <32 weeks and birth weight of <1,500 g were randomized to receive either caffeine or aminophylline treatment for apnea of prematurity." | 5.09 | Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment. ( Bertini, G; Dani, C; Martelli, E; Reali, MF; Rubaltelli, FF; Tronchin, M; Wiechmann, L, 2000) |
| "Thirty-two premature infants receiving nasal CPAP for apnea or mild respiratory distress were enrolled." | 5.09 | Lung recruitment and breathing pattern during variable versus continuous flow nasal continuous positive airway pressure in premature infants: an evaluation of three devices. ( Arnold, GK; Courtney, SE; Habib, RH; Pandit, PB; Pyon, KH; Saslow, JG, 2001) |
| "Apnea of prematurity (AOP) is frequently managed with nasal continuous positive airway pressure (NCPAP)." | 5.09 | High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. ( Hudson-Mason, A; Lemke, RP; Osiovich, H; Sreenan, C, 2001) |
| "Aminophylline and caffeine are commonly used for prophylaxis of apnea in premature infants." | 5.08 | Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline. ( Brendstrup, L; Greisen, G; Larsen, PB; Lundstrøm, KE; Skov, L, 1995) |
| " Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia." | 5.08 | Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995) |
| "Twelve spontaneously breathing preterm infants with idiopathic recurrent apnea were studied in a randomized controlled crossover trial." | 5.08 | Effect of nursing in the head elevated tilt position (15 degrees) on the incidence of bradycardic and hypoxemic episodes in preterm infants. ( Bucher, HU; Duc, G; Jenni, OG; Keel, M; von Siebenthal, K; Wolf, M, 1997) |
| "This study determined the effect of modifying a single aspect of the intermediate care environment on the incidence of apnea and rate of weight gain in convalescent preterm infants." | 5.08 | Effect of standard rest periods on apnea and weight gain in preterm infants. ( D'Auria, J; Holditch-Davis, D; O'Hale, A; Torres, C, 1997) |
| "The efficacy of nasal intermittent positive pressure ventilation (NIPPV) in treating apnea of prematurity was evaluated." | 5.08 | Efficacy of nasal intermittent positive pressure ventilation in treating apnea of prematurity. ( Lin, CH; Lin, YJ; Wang, ST; Yeh, TF, 1998) |
| "Placing preterm infants suffering idiopathic apnea of prematurity on the VPS had an effect on the infants' respiratory effort and achieved a reduction in the number of apneic episodes secondary to central and mixed apnea." | 5.07 | The effect of vertical pulsating stimulation on apnea of prematurity. ( Jirapaet, K, 1993) |
| "To assess if there was any advantage in the prophylactic use of theophylline to prevent apnea in preterms, we treated 56 preterms (Group A) < 34 weeks gestation with theophylline infusion and compared these with 25 age and weight matched preterms (Group B) who received no therapy." | 5.07 | Prophylactic theophylline infusion for prevention of apnea of prematurity. ( Ashavaid, TF; Merchant, RH; Sakhalkar, VS, 1992) |
| " The frequency and extent of apnea and bradycardia during a 6-hour period in a patient receiving nasal continuous positive airway pressure were compared with a similar crossover period of nasal intermittent positive-pressure ventilation." | 5.06 | Nasal intermittent positive-pressure ventilation offers no advantages over nasal continuous positive airway pressure in apnea of prematurity. ( Finer, NN; Peters, KL; Ryan, CA, 1989) |
| "01), apnea/bradycardia (heart rate less than 90/min) requiring intervention to increase the heart rate (P less than ." | 5.06 | A randomized trial to develop criteria for administering erythrocyte transfusions to anemic preterm infants 1 to 3 months of age. ( Christensen, RD; Kimura, RE; Koenig, JM; Noble, NA; Ross, MP; Rothstein, G; Simmons, MA, 1989) |
| "To investigate claims that oscillating mattresses reduce apnea of prematurity and improve growth and neurobehavioural development, we performed a randomized clinical trial using a predetermined sample size." | 5.06 | Randomized clinical trial of an oscillating air mattress in preterm infants: effect on apnea, growth, and development. ( Campbell, D; Saigal, S; Watts, J, 1986) |
| " The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs." | 5.05 | Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020) |
| "Apnea of prematurity affects the majority of infants born before 34 weeks of complete gestation." | 5.05 | [APNEA OF PREMATURITY - PATHOPHYSIOLOGY, TREATMENT & PROGNOSIS]. ( Erlichman, I; Eventov-Friedman, S; Gileles-Hillel, A; Reiter, J, 2020) |
| " In the large international Caffeine for Apnea of Prematurity trial, caffeine improved survival without neurodevelopmental disability at 18 months and demonstrated long term safety up to 11 years." | 5.05 | Neurodevelopmental outcomes after neonatal caffeine therapy. ( Grunau, RE; Synnes, A, 2020) |
| "Caffeine is an effective treatment for apnea of prematurity and has several important benefits, including decreasing respiratory morbidity and motor impairment." | 5.05 | Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose? ( Patel, RM; Saroha, V, 2020) |
| "The Caffeine for Apnea of Prematurity (CAP) trial showed that caffeine was safe when used with standard dosing and provided both pulmonary and neurological benefits to preterm infants." | 5.05 | National and international guidelines for neonatal caffeine use: Are they evidenced-based? ( Eichenwald, EC, 2020) |
| "19 infants admitted with a diagnosis of infantile apnea who were found to have periodic breathing were given oral theophylline to determine its effect." | 5.05 | An evaluation of theophylline for idiopathic apnea of infancy. ( Coward, JH; Duffley, LM; Finer, NN; Peters, KL, 1984) |
| "This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant." | 5.05 | The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981) |
| "Theophylline is commonly used to treat apnea of prematurity." | 5.05 | Limitations of theophylline in the treatment of apnea of prematurity. ( Cabal, L; Rambhatla, S; Sims, ME; Wu, PY; Yau, G, 1985) |
| "A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity." | 5.05 | Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study. ( Alpan, G; Arad, I; Dgani, Y; Eyal, F; Glick, B; Peleg, O; Sagi, E, 1985) |
| "The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants." | 5.05 | Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985) |
| "The pharmacokinetics of theophylline were examined in eight low-birth-weight infants (gestation: 26-32 weeks: birth-weight: 887-1,480 gm), who received the drug for treatment of primary apnea." | 5.04 | Theophylline pharmacokinetics in premature infants with apnea. ( Giacoia, G; Jusko, WJ; Koup, JR; Menke, J, 1976) |
| "It has been suggested that idiopathic apnea of prematurity is related to hypoxia from pulmonary instability or an immaturity of central respiratory control mechanisms." | 5.04 | Apnea of prematurity. Comparative therapeutic effects of cutaneous stimulation and nasal continuous positive airway pressure. ( Fanaroff, AA; Katona, PG; Kattwinkel, J; Klaus, MH; Nearman, HS, 1975) |
| " After one week the ventilation weaning, the child presented episodes of cyanosis associated with sudden oxygen desaturation, skin pallor, apnea, and bradycardia." | 5.01 | Apnea events in neonatal age: A case report and literature review. ( Catanzaro, S; Cimino, C; Corsello, G; Falsaperla, R; Vitaliti, G, 2019) |
| " While robust evidence supports the use of standard doses of caffeine for apnea of prematurity or to facilitate successful extubation, much remains unknown regarding the boundaries of efficacy and safety for this common therapeutic agent." | 5.01 | Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine. ( McPherson, C; Rostas, SE, 2019) |
| "Placebo-controlled trials have shown that caffeine is highly effective in treating apnoea of prematurity and reduces the risk of bronchopulmonary dysplasia (BPD) and neurodevelopmental impairment (NDI)." | 4.98 | High versus standard dose caffeine for apnoea: a systematic review. ( Hutten, GJ; Miedema, M; Onland, W; van Kaam, AH; Vliegenthart, R, 2018) |
| "Apnea of prematurity (AOP) is a common and pervasive problem in very low birth weight infants." | 4.98 | Caffeine: an evidence-based success story in VLBW pharmacotherapy. ( Dobson, NR; Hunt, CE, 2018) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 4.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| " As intermittent hypoxemia is a consequence of immature respiratory control and resultant apnea superimposed upon an immature lung, improvements in clinical care must include a thorough knowledge of premature lung development and pathophysiology that is unique to premature birth." | 4.93 | Cardiorespiratory events in preterm infants: etiology and monitoring technologies. ( Di Fiore, JM; Gauda, E; MacFarlane, P; Martin, RJ; Poets, CF, 2016) |
| " Despite aggressive respiratory support including mechanical ventilation, continuous positive airway pressure, oxygen and caffeine therapy to reduce apnea and accompanying intermittent hypoxemia, the incidence of intermittent hypoxemia events continues to increase during the first few months of life." | 4.93 | Cardiorespiratory events in preterm infants: interventions and consequences. ( Di Fiore, JM; Gauda, E; MacFarlane, P; Martin, RJ; Poets, CF, 2016) |
| " Various physiological protective reflex responses provide a plausible biological link between gastro-esophageal reflux and apnea and bradycardia in premature." | 4.93 | [Gastroesophageal reflux in premature: a case report]. ( Ndour, D, 2016) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g." | 4.90 | Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014) |
| " It is thanks to the efforts of Barbara Schmidt and the Caffeine for Apnea of Prematurity (CAP) Trial Group that we now have high-quality and reliable data not only on short-term but also long-term outcomes of caffeine use for apnea of prematurity." | 4.90 | Caffeine for apnea of prematurity: a neonatal success story. ( Bassler, D; Kreutzer, K, 2014) |
| "Central apnea, defined as cessation of breathing for ≥20s, is frequent in premature infants born at <34 weeks׳ gestation but uncommon among healthy late preterm (34(0/7)-36(6/7) weeks׳ gestation) and term (≥37 weeks׳ gestation) infants, where it is usually a clinical manifestation of a neurological or metabolic problem." | 4.90 | Apnea in acute bilirubin encephalopathy. ( Amin, SB; Bhutani, VK; Watchko, JF, 2014) |
| " Respiratory instability characterized by apnea and periodic breathing occurs in premature infants because of immature development of the respiratory network." | 4.89 | Apnea of prematurity--perfect storm. ( Di Fiore, JM; Gauda, EB; Martin, RJ, 2013) |
| "Apnea of prematurity is a common disorder of respiratory control among preterm infants, with potentially serious adverse consequences on infant development." | 4.89 | Forecasting respiratory collapse: theory and practice for averting life-threatening infant apneas. ( Bliss, DW; Paydarfar, D; Williamson, JR, 2013) |
| "Apnea of prematurity and gastroesophageal reflux (GER) are both common occurrences in preterm infants and widely perceived to be causally related." | 4.89 | Neonatal apnea and gastroesophageal reflux (GER): is there a problem? ( Abu Jawdeh, EG; Martin, RJ, 2013) |
| "Common neurologic morbidities encountered in very preterm and extremely preterm infants (intracranial hemorrhage, white matter injury and periventricular leukomalacia, and apnea of prematurity) are much less common in moderately preterm and late preterm infants." | 4.89 | Neurologic and metabolic issues in moderately preterm, late preterm, and early term infants. ( Laptook, AR, 2013) |
| " Most preterm infants exhibit recurrent apnea, resulting in repetitive oscillations in O(2) saturation (intermittent hypoxia, IH)." | 4.89 | Carotid chemoreceptor development and neonatal apnea. ( MacFarlane, PM; Martin, RJ; Ribeiro, AP, 2013) |
| " The carotid body senses dynamic changes in arterial oxygen and carbon dioxide tension and reflexly alters ventilation and plays an essential role in terminating apnea." | 4.89 | Inflammation in the carotid body during development and its contribution to apnea of prematurity. ( Chavez-Valdez, R; Gauda, EB; Kostuk, EW; Mason, A; Pichard, LE; Shirahata, M, 2013) |
| "Apnea of prematurity is a significant problem due to immaturity of the central neural control circuitry responsible for integrating afferent input and central rhythm." | 4.88 | Apnea of prematurity. ( Martin, RJ; Wilson, CG, 2012) |
| " This outline provides a discussion of the physiological underpinnings for some of the clinical conditions seen in this group of infants, including hypothermia, hypoglycemia, respiratory distress syndrome, transient tachypnea, severe respiratory failure, apnea, feeding difficulties, jaundice, and increased susceptibility to infections." | 4.88 | Developmental physiology of late and moderate prematurity. ( Raju, TN, 2012) |
| "The introduction of methylxanthines, especially caffeine, for the treatment of apnea of prematurity has been one of the most important and effective therapies in the neonatal intensive care unit (NICU) to date." | 4.88 | Evidence-based methylxanthine use in the NICU. ( Spitzer, AR, 2012) |
| "Apnea of prematurity (AOP) is a significant clinical problem manifested by an unstable respiratory rhythm reflecting the immaturity of respiratory control systems." | 4.87 | Apnea of prematurity: pathogenesis and management strategies. ( Mathew, OP, 2011) |
| " We review current evidence for and against an association between GER and apnea, failure to thrive, wheezing and respiratory diseases." | 4.87 | Myth: gastroesophageal reflux is a pathological entity in the preterm infant. ( Brockmann, PE; Poets, CF, 2011) |
| "Prematurity apnea remains a major clinical problem that requires treatment choices which are sometimes difficult." | 4.86 | [Apnea of prematurity: what's new?]. ( El Ayoubi, M; Lescure, S; Lopez, E; Moriette, G, 2010) |
| "To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea." | 4.86 | Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010) |
| " This ubiquitous trimethylxanthine, pervasively used in the human diet and beverages, significantly impacts on major acute neonatal morbidities including apnea of prematurity, bronchopulmonary dysplasia, patent ductus arteriousus with or without surgical ligation and post-operative apnea." | 4.86 | Caffeine impact on neonatal morbidities. ( Aranda, JV; Beharry, K; Davis, J; Natarajan, G; Valencia, GB, 2010) |
| "Although there is a large body of literature describing infants who experience apnea of prematurity and apparent life-threatening events, there is no consensus regarding the use of home monitoring." | 4.85 | Indications for home apnea monitoring (or not). ( Silvestri, JM, 2009) |
| " Anesthetic management of premature infants is often difficult due to their comorbidities and propensity for apnea and bradycardia." | 4.85 | Spinal anesthesia in preterm infant undergoing herniorrhaphy. ( Libby, A, 2009) |
| "Apnea of prematurity (AOP) remains a major clinical problem in present day neonatology that warrants frequent evaluations and imposes challenges in therapeutic strategies." | 4.84 | Neonatal apnea: what's new? ( Abu-Shaweesh, JM; Martin, RJ, 2008) |
| "Idiopathic apneas of prematurity remain an alarming problem in neonatology." | 4.84 | [Sensory stimulations for the treatment of idiopathic apneas of prematurity]. ( Gaugler, C; Marlier, L; Messer, J, 2007) |
| "Gastroesophageal reflux and apnea of prematurity are both common occurrences in premature infants." | 4.84 | Infant apnea and gastroesophageal reflux: a critical review and framework for further investigation. ( Hibbs, AM; Martin, RJ; Orenstein, SR; Slocum, C, 2007) |
| "Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence especially in preterm neonates." | 4.84 | Apnea in the newborn. ( Agarwal, R; Aggarwal, R; Deorari, AK; Jeevasankar, M; Mishra, S; Paul, VK, 2008) |
| " Continuous positive airway pressure applied through nasal prongs is an effective, less-invasive method to improve gas exchange and reduce apnea in these infants." | 4.83 | Continuous positive airway pressure: early, late, or stay with synchronized intermittent mandatory ventilation? ( Bancalari, E; del Moral, T, 2006) |
| " Both the presence and severity of apnea of prematurity progressively decrease the higher the postmenstrual age." | 4.83 | Ontogeny of autonomic regulation in late preterm infants born at 34-37 weeks postmenstrual age. ( Hunt, CE, 2006) |
| " A critical review of the evidence for potential sequelae of GER in preterm infants shows that 1) apnea is unrelated to GER in most infants, 2) failure to thrive practically does not occur with GER, and 3) a relationship between GER and chronic airway problems has not yet been confirmed in preterm infants." | 4.82 | Gastroesophageal reflux: a critical review of its role in preterm infants. ( Poets, CF, 2004) |
| "To determine the role of carnitine supplementation in premature infants on apnea of prematurity, length of ventilation and duration of hospital stay." | 4.82 | Role of carnitine supplementation in apnea of prematurity: a systematic review. ( Kabra, NS; Kumar, M; Paes, B, 2004) |
| "To determine whether treatment with carnitine will reduce the frequency of apnea, the duration of ventilation and the duration of hospital stay in preterm infants with recurrent apnea." | 4.82 | Carnitine supplementation for preterm infants with recurrent apnea. ( Kabra, NS; Kumar, M; Paes, B, 2004) |
| "Gastroesophageal reflux (GER) and apnea are both common occurrences in premature infants but their relationship is controversial." | 4.82 | Does gastroesophageal reflux cause apnea in preterm infants? ( Di Fiore, JM; Martin, RJ; Molloy, EJ, 2005) |
| " A clear picture is, therefore, emerging of the physiological mechanisms that underlie apnea of prematurity." | 4.82 | Control of breathing and neonatal apnea. ( Abu-Shaweesh, JM; Martin, RJ, 2005) |
| "Apnea, the cessation of respiratory airflow, can begin in many preterm infants in the first week of life and can last until the day of discharge or beyond." | 4.82 | A primer on Apnea of prematurity. ( Stokowski, LA, 2005) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 4.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| "All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 4.81 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001) |
| "The main objective was to determine in preterm infants with recurrent apnea, if treatment with CPAP compared with treatment with theophylline leads to a clinically important reduction in apnea or use of mechanical ventilation, without clinically important side effects." | 4.81 | Continuous positive airway pressure versus theophylline for apnea in preterm infants. ( Davis, PG; Henderson-Smart, DJ; Subramaniam, P, 2001) |
| "Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence in sick neonates." | 4.81 | Apnea in the newborn. ( Aggarwal, R; Deorari, AK; Paul, VK; Singhal, A, 2001) |
| "Apnea of prematurity is almost universal in infants who are born before 34 weeks gestation." | 4.81 | Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity. ( Davis, PG; de Paoli, AG; Lemyre, B, 2002) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 4.81 | Kinesthetic stimulation for preventing apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2002) |
| "Incidence and severity of apnea and bradycardia in preterm infants may be related to the immaturity of the respiratory control mechanisms." | 4.80 | [Follow-up of the premature infant: prevention of severe diseases and sudden death. Role of polysomnography]. ( François, G; Ravet, F, 1998) |
| "In preterm infants with recurrent apnea, how does treatment with doxapram compare with treatment with theophylline in leading to a clinically important reduction in apnea and use of mechanical ventilation, without clinically important side effects." | 4.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 4.80 | Kinesthetic stimulation for preventing apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2000) |
| "Main question: in preterm infants with apnea, does the use of kinesthetic stimulation lead to clinically important reductions in clinical apnea and bradycardia (>50% reduction in number of episodes), use of mechanical ventilation (IPPV) or continuous positive airways pressure (CPAP), and neurodevelopmental disability, without clinically important side effects." | 4.80 | Kinesthetic stimulation for treating apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2000) |
| "A single small study of 20 infants (Saigal 1986) demonstrated a significant benefit to the infants receiving theophylline compared to those on an oscillating water bed in terms of mean rates of clinically important apnea (apnea > 14 seconds and bradycardia < 100, and cyanosis or receiving stimulation)." | 4.80 | Kinesthetic stimulation versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2000) |
| "The main objective was to determine in preterm infants with recurrent apnea, if treatment with CPAP compared with treatment with theophylline leads to a clinically important reduction in apnea or use of mechanical ventilation, without clinically important side effects." | 4.80 | Continuous positive airway pressure versus theophylline for apnea in preterm infants. ( Davis, PG; Henderson-Smart, DJ; Subramanian, P, 2000) |
| "All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 4.80 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 4.80 | Prophylactic methylxanthine for preventing of apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 4.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| "Apnea of prematurity is almost universal in infants who are born before 34 weeks gestation." | 4.80 | Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity. ( Davis, PG; De Paoli, AG; Lemyre, B, 2000) |
| " theophylline, aminophylline or caffeine) for the treatment of apnea in preterm infants." | 4.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea is a disorder of respiratory control commonly seen in premature infants." | 4.80 | Apnea of prematurity: diagnosis, implications for care, and pharmacologic management. ( Albanna, S; Botwinski, C; McWilliam, P; Theobald, K, 2000) |
| "Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation." | 4.80 | Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000) |
| "Apnea of prematurity is one of the most common problems in the neonatal intensive care unit." | 4.79 | Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996) |
| "The neurodevelopmental outcome of term infants with acute life-threatening events (ALTE) and preterm infants with persistent apnea of prematurity were compared to matched control populations." | 4.78 | Neurodevelopmental outcome in infants with apnea. ( Koons, AH, 1992) |
| "Apnea is a common, treatable disorder of respiration in premature infants, which usually resolves over time." | 4.78 | Apnea of prematurity. ( Martin, RJ; Miller, MJ, 1992) |
| "The incidence and proposed mechanisms of apnea of infancy and apnea of prematurity are briefly reviewed, and the use of methylxanthines in managing these conditions is discussed." | 4.77 | Management of apnea in infants. ( Blanchard, J; Kriter, KE, 1989) |
| " Caffeine is used for the treatment of apnea of prematurity and as an additive in several analgesics and migraine remedies, and as a panacea for hyperkinetic children." | 4.77 | Caffeine: a new look at an age-old drug. ( Gupta, P; Somani, SM, 1988) |
| "Episodic apnea leading to asphyxia is a relatively common disorder of young children." | 4.77 | Sleep apnea in infancy and childhood. ( Thach, BT, 1985) |
| "Caffeine and theophylline are effective in the treatment of apnea in the newborn infant." | 4.76 | Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979) |
| "Apnea of prematurity cannot be reliably measured with current monitoring techniques." | 4.12 | Multichannel esophageal signals to monitor respiratory rate in preterm infants. ( Bürgin, C; Gupta, N; Haeberlin, A; Jost, K; Kreuzer, S; Niederhauser, T; Schulzke, SM; Simmen, P; Suter, L; Trachsel, D, 2022) |
| "Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity." | 4.12 | Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport. ( Andersen, L; Ariagno, S; Collura, C; Thorvilson, M, 2022) |
| "Apnea of prematurity (AOP) is a critical condition for preterm infants which can lead to several adverse outcomes." | 4.12 | The effect of apnea length on vital parameters in apnea of prematurity - Hybrid observations from clinical data and simulation in a mathematical model. ( Andriessen, P; Bovendeerd, P; Kommers, D; Lensen, I; van Pul, C; Varisco, G, 2022) |
| "The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity." | 4.12 | The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022) |
| "Caffeine is routinely used in preterm infants for apnea of prematurity." | 4.12 | Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range? ( Aghai, ZH; Amendolia, B; Bhat, V; Chung, J; Nakhla, T; Saslow, J; Slater-Myer, L; Tran Lopez, K, 2022) |
| " The most common milestone sequence was CPAP discontinuation, caffeine discontinuation, thermoregulation, apnea resolution, and full oral feeds." | 4.12 | Achievement of maturational milestones among very low birth weight infants. ( Ahmad, SM; Fairchild, KD; Sinkin, RA; Slevin, CC; Sullivan, BA, 2022) |
| "Apnea of prematurity can persist despite caffeine therapy in preterm infants." | 4.02 | The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age. ( Engbers, AGJ; Flint, RB; Knibbe, CAJ; Koch, BCP; Poets, CF; Reiss, IKM; Simons, SHP; Völler, S, 2021) |
| "A frequent challenge in Neonatology is the high frequency of spontaneously occurring hypoxemic events, a majority of which are associated with apnea or hypoventilation." | 4.02 | Are we over-treating hypoxic spells in preterm infants? ( Conlon, S; Di Fiore, JM; Martin, RJ, 2021) |
| "Caffeine citrate is a commonly used methylxanthine for pharmacologic treatment of apnea of prematurity." | 3.96 | Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ( Di, X; Fan, J; Guo, A; Hu, X; Huang, L; Xie, H; Xue, J; Zhao, P; Zhu, Z, 2020) |
| "Caffeine to prevent or treat apnea of prematurity in the newborn period is now standard of care for infants born very preterm." | 3.96 | Childhood respiratory outcomes after neonatal caffeine therapy. ( Cheong, JLY; Doyle, LW, 2020) |
| " It appears that infants with apnea of prematurity and those receiving assisted ventilation are the most likely to benefit from caffeine." | 3.96 | When to start and stop caffeine and why respiratory status matters. ( Davis, PG, 2020) |
| "Caffeine is the preferred pharmacologic treatment for apnea of prematurity." | 3.96 | Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa. ( Ayede, AI; Ekhaguere, OA; Ezeaka, CV, 2020) |
| " High doses of caffeine may produce better control of apnea." | 3.96 | Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns. ( Aranda, JV; Beharry, KD, 2020) |
| " Nearly 90% of premature infants experience chronic intermittent hypoxia (IH) because of high incidence of apnea of prematurity, which is characterized by periodic stoppage of breathing." | 3.91 | Long-term facilitation of catecholamine secretion from adrenal chromaffin cells of neonatal rats by chronic intermittent hypoxia. ( Fox, AP; Khan, SA; Makarenko, VV; Nanduri, J; Peng, YJ; Prabhakar, NR, 2019) |
| " Although those patients experience frequent apneas and sleep-wake disturbances during their hospital stay, clinicians still rely on clinical scales to assess pain and stress burden." | 3.91 | The implementation of an apnea-based perinatal stress calculator. ( Bollen, B; Caicedo, A; Deviaene, M; Jansen, K; Lavanga, M; Moeyersons, J; Naulaers, G; Ortibus, E; Van Huffel, S; Varon, C; Wel, O, 2019) |
| "The factors affecting the safety and efficacy of aminophylline use in the treatment of apnea of prematurity (AOP) in the neonatal intensive care unit (NICU) are not clear." | 3.91 | Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit. ( Dong, Z; Lu, X; Lyu, Q; Mao, Y; Miao, C; Ye, C; Yu, L; Zhang, J, 2019) |
| "Doxapram is a treatment option for severe apnea of prematurity (AOP)." | 3.91 | Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. ( de Jongh, FH; de Waal, CG; Hutten, GJ; Kraaijenga, JV; van Kaam, AH, 2019) |
| "The factors influencing the severity of apnea-related hypoxemia and bradycardia are incompletely characterized, especially in infants receiving noninvasive respiratory support." | 3.91 | Physiological instability after respiratory pauses in preterm infants. ( Ali, SK; Dargaville, PA; Gale, TJ; Lim, K; Marshall, AP, 2019) |
| " We hypothesized that these sounds would reduce apnea and intermittent hypoxemia, enhance parasympathetic outflow, and improve cardiovascular patterns." | 3.88 | A prospective observational cohort study of exposure to womb-like sounds to stabilize breathing and cardiovascular patterns in preterm neonates. ( Bhatt, RR; Harper, RM; Karp, HN; Kesavan, K; Parga, JJ; Sim, MS; Zeltzer, L, 2018) |
| " Cases were significantly more likely to be diagnosed with obstructive sleep apnea (p = 0." | 3.88 | Post-discharge outcomes of failed car seat tolerance screens: A case-control and follow-up study. ( Davis, NL; Sharma, P, 2018) |
| " We introduce a novel application of singlepoint Bayesian online changepoint detection to predict clinical state transitions, and apply this framework to detecting pathological transitions in preterm infants with episodes of apnea and bradycardia." | 3.88 | Bayesian Online Changepoint Detection Of Physiological Transitions. ( Chang, J; Gee, AH; Ghosh, J; Paydarfar, D, 2018) |
| "Apnea of prematurity (AOP) can affect even 85-100% of premature newborns and is related to lack of full maturity of organs." | 3.85 | [Apnea of prematurity - characteristic and treatment]. ( Dołęgowska, B; Goryniak, A; Śleboda, D; Szczęśniak, A, 2017) |
| "Children enrolled in the CAP (Caffeine for Apnea of Prematurity) randomized controlled trial and assessed at the Royal Women's Hospital in Melbourne at 11 years of age had expiratory flow rates measured according to the standards of the American Thoracic Society." | 3.85 | Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth. ( Cheong, JLY; Doyle, LW; Ranganathan, S, 2017) |
| "Apnea of prematurity is one of the most common diagnoses in the NICU." | 3.83 | Apnea of Prematurity. ( Eichenwald, EC, 2016) |
| "Caffeine citrate is the treatment of choice for apnea of prematurity (AOP)." | 3.83 | The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study. ( Carnielli, VP; Fabbri, L; Ferrari, F; Kiechl-Kohlendorfer, U; Lasagna, G; Lista, G; Papagaroufalis, K; Polackova, R; Saenz, P, 2016) |
| "Apnea, bradycardia, and oxygen desaturation events are a common in neonatal intensive care units, with relevant literature to date largely focusing on very low birth weight and extremely low birth weight infants." | 3.83 | Diagnostic Evaluation and Home Monitor Use in Late Preterm to Term Infants With Apnea, Bradycardia, and Desaturations. ( Amberson, M; Freiberger, C; Montenegro, B; Mukhopadhyay, S; Rhein, LM; Veit, L, 2016) |
| "Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)." | 3.83 | Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016) |
| "This study aimed to evaluate predictive factors involved in efficacy and safety in Japanese infants who received theophylline therapy to prevent apnea of prematurity (AOP) after weaning from mechanical ventilation." | 3.83 | Predictive Factors for Efficacy and Safety of Prophylactic Theophylline for Extubation in Infants with Apnea of Prematurity. ( Douchi, T; Irie, T; Irikura, M; Ishitsuka, Y; Kondo, T; Kondo, Y; Mitarai, F; Orita, Y; Shimodozono, Y; Takeda, Y, 2016) |
| " Those in the center of the co-existent knowledge map of Chinses keywords were "preterm infants", "apnea", "primary apnea", "naloxone" and "aminophylline"; while "apnea", "preterm infants" and "caffeine" located in the central place of the co-existent knowledge map of English keywords." | 3.83 | [Current research status of drug therapy for apnea of prematurity]. ( Chen, C; Mu, DZ; Shi, J; Shu, XX; Tang, J; Yang, XY, 2016) |
| "The possible pathophysiology of the relationship between gastro-esophageal reflux disease and apnea of prematurity has been widely investigated." | 3.81 | Gaviscon and domperidon responsive apnea episodes associated with gastro-esophageal reflux disease in twins. ( Bilgin, H; Eren, A; Kara, S, 2015) |
| "In 2006 the apnea of prematurity (AOP) consensus group identified inaccurate counting of apnea episodes as a major barrier to progress in AOP research." | 3.80 | Accurate automated apnea analysis in preterm infants. ( Clark, MT; Delos, JB; Fairchild, KD; Guin, LE; Kattwinkel, J; Lake, DE; Lee, H; Moorman, R; Paget-Brown, AO; Rusin, CG; Smoot, TJ; Vergales, BD, 2014) |
| " We prospectively compared the safety profile of ECC and LP in preterm infants with apnea of prematurity." | 3.80 | Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity. ( Arand, J; Engel, C; Poets, CF; Vatlach, S, 2014) |
| "Apnea of prematurity is very frequent in premature newborns (PNB)." | 3.80 | Instrumentation for the detection and interruption of apnea episodes for premature newborn. ( Camargo, VC; Freitas de Amorim, M; Honorato da Silva, S; Nohama, P, 2014) |
| "It is common practice for premature infants undergoing elective inguinal hernia (IH) repair to be hospitalized for postoperative apnea monitoring." | 3.79 | Postoperative apnea after inguinal hernia repair in formerly premature infants: impacts of gestational age, postconceptional age and comorbidities. ( Arıkan, A; Ozdemir, T, 2013) |
| " Indications for caffeine use in that study were predominantly for treatment of apnea and facilitation of extubation rather than prophylaxis." | 3.79 | Methylxanthine use for apnea of prematurity among an international cohort of neonatologists. ( Abu Jawdeh, EG; Argus, BM; Bandyopadhyay, A; Davis, PG; Limrungsikul, A; Martin, RJ; Nakad, PE; O'Riordan, M; Supapannachart, S; Yunis, KA, 2013) |
| "To investigate for any association between episodes of apnea, desaturation and bradycardia and necrotizing enterocolitis (NEC)." | 3.79 | Episodes of apnea, desaturation and bradycardia and the development of necrotizing enterocolitis in preterm infants: a case-control study. ( Ali, N; Bensouda, B; Mandel, R; Sant'Anna, GM; Tarazi, SE, 2013) |
| "Apnea of prematurity (AOP) occurs frequently in preterm infants and a variable proportion of AOP can be induced by gastroesophageal reflux (GER)." | 3.79 | A thickened formula does not reduce apneas related to gastroesophageal reflux in preterm infants. ( Aceti, A; Battistini, B; Corvaglia, L; Faldella, G; Legnani, E; Mariani, E; Martini, S; Spizzichino, M, 2013) |
| "To compare apnea events recorded by bedside cardiorespiratory monitor and nursing documentation with those detected by visual inspection of continuous electronic cardiorespiratory waveform." | 3.79 | Monitoring apnea of prematurity: validity of nursing documentation and bedside cardiorespiratory monitor. ( Amin, SB; Burnell, E, 2013) |
| "To investigate the usefulness of Multichannel intraluminal impedance-pH (MII-pH) monitoring as compared with conventional pH monitoring for detecting Gastroesophageal reflux (GER) episodes and apnea-related symptom association in preterm infants and neonates." | 3.78 | Impedance-pH monitoring and conventional pH monitoring are complementary methods to detect association between gastroesophageal reflux and apnea-related symptoms in preterm infants and neonates. ( Choi, JH; Kim, HS; Ko, JS; Moon, JS; Seo, JK; Shim, JO; Shin, MS, 2012) |
| "To determine the cost-effectiveness of treatment with caffeine compared with placebo for apnea of prematurity in infants with birth weights less than 1250 g, from birth through 18 to 21 months' corrected age." | 3.77 | Economic evaluation of caffeine for apnea of prematurity. ( Doyle, LW; Dukhovny, D; Kamholz, KL; Kok, JH; Lorch, SA; Mao, W; Roberts, RS; Schmidt, B; Wang, N; Zupancic, JA, 2011) |
| "Apnea of prematurity is one of the most common diagnoses in the NICU." | 3.77 | Variation in diagnosis of apnea in moderately preterm infants predicts length of stay. ( Eichenwald, EC; Escobar, GJ; Mao, WY; McCormick, MC; Richardson, DK; Zupancic, JA, 2011) |
| "This study evaluated the optimal timing for repair, incarceration risk, and postoperative apnea rate in premature infants with inguinal hernias." | 3.77 | A critical review of premature infants with inguinal hernias: optimal timing of repair, incarceration risk, and postoperative apnea. ( Gleason, JM; Lee, SL; Sydorak, RM, 2011) |
| "We examined associations of daily ambient air pollution concentrations with central apnea (prolonged pauses in breathing) and bradycardia (low heart rate) events among infants prescribed home cardiorespiratory monitors." | 3.77 | Ambient air pollution and apnea and bradycardia in high-risk infants on home monitors. ( Flanders, WD; Freed, G; Klein, M; Mulholland, JA; Peel, JL; Tolbert, PE, 2011) |
| " SI and a Fisher exact test with variable association windows were calculated for obstructive apnea (OA)." | 3.77 | Temporal association of polysomnographic cardiorespiratory events with GER detected by MII-pH probe in the premature infant at term. ( Cristofalo, E; Gauda, E; Glen, DR; Katz, R; McGinley, B; Nunez, J, 2011) |
| "To measure the success rate or the percentage of infants who have no additional events of various apnea- or bradycardia-free intervals after correcting for gestational age, postmenstrual age of the last apnea or bradycardia event, and the severity of the event." | 3.77 | Epidemiology of apnea and bradycardia resolution in premature infants. ( Escobar, GJ; Lorch, SA; Srinivasan, L, 2011) |
| " The unique presenting symptom was apnea, which required respiratory support by nasal intermittent positive pressure ventilation." | 3.76 | Influenza A/H1N1 virus in very low-birth-weight premature infant: case report. ( Barak, S; Chulski, E; Kushnir, A; Miron, D, 2010) |
| " Apnea ≥10 s in duration, bradycardia ≤80 b." | 3.76 | Characterization of cardiorespiratory events following gastroesophageal reflux in preterm infants. ( Arko, M; Di Fiore, J; Herynk, B; Hibbs, AM; Martin, R, 2010) |
| "Apnea of prematurity (AOP) is a disturbance in respiratory rhythm defined by idiopathic pauses in breathing that reduce blood oxygen levels and/or heart rate." | 3.76 | Heritability of apnea of prematurity: a retrospective twin study. ( Bednarek, F; Bloch-Salisbury, E; Boyd, T; Hall, MH; Paydarfar, D; Sharma, P, 2010) |
| "Clinically relevant apneas, which are common in preterm infants, may adversely affect later neuropsychological condition in this group of patients." | 3.75 | Differential diagnosis of apneas in preterm infants. ( Dittrichová, J; Melichar, J; Miletín, J; Paul, K, 2009) |
| "To characterize esophageal motility during episodes of prolonged apnea in premature infants." | 3.75 | Apnea-associated reduction in lower esophageal sphincter tone in premature infants. ( Omari, TI, 2009) |
| " Extreme events included central apnea >30 seconds, bradycardia >10 seconds, and desaturation >10 seconds at hemoglobin-oxygen saturation value with pulse oximetry <80%." | 3.75 | Risk factors for extreme events in infants hospitalized for apparent life-threatening events. ( Al-Kindy, HA; Côté, A; Gélinas, JF; Hatzakis, G, 2009) |
| "Administration of caffeine citrate (caffeine) has been a central component of the treatment of apnea of prematurity." | 3.75 | Acute hemodynamic effects of caffeine administration in premature infants. ( Bin-Nun, A; Ionchev, A; Meadow, W; Soloveychik, V; Sriram, S, 2009) |
| " We aimed to measure objectively the effects of feeding on GER, apnea, bradycardia and desaturations." | 3.75 | Apnea, bradycardia and desaturation in preterm infants before and after feeding. ( Arko, M; Di Fiore, J; Hibbs, AM; Martin, RJ; Slocum, C, 2009) |
| " Data included ventilator and incubator settings, body temperature, apnea and bradycardia spells, use of methylxanthines, feeding method, and requirements for intravenous fluids." | 3.75 | Infant functional status: the timing of physiologic maturation of premature infants. ( Bakewell-Sachs, S; Escobar, GJ; Lorch, SA; Medoff-Cooper, B; Silber, JH, 2009) |
| " Number of apnea episodes, weight at 28 days of life and days of hospital stay were similar in both periods." | 3.74 | A very strict guideline reduces the number of erythrocyte transfusions in preterm infants. ( Barros, MM; Bordin, JO; Chiba, A; da Cunha, DH; dos Santos, AM; Guinsburg, R; Kopelman, BI; Mimica, AF, 2008) |
| "High humidity high flow nasal cannula has become a widely used alternative for nasal continuous positive airway pressure for the treatment of apnea of prematurity." | 3.74 | Subcutaneous scalp emphysema, pneumo-orbitis and pneumocephalus in a neonate on high humidity high flow nasal cannula. ( Jasin, LR; Kern, S; Rone, JM; Thompson, S; Walter, C; Yohannan, MD, 2008) |
| "Apnea and bradycardia of prematurity (ABP) are possible risks towards damage of the developing brain." | 3.74 | Factors influencing apnea and bradycardia of prematurity - implications for neurodevelopment. ( Hermann, C; Keller, T; Kribs, A; Pillekamp, F; Roth, B; von Gontard, A, 2007) |
| " A heart rate less than 50 beats per minute (bpm) for more than 3 seconds or an apnea lasting for more than 15 seconds with a heart rate less than 60 bpm were defined as abnormal." | 3.74 | Cardiorespiratory events recorded on home monitors: the effect of prematurity on later serious events. ( Allegaert, K; Daniels, H; Debeer, A; Devlieger, H; Naulaers, G; Rayyan, M, 2007) |
| " The factors associated with a greater risk of mechanical ventilation and a longer PICU stay were the association of two or more risk factors (42/284; 15%), the presence of apnea (73/284; 25." | 3.74 | [Severe bronchiolitis. Epidemiology and clinical course of 284 patients]. ( Casado Flores, J; de la Calle Cabrera, T; Espínola Docio, B; García Teresa, MA; López Guinea, A; Martín Sobrino, MA; Serrano, A, 2007) |
| "Postoperative apneas are reported in up to 49% of premature infants undergoing anesthesia for inguinal hernia repair." | 3.74 | The frequency of apneas in premature infants after inguinal hernia repair: do they need overnight monitoring in the intensive care unit? ( Ansermino, M; Milner, R; Murphy, JJ; Swanson, T, 2008) |
| "The aim of this study is to evaluate the risks and benefits associated with the use of low-dose morphine in preterm infants with CPAP, especially apnea." | 3.74 | Analgosedation with low-dose morphine for preterm infants with CPAP: risks and benefits. ( Enders, J; Gebauer, C; Knüpfer, M; Pulzer, F; Robel-Tillig, E, 2008) |
| "Apnea of prematurity (AoP) is, in part, a reflection of brainstem-mediated respiratory control system maturation." | 3.73 | Transient bilirubin encephalopathy and apnea of prematurity in 28 to 32 weeks gestational age infants. ( Amin, SB; Charafeddine, L; Guillet, R, 2005) |
| "Doxapram is a respiratory stimulant widely used for the treatment of idiopathic apnea of prematurity, although it has been demonstrated that it can induce a transient decrease of cerebral blood flow and that isolated mental delay in infants weighing <1,250 g is associated with the total dosage and duration of doxapram therapy." | 3.73 | Brain hemodynamic effects of doxapram in preterm infants. ( Bertini, G; Dani, C; Filippi, L; Pezzati, M; Pratesi, S; Rubaltelli, FF; Tronchin, M, 2006) |
| "To examine the temporal relationship between apnea and gastroesophageal reflux (GER) and to assess the effect of GER on apnea duration." | 3.73 | Apnea is not prolonged by acid gastroesophageal reflux in preterm infants. ( Arko, M; Di Fiore, JM; Kimball, A; Martin, RJ; Whitehouse, M, 2005) |
| " Of all apneas 89% were preceded by a decrease in tidal volume of at least 33% (435/487; p < 0." | 3.73 | Antecedents of respiratory pauses in extremely low birth weight infants supported by proportional assist ventilation. ( Hofmiller, A; Rieger-Fackeldey, E; Schulze, A, 2006) |
| "Apnea of prematurity (AOP) is found in >50% of premature infants and is almost universal in infants who are <1000 g at birth." | 3.73 | Summary proceedings from the apnea-of-prematurity group. ( Finer, NN; Higgins, R; Kattwinkel, J; Martin, RJ, 2006) |
| "Adverse cardiorespiratory events including apnea, bradycardia, and desaturations have been described following administration of the first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B (DTP-IPV-Hib) immunization to preterm infants." | 3.73 | Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants. ( Lee, J; Robinson, JL; Spady, DW, 2006) |
| "Caffeine citrate is commonly used for prophylaxis and treatment of apnea in preterm babies." | 3.73 | [Caffeine citrate utilization for treatment of apnea in French neonatal units]. ( Baudon, JJ; Biran-Mucignat, V; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| "Apnea of prematurity develop during the first days of life and usually resolve by the time the infant reaches 36-37 weeks postmenstrual age." | 3.73 | [Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate]. ( Baudon, JJ; Biran-Mucignat, V; Boelle, PY; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| "Young infants with bronchiolitis are at risk for apnea." | 3.73 | Identifying hospitalized infants who have bronchiolitis and are at high risk for apnea. ( Greenes, DS; Harper, MB; Willwerth, BM, 2006) |
| "It is standard practice to defer discharge of premature infants until they have achieved a set number of days without experiencing apnea." | 3.72 | Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity. ( Eichenwald, EC; O'Brien, BJ; Richardson, DK; Weinstein, MC; Zupancic, JA, 2003) |
| " In this statement, the most recent research information concerning extreme limits for a prolonged course of apnea of prematurity is reviewed." | 3.72 | Apnea, sudden infant death syndrome, and home monitoring. ( , 2003) |
" Cases had longer hospital (11 vs 7days) and neonatal intensive care unit stays (10 vs 7 days), and more frequent apnea-bradycardia (30% vs 5%), pneumonia (12% vs 1%), and suspected sepsis diagnoses (27% vs 3%), P | 3.72 | The association between respiratory distress and nonpulmonary morbidity at 34 to 36 weeks' gestation. ( As-Sanie, S; Mercer, B; Moore, J, 2003) | |
| " Apnea of prematurity is defined as the cessation of breathing for longer than 20 seconds or that of any duration if accompanied by cyanosis and sinus bradycardia, for infants born before 37 weeks of gestation." | 3.72 | Consanguinity and apnea of prematurity. ( Beydoun, H; Khogali, M; Melki, I; Tamim, H; Yunis, K, 2003) |
| " In the case of apneic attacks where SpO2 was < or =85%, the cerebral circulation in preterm low-birthweight neonates was extensively changed and, therefore, attention should be paid to changes in the concentration of SpO2 when managing apnea of prematurity in NICU." | 3.72 | Evaluation of change of cerebral circulation by SpO2 in preterm infants with apneic episodes using near infrared spectroscopy. ( Nakamura, H; Nakao, H; Uetani, Y; Yamamoto, A; Yokoyama, N; Yonetani, M, 2003) |
| "To determine whether apnea in preterm infants is associated with abnormal neurodevelopmental outcome." | 3.72 | Apnea is associated with neurodevelopmental impairment in very low birth weight infants. ( Barrington, KJ; Cormier, C; Janvier, A; Khairy, M; Kokkotis, A; Messmer, D, 2004) |
| "An approximate 80% reduction in the frequency of apnea was found with only minimal side effects following low-dose doxapram." | 3.71 | Low-dose doxapram therapy for idiopathic apnea of prematurity. ( Fujimura, M; Itahashi, K; Kajiwara, M; Yamazaki, T, 2001) |
| " This study evaluates the effect of caffeine on oxygen consumption and metabolic rate in premature infants with idiopathic apnea." | 3.71 | Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. ( Bauer, J; Hentschel, R; Linderkamp, O; Maier, K, 2001) |
| "Apnea of prematurity is common and none of the treatments being used are fully effective and free of significant adverse side effects." | 3.71 | Inhalation of low (0.5%-1.5%) CO2 as a potential treatment for apnea of prematurity. ( Al-Aif, S; Alvaro, R; Cates, D; Kwiatkowski, K; Manfreda, J; Rigatto, H, 2001) |
| " Three premature neonates received inadvertent intravenous overdoses of theophylline for apnea of prematurity while in newborn intensive care." | 3.71 | Theophylline toxicokinetics in premature newborns. ( Jarrett, RV; Kauffman, RE; Lowry, JA; Pettett, G; Wasserman, G, 2001) |
| "Premature infants who are discharged from intensive care nurseries are known to be at increased risk for apnea, bradycardia, and oxygen desaturation while in the upright position." | 3.71 | Respiratory instability of term and near-term healthy newborn infants in car safety seats. ( Coleman, JM; deRegnier, RA; Merchant, JR; Porter, S; Worwa, C, 2001) |
| "Premature infants need to attain both medical stability and maturational milestones (specifically, independent thermoregulation, resolution of apnea of prematurity, and the ability to feed by mouth) before safe discharge to home." | 3.71 | Inter-neonatal intensive care unit variation in discharge timing: influence of apnea and feeding management. ( Blackwell, M; Eichenwald, EC; Lloyd, JS; Richardson, DK; Tran, T; Wilker, RE, 2001) |
| "Episodes of apnea, desaturation, and bradycardia are common in preterm infants." | 3.71 | Cardiorespiratory events in preterm infants referred for apnea monitoring studies. ( Arko, MK; Betkerur, A; Di Fiore, JM; Kenney, SR; Krauss, A; Martin, RJ; Miller, MJ; Zadell, A, 2001) |
| " Apneas of greater than 10 seconds were recorded, as well as the occurrence of bradycardia or desaturation." | 3.71 | Apnea at discharge and gastro-esophageal reflux in the preterm infant. ( Barrington, KJ; Rich, W; Tan, K, 2002) |
| " Fifteen of the 20 preterm infants demonstrated a tendency to have short apneas (2 to 5 seconds) on squeezing, 88% of which were central in origin." | 3.70 | A possible role for the Hering-Breuer deflation reflex in apnea of prematurity. ( Hannam, S; Ingram, DM; Milner, AD, 1998) |
| "Doxapram, a respiratory stimulant, is used to treat idiopathic apnea of prematurity." | 3.70 | Second-degree atrioventricular heart block after doxapram administration. ( De Villiers, GS; Kalis, NN; Van der Merwe, PL; Walele, A, 1998) |
| "Continuous monitoring of premature infants with apnea is mandatory in order to define the pathophysiology and the type of apnea, and to assess the efficacy and tolerance of the treatment." | 3.70 | [Treatment of apnea in prematurity]. ( Boutroy, MJ; Hascoët, JM, 1998) |
| "To determine whether predischarge event recording (PDER) can accurately identify preterm infants with resolving apnea of prematurity (AOP) at risk for postdischarge complications." | 3.70 | Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity. ( DeCristofaro, JD; Katz, S; Subhani, M, 2000) |
| "Theophylline has been widely used to treat apnea of premature neonates." | 3.70 | Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ( Ahn, HW; Choi, JH; Park, KJ; Shin, WG; Suh, OK, 1999) |
| " The study population consist of 5 preterms (26 to 30 weeks of gestational age), in the second week of postnatal age, affected by apnea of prematurity." | 3.70 | [Evaluation of cerebral oxygenation in newborns with prematurity apnea: new frequency domain NIR oximeter]. ( Donzelli, G; Pratesi, S, 2000) |
| "To elucidate risk factors for apnea in preterm infants discharged from the hospital and in full-term healthy infants." | 3.69 | Infant apnea detection after herniorrhaphy. ( Bell, C; Dubose, R; Hughes, CW; Mooney, S; O'Connor, TZ; Oh, TH; Rosen, C; Seashore, J; Touloukian, R, 1995) |
| " Twenty-three desaturations were associated with prolonged apneic pauses and 54 with bradycardia; 19 of these were associated with both apnea and bradycardia." | 3.69 | Prolonged episodes of hypoxemia in preterm infants undetectable by cardiorespiratory monitors. ( Poets, CF; Richard, D; Southall, DP; Stebbens, VA, 1995) |
| "Administration of 100% O2 to preterm infants induces an apnea that is usually central." | 3.69 | Induction of mixed apneas by inhalation of 100% oxygen in preterm infants. ( Alvarez, J; Alvaro, R; Cates, D; Kwiatkowski, K; Rigatto, H, 1994) |
| "Methylxanthine use in the treatment of apnea of prematurity is well documented." | 3.69 | Impact of theophylline use in Wolff-Parkinson-White syndrome. ( Abedin, M; Agwunobi, J; Beeram, M; Sinkford, S; Young, M, 1996) |
| "Physiological recordings were undertaken to study the temporal relationship between apnea, defined as pauses in nasal airflow (PNA), and desaturation in preterm infants." | 3.69 | Temporal relationship between pauses in nasal airflow and desaturation in preterm infants. ( Pryce, A; Southall, DP; Spencer, SA; Watkin, SL, 1996) |
| "We have shown previously that administration of 100% O2 to preterm infants induces an apnea which in about 20% of cases has an obstructive component." | 3.69 | Low baseline oxygenation predisposes preterm infants to mixed apneas during inhalation of 100% oxygen. ( Al-Saedi, S; Alvaro, R; Cates, D; Kwiatkowski, K; Rigatto, H; Zia Haider, A, 1996) |
| "Apnea of prematurity remains among the most commonly diagnosed conditions in the Newborn Intensive Care Unit and may prolong hospital stays in some infants." | 3.69 | Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. ( Aina, A; Eichenwald, EC; Stark, AR, 1997) |
| "Most neonatologists include an apnea-free period in the criteria for the discharge of preterm infants." | 3.69 | Margin of safety for discharge after apnea in preterm infants. ( Darnall, RA; Kattwinkel, J; Nattie, C; Robinson, M, 1997) |
| "The neurodevelopmental outcome of premature infants with persistent apnea of prematurity (AOP) is reported." | 3.68 | Neurodevelopmental outcome of infants with apnea of infancy. ( Hegyi, T; Hiatt, M; Jadeja, N; Koons, AH; Mojica, N; Ostfeld, B, 1993) |
| " Interpretation of these findings suggested that the transient cerebral hyperperfusion following bradycardia compensates for the hypoxic-ischemic episode, sustained during the preceding epoch of apnea and bradycardia." | 3.68 | Cerebral hyperperfusion following episodes of bradycardia in the preterm infant. ( Casaer, P; Daniels, H; Ramaekers, VT, 1993) |
| "Fourteen healthy term-born infants, nine preterm infants with apnea in the nursery, and 10 preterm infants without apnea." | 3.68 | Episodes of bradycardia during early infancy in the term-born and preterm infant. ( Cabal, LA; Hodgman, JE; Hoppenbrouwers, T, 1993) |
| "Apnea of prematurity is a common problem in neonatal intensive care nurseries." | 3.68 | Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity. ( Hindmarsh, KW; Kalapurackal, M; Sankaran, K; Tan, L, 1993) |
| "We tested the hypotheses that (1) preterm infants with bronchopulmonary dysplasia (BPD) have an increased incidence of obstructive apneas as compared to those without BPD (control) and (2) the respiratory pattern during obstructive apneas may be associated with more pronounced hypoventilation." | 3.68 | The incidence of obstructive apneas in preterm infants with and without bronchopulmonary dysplasia. ( Alvarez, J; Fajardo, C; Kwiatkowski, K; Rigatto, H; Wong, A, 1993) |
| "Preterm and ex-preterm infants are at risk for life-threatening apnea after general anesthesia." | 3.68 | Are all preterm infants younger than 60 weeks postconceptual age at risk for postanesthetic apnea? ( Lerman, J; Malviya, S; Swartz, J, 1993) |
| " Immaturity at delivery, metabolic acidosis, respiratory distress syndrome and recurrent apnea are important mechanisms of cerebral injury contributing to severity of PVH-IVH." | 3.68 | Neonatal complications and risk of intraventricular-periventricular hemorrhage. ( Ciarlini, G; Ferrari, B; Luzietti, R; Merialdi, A; Tonni, G; Vadora, E, 1992) |
| "14 kg; gestation, 29 weeks) on 80 occasions, to determine the time course of the response and its relationship with spontaneous apnea occurrence." | 3.68 | Response to external obstruction in preterm infants with apnea. ( Milner, AD; Stokes, GM; Upton, CJ, 1992) |
| " Apnea has been reported following caregiving during peak hours of activity in a neonatal intensive care unit (NICU)." | 3.68 | Reducing the hypoxemia, bradycardia, and apnea associated with suctioning in low birthweight infants. ( Evans, JC, 1992) |
| "The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated." | 3.68 | Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992) |
| "Because postoperative apnea and bradycardia in premature infants following inguinal herniorrhaphy remains a concern, outpatient repair has not been recommended." | 3.68 | Outpatient inguinal herniorrhaphy in premature infants: is it safe? ( Greenholz, SK; Hough, VJ; Marr, CC; Melone, JH; Schwartz, MZ; Taub, JE; Tyson, KR, 1992) |
| "In order to analyze the effects of maturity and apnea frequency on the respiratory control of preterm infants, we studied their responses to tube breathing using tubes equivalent to two anatomical dead spaces." | 3.68 | Response to tube breathing in preterm infants with apnea. ( Milner, AD; Stokes, GM; Upton, CJ, 1992) |
| " We measured the CO2 response in 11 infants with or without apnea, who were born at 26-33 weeks gestation and were 12 to 215 days old at the time of the study." | 3.68 | Compact apparatus for measurement of ventilatory response to carbon dioxide in newborns and infants. ( Katayama, M; Kobayashi, K; Miyasaka, K, 1992) |
| "The ventilatory effects of doxapram in the initial pharmacotherapy for apnea in the newborn were evaluated in 8 premature infants with idiopathic apnea." | 3.68 | Doxapram for the initial treatment of idiopathic apnea of prematurity. ( Bairam, A; Faulon, M; Monin, P; Vert, P, 1992) |
| " Posttransfusion pneumocardiograms revealed significant reduction of periodic breathing, of apnea episodes with 11-15 second duration, of apnea density, and of heart rate." | 3.68 | Transfusion-induced changes in the breathing pattern of healthy preterm anemic infants. ( Heimler, R; Sasidharan, P, 1992) |
| " Six-second apnea density was less than 1% in one group and greater than or equal to 5% in the other." | 3.68 | Relationship between determinants of oxygen delivery and respiratory abnormalities in preterm infants with anemia. ( Bifano, EM; Borer, J; Smith, F, 1992) |
| " Nursing documentation failed to detect 11 infants with prolonged apnea and bradycardia." | 3.68 | Undetected apnea and bradycardia in infants. ( Graff, M; Hegyi, T; Hiatt, IM; Rovell, K; Soriano, C, 1991) |
| " To adjust for circulation time, values for PACO2 were made lowest for the last breath before apnea and highest for the first breath after apnea." | 3.68 | The ventilatory response to endogenous CO2 in preterm infants. ( Cates, DB; Hasan, SU; Kwiatkowski, KA; Rigatto, H, 1991) |
| "From a group of 50 premature newborns with central and mixed apnea, 34 received a loading dose of 4." | 3.68 | [Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ( Belmont-Gómez, A; Calderón-Mandujano, B; González-Treviño, J; Juárez-Olguín, H; Prado-Serrano, A; Rodríguez-Palomares, C; Udaeta-Mora, E, 1991) |
| "We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects." | 3.68 | Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991) |
| "The occurrence of central apnea of 15 seconds or longer, transient episodes of bradycardia (TEB), and periodic breathing were studied in 66 healthy premature infants when at least 1 week old and between 32 and 36 weeks postconceptual age." | 3.68 | Apnea, transient episodes of bradycardia, and periodic breathing in preterm infants. ( Cabal, LA; Gonzalez, F; Hodgman, JE; Hoppenbrouwers, T, 1990) |
| "Recordings of breathing movements and heart rate (pneumograms) were obtained prospectively in 89 preterm infants at 0-28 days of age to determine if those who develop apnea and/or bradycardia with cyanosis (Group 1) differ from those who do not (Group 2)." | 3.68 | Prospective pneumogram recordings in preterm infants with and without clinical apnea and bradycardia. ( Kelly, DH; McCulloch, KM, 1990) |
| "In an attempt to determine whether plasma beta-endorphin (beta-ED) concentrations correlate with occurrence of apnea in preterm infants, measurements were made in three groups of infants." | 3.67 | Plasma beta-endorphin concentration in infants with apneic spells. ( Hindmarsh, KW; Sankaran, K; Watson, VG, 1984) |
| "Polygraphic monitoring studies were performed on more than 150 older preterm infants (postconceptional ages of 36 weeks or more) and full-term neonates to evaluate unexplained or persistent apnea." | 3.67 | Hypoxemia associated with feeding in the preterm infant and full-term neonate. ( Frost, JD; Glaze, DG; Rosen, CL, 1984) |
| "It has been suggested that apnea of prematurity may be caused by "immaturity" of central control of breathing." | 3.67 | Apnea of prematurity: I. Lung function and regulation of breathing. ( Bancalari, E; Gerhardt, T, 1984) |
| "Medical records of 261 hospitalized patients less than 1 year old with documented respiratory syncytial virus (RSV) infection were reviewed to determine the incidence of RSV-associated apnea and the accompanying risk of subsequent apnea or death." | 3.67 | Respiratory syncytial virus-related apnea in infants. Demographics and outcome. ( Anas, NG; Brooks, JG; Church, NR; Hall, CB, 1984) |
| "Airway obstruction is a cause of apnea in preterm infants." | 3.67 | Apnea of prematurity: II. Respiratory reflexes. ( Bancalari, E; Gerhardt, T, 1984) |
| "Caffeine, used for treatment of idiopathic apnea in preterm infants, may have a vasoconstrictive effect on cerebral vessels." | 3.67 | Does caffeine affect cerebral blood flow in the preterm infant? ( Baan, J; Ruys, JH; Stijnen, T; Van Bel, F; Van de Bor, M, 1989) |
| "Administering caffeine citrate is a safe, noninvasive way to treat premature infants with persistent apnea." | 3.67 | Caffeine citrate in the NICU. ( Flood, E, 1989) |
| " Spontaneous prolonged apneic spells were recorded in both infants, and these consisted of two distinctly different apnea types." | 3.67 | Characterization of prolonged apneic episodes associated with respiratory syncytial virus infection. ( Pickens, DL; Schefft, GL; Storch, GA; Thach, BT, 1989) |
| "Twenty-nine premature infants were studied to determine whether neonatal asphyxia, apnea, and low blood pressure in the first day of life are associated with elevated plasma beta-endorphin concentrations." | 3.67 | Cardiorespiratory depression and plasma beta-endorphin levels in low-birth-weight infants during the first day of life. ( Davidson, S; Gil-Ad, I; Laron, Z; Reisner, SH; Rogovin, H, 1987) |
| "Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2." | 3.67 | Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986) |
| "Eighteen infants with idiopathic apnea of prematurity refractory to therapeutic levels of aminophylline were treated with incremental doses of doxapram beginning at 0." | 3.67 | Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, G, 1987) |
| "Upper gastrointestinal examinations with simultaneous cardiorespiratory monitoring were performed in 39 older premature infants with persistent apnea." | 3.67 | Upper GI examinations in older premature infants with persistent apnea: correlation with simultaneous cardiorespiratory monitoring. ( Fujioka, M; Itani, Y; Niitsu, N; Nishimura, G; Oono, T, 1988) |
| "Five neonates (4 premature) and 16 infants (6 prematurely born), 15-588 days old, received caffeine as citrate salt for apnea." | 3.67 | Developmental changes of caffeine elimination in infancy. ( Badoual, J; Carrier, O; d'Athis, P; Moran, C; Olive, G; Pons, G; Rey, E; Richard, MO, 1988) |
| " During the initial study, 15 infants exhibited one or more episodes of short apnea (greater than or equal to 10 sec) and three infants exhibited prolonged apnea (greater than or equal to 20 sec)." | 3.67 | Respiratory control during nipple feeding in preterm infants. ( Mathew, OP, 1988) |
| "In an effort to establish the minimum effective dose of theophylline in the treatment of idiopathic apnea of prematurity, a prospective trial of 22 infants with at least 0." | 3.67 | The dose response of theophylline in the treatment of apnea of prematurity. ( Finer, NN; Muttitt, SC; Tierney, AJ, 1988) |
| " We elicited a previously described upper airway reflex in 10 sleeping preterm infants with apnea of prematurity by instilling physiologic saline into the oropharynx and recording respiration, heart rate, and swallowing." | 3.67 | Prolonged apnea associated with upper airway protective reflexes in apnea of prematurity. ( Pickens, DL; Schefft, G; Thach, BT, 1988) |
| "We prospectively studied the stress perception of ten mothers of preterm infants on apnea monitors (birth weight, 1255 +/- 295 g) and ten mothers of term infants on monitors (3156 +/- 700 g) and compared them with 15 mothers of preterm infants (1450 +/- 305 g) and 15 mothers of term infants (3360 +/- 595 g) not on monitors." | 3.67 | Mothers of preterm and full-term infants on home apnea monitors. ( Chen, A; Garcia Coll, C; Oh, W; Vohr, BR, 1988) |
| "Apnea, bradycardia, and neuromuscular hyperirritability have been associated with magnesium (Mg) deficiency in young human infants and weanling animals." | 3.67 | Magnesium therapy in premature neonates with apnea neonatorum. ( Caddell, JL, 1988) |
| "Pharmacokinetics of doxapram were determined in 13 infants with idiopathic apnea of prematurity uncontrolled by aminophylline and caffeine." | 3.67 | Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ( Beaudry, MA; Bradley, JM; Gramlich, LM; LeGatt, D, 1988) |
| "Pneumogram (PG) recordings were performed in 87 very low birthweight (VLBW) asymptomatic infants just prior to hospital discharge to determine the relationships between: 1) a prior history of apnea of prematurity (AOP) and cardiorespiratory pattern; and 2) cardiorespiratory pattern at hospital discharge and postconceptional age." | 3.67 | Respiratory pattern at hospital discharge in asymptomatic preterm infants. ( Hageman, JR; Holmes, D; Hunt, CE; Suchy, S, 1988) |
| "Theophylline and caffeine are two xanthine-derivated drugs frequently administered for their stimulating effects on the respiratory center in premature babies presenting with "idiopathic apnea"." | 3.67 | [Xanthines in apnea of premature infants. Influence on gastroesophageal reflux]. ( Sacré, L; Vandenplas, Y, 1987) |
| "We measured the frequency distribution and the ventilatory correlates of the various types of apneas 3 to 15 s long during sleep in eight term infants (birth weight 3." | 3.67 | A developmental study on types and frequency distribution of short apneas (3 to 15 seconds) in term and preterm infants. ( Caces, R; Cates, D; Kwiatkowski, K; Lee, D; Rigatto, H, 1987) |
| "This review provides an understanding of current problems related to apnea of infancy." | 3.67 | Infant apnea. ( Fox, WW; Spitzer, AR, 1986) |
| " If no cause is found, the diagnosis of idiopathic infantile apnea is made." | 3.67 | Infantile apnea. ( McCulloch, K; Vidyasagar, D, 1986) |
| " The revealing sign was the occurrence, at age 11 days, of frequent apneas with bradycardia, needing mechanical ventilation associated with adapted antibiotic therapy for 14 days." | 3.67 | [Apnea disclosing Chlamydia trachomatis infection in a premature infant]. ( Dehan, M; Gabilan, JC; Magny, JF; Ropert, JC; Saby, MA; Zouari, A, 1986) |
| "Apnea in preterm infants has been classified as obstructive, central (nonobstructive), and mixed, based on the presence or absence of upper airway obstruction." | 3.67 | Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants. ( Carlo, WA; Martin, RJ; Miller, MJ, 1985) |
| "Idiopathic apnea in preterm infants, more than 30 weeks of gestation, after the first week of life is uncommon and poorly understood." | 3.67 | Ventilatory control and carbon dioxide response in preterm infants with idiopathic apnea. ( Barberis, C; Cabal, LA; Durand, M; Georgie, S; Gonzalez, F; Hodgman, JE; Hoppenbrouwers, T, 1985) |
| " Using techniques to quantitate airflow and pharyngeal airway pressures, we have reported many descriptive aspects of the apnea in these infants." | 3.67 | Observations made on severe apneic spells in two infants at risk for sudden death. ( Mathew, OP; Roberts, JL; Thach, BT, 1985) |
| "Theophylline, aminophylline, and caffeine are methylxanthines frequently used in the treatment of idiopathic apnea of prematurity." | 3.67 | Early childhood developmental follow-up of infants with GMH/IVH: effect of methylxanthine therapy. ( Duncan, CC; Ehrenkranz, RA; Ment, LR; Scott, DT, 1985) |
| "A 2750-g female infant was born at 36 weeks' gestation to a 40-year-old woman treated with clonazepam throughout her pregnancy." | 3.67 | Neonatal apnea associated with maternal clonazepam therapy: a case report. ( Coleman, JM; Edgren, BE; Fisher, JB; Mammel, MC, 1985) |
| "The effect of episodes of apnea with bradycardia on cerebral circulation was studied during 101 episodes in 15 premature infants." | 3.67 | Episodes of apnea and bradycardia in the preterm newborn: impact on cerebral circulation. ( Perlman, JM; Volpe, JJ, 1985) |
| "Twelve-hour urinary excretion of 4-hydroxy-3-methoxymandelic acid (VMA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) was studied in 20 premature infants, 8 without apnea and 12 with apnea." | 3.66 | Study of neurotransmitters in premature infants with or without apnea of prematurity. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1982) |
| "Urinary excretion of various catecholamine metabolites (4-hydroxy-3-methoxymandelic acid, homovanillic acid, 3-methoxy-4-hydroxphenylglycol) was studied in preterm infants with idiopathic apnea treated with theophylline." | 3.66 | Effect of theophylline on neurotransmitters in preterm infants with apnea. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1983) |
| "The interactive effect of caffeine and continuous distending airway pressure was evaluated in two premature neonates with apnea." | 3.66 | Interaction of caffeine and continuous distending airway pressure in neonatal apnea. ( Aranda, JV; Outerbridge, EW; Trippenbach, T, 1983) |
| "We assessed the relation between clinical apnea and brain-stem neuronal function in 58 preterm babies." | 3.66 | Clinical apnea and brain-stem neural function in preterm infants. ( Campbell, DJ; Henderson-Smart, DJ; Pettigrew, AG, 1983) |
| "Fourteen preterm infants with apnea (body weight, 1052 +/- 44 g; gestational age, 30." | 3.66 | Effects of aminophylline on respiratory center and reflex activity in premature infants with apnea. ( Bancalari, E; Gerhardt, T; McCarthy, J, 1983) |
| " Nearly all bradycardia (V-shaped, U-shaped bradycardia, combination of bradycardia and apnea) were correctly classified." | 3.66 | Microprocessor-based long term cardiorespirography. I. Heart rate changes and apneic attacks. ( Betz, R; Hörnchen, H; Roebruck, P; Siller, V, 1983) |
| "Seventy-six premature infants with clinical apnea, bradycardia, or cyanosis were studied with polygraph recordings of heart rate, nasal thermistor detection of airflow, and impedance pneumography." | 3.66 | Episodic airway obstruction in premature infants. ( Dransfield, DA; Fox, WW; Spitzer, AR, 1983) |
| "An acoustic monitor to detect apnea in infants has been developed." | 3.66 | Apnea monitoring by acoustic detection of airflow. ( DiBenedetto, J; Krasner, J; Stark, AR; Werthammer, J, 1983) |
| " We suggest that idiopathic apnea of prematurity is not associated with depletion of catecholamine stores in the central nervous system." | 3.66 | Cerebrospinal fluid concentration of biogenic amine metabolites in idiopathic apnea of prematurity. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1983) |
| "Three cases of hernia repair and simultaneous resolution of prolonged neonatal apnea are reported." | 3.66 | Resolution of prolonged neonatal apnea with hernia repair. ( Mellish, RW; Yeaton, HL, 1983) |
| " Despite apnea monitoring systems, 136/203 (67%) apneic episodes greater than or equal to 20 seconds in duration, including 19 episodes greater than or equal to 50 seconds in duration, were not recorded by nursing staff." | 3.66 | Undetected episodes of prolonged apnea and severe bradycardia in preterm infants. ( Alexander, JR; Farndon, PA; Jones, RA; Kong, C; Levitt, GA; Richards, JM; Southall, DP; Wilson, AJ, 1983) |
| "001); apnea requiring bag and mask resuscitation with oxygen (P less than ." | 3.66 | Risk factors in retrolental fibroplasia. ( Aranda, JV; Easdown, J; Gunn, TR; Outerbridge, EW, 1980) |
| "Cardiorespirographic studies were performed in 11 prematures with episodes of apnea and bradycardia (gestational age: x = 31 weeks, birth weight: x = 1390g)." | 3.66 | [Cardiorespirographic studies in prematures with apnea and bradycardia during spontaneous breathing and CPAP-therapy (author's transl)]. ( Hürter, P; Larsen, H; Pörksen, C, 1980) |
| " A series of 10 newborn infants weighing 1 200 g or less, and requiring nasal IPPV for 5 to 14 days because of intractable apnea has been reported." | 3.66 | Prolonged intermittent positive pressure ventilation by nasal prongs in intractable apnea of prematurity. ( Agostino, R; Bucci, G; Colarizi, P; Marzetti, G; Mendicini, M; Moretti, C; Panero, A; Picece-Bucci, S, 1981) |
| "The site of upper airway obstruction during mixed and obstructive apnea was investigated in nine preterm infants with clinical apnea." | 3.66 | Pharyngeal airway obstruction in preterm infants during mixed and obstructive apnea. ( Mathew, OP; Roberts, JL; Thach, BT, 1982) |
| " The clinical appearance of these six neonates included respiratory distress, cyanosis, and/or apnea." | 3.66 | beta-hemolytic streptococcal infection appearing as persistent fetal circulation. ( Desai, R; Farooki, ZQ; Shankaran, S, 1982) |
| "Simultaneous blood and saliva samples were drawn for determination of caffeine and theophylline concentrations in 17 infants receiving caffeine or theophylline therapy for apnea of prematurity." | 3.66 | Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants. ( Bada, HS; Khanna, NN; Somani, SM, 1980) |
| "The relation between plasma concentration of theophylline and number of apnea preterm infants was studied in six patients." | 3.66 | Plasma concentration-effect relationship of theophylline in treatment of apnea in preterm infants. ( Lagercrantz, H; Rane, A; Tunell, R, 1980) |
| "7 micrograms/ml) on metabolic rate were observed in 11 premature infants with severe idiopathic apnea of prematurity." | 3.66 | Oxygen consumption in apneic premature infants after low-dose theophylline. ( Auld, PA; Krauss, AN; Milsap, RL, 1980) |
| "Theophylline disposition was examined in 17 premature neonates (birth weight 760--1,480 g) at cessation of therapy for primary apnea Mean +/- SD of clearance (22." | 3.66 | Factors affecting theophylline pharmacokinetics in premature infants with apnea. ( Giacoia, G; Hilligoss, DM; Jusko, WJ; Koup, JR, 1980) |
| " This study was performed to examine the development of premature infants treated with theophylline in the neonatal period for apnea." | 3.66 | Developmental outcome of premature infants treated with theophylline. ( Eitzman, DV; Holstrum, WJ; Nelson, RM; Resnick, MB, 1980) |
| "We studied the changes in PO2 during 72 isolated episodes of apnea of prematurity in 20 low-birth-weight infants." | 3.66 | Continuous monitoring of PO2 during apnea of prematurity. ( Dangman, BC; Hegyi, T; Hiatt, IM; Indyk, L; James, LS, 1981) |
| "495 kg) with apnea due to periodic breathing (apneic interval = 5 to 10 seconds) or with "serious apnea" (greater than or equal to 20 seconds) were studied before and after the administration of theophylline." | 3.66 | Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. ( Davi, MJ; Rigatto, H; Sankaran, K; Seshia, MM; Simons, FE; Simons, KJ, 1978) |
| "In summary, apnea of prematurity is both a primary and a secondary disorder--a reflection of CNS immaturity as well as a response to an underlying problem." | 3.66 | Apnea in the premature infant: an overview of causes and treatment. ( Messerly, AM; Sham, B, 1978) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 3.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| "The pharmacokinetic profile of caffeine was studied in 32 premature newborn infants with apnea: 12 following a single intravenous dose; 3 after a single oral dose; 7 during treatment with an initial empirical (high) maintenance dose schedule; and 10 during treatment with a revised (lower) dose schedule." | 3.66 | Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ( Aldridge, A; Aranda, JV; Collinge, JM; Cook, CE; Gorman, W; Loughnan, PM; Neims, AH; Outerbridge, EW, 1979) |
| "The effects of aminophylline on renal function in 10 premature infants with idiopathic apnea are evaluated." | 3.66 | The effects of theophylline on renal function in the premature newborn. ( Harkavy, KL; Jose, P; Scanlon, JW, 1979) |
| "Plasma concentrations of theophylline and caffeine in seven premature neonates receiving theophylline orally for treatment of apnea at age one to 9 days were measured by high performance liquid chromatography, ultraviolet spectrophotometry, and mass spectrometry." | 3.66 | Metabolism of theophylline to caffeine in premature newborn infants. ( Aranda, JV; Baltassat, P; Bethenod, M; Bory, C; Frederich, A; Porthault, M, 1979) |
| " No apnea was seen before timolol maleate administration, and no further spells were noted after subsequent cyclocryotherapy without timolol maleate treatment." | 3.66 | Apneic spells associated with timolol therapy in a neonate. ( Bromberg, BB; Olson, RJ; Zimmerman, TJ, 1979) |
| " This polygraphic study was designed to test and extend our previous finding that gently oscillating water beds reduce apnea in premature infants." | 3.66 | Reduction of sleep apnea and bradycardia in preterm infants on oscillating water beds: a controlled polygraphic study. ( Baldwin, RB; Guilleminault, C; Korner, AF; Van den Hoed, J, 1978) |
| "The influence of short-term aminophylline treatment on sleep behaviour was studied in six preterms infants with recurrent apnea." | 3.66 | Sleep and aminophylline treatment of apnea in preterm infants. ( Albani, M; Gabriel, M; Witolla, C, 1978) |
| " Theophylline treatment was not efficient in the prevention of apnea when a serious underlying disease was present." | 3.66 | Kinetics and efficacy of theophylline in the treatment of apnea in the premature newborn. ( Assael, BM; Bonati, M; Caccamo, ML; Gerna, M; Latini, R; Mandelli, M; Marini, A; Sereni, F; Tognoni, G, 1978) |
| "The present study is a report on 9 premature infants treated with aminophylline for relief of apnea." | 3.66 | Alterations in state in apneic pre-term infants receiving theophylline. ( Auld, PA; Dietrich, J; Drayer, DE; Krauss, AN; Reidenberg, M, 1978) |
| "To the well known methods for prevention of neonatal apnea like stimulation, CPAP, and mechanical ventilation the treatment with theophylline has been added recently." | 3.66 | [Prevention of neonatal apnea with theophylline (author's transl)]. ( Frisch, H; Irnberger, E; Müller, W, 1978) |
| "The effect of aminophylline on lung function was studied in 14 premature infants with apnea (gestational age, 30." | 3.66 | Aminophylline therapy for idiopathic apnea in premature infants: effects on lung function. ( Bancalari, E; Gerhardt, T; McCarthy, J, 1978) |
| " Measurements of expiratory airflow and respiratory effort indicated that 36 of 43 spells were mixed, consisting of central apnea preceded or followed by airway obstruction." | 3.66 | Spontaneous neck flexion and airway obstruction during apneic spells in preterm infants. ( Stark, AR; Thach, BT, 1979) |
| " Cardiac slowing/bradycardia often coincide with respiratory arrest/apnea." | 3.65 | Cardiac slowing and respiratory arrest in preterm infants. ( Albani, M; Gabriel, M, 1976) |
| "The sleep state characteristics of infant sleep apnea were studied in 36 twins examined by polygraphy at 40, 44, and 52 weeks after conception." | 3.65 | The sleep state characteristics of apnea during infancy. ( Fineberg, N; Gould, JB; James, O; Lee, AF; Sander, L; Teager, H, 1977) |
| " No over-all pattern relating sleep state to frequency of apnea could be detected for individual infants." | 3.65 | Sleep state, apnea and bradycardia in pre-term infants. ( Auld, PA; Krauss, AN; Solomon, GE, 1977) |
| "Polygraphic recordings were performed in seven preterm infants who had been given phenobarbital (phenobarbitone) to evaluate its effect on neonatal sleep behavior and on the incidence of neurogenic apnea and/or bradycardia." | 3.65 | Rapid eye movement sleep, apnea, and cardiac slowing influenced by phenobarbital administration in the neonate. ( Albani, M; Gabriel, M, 1977) |
| "The efficacy of theophylline in preventing severe apnea was evaluated in 17 low-birthweight infants (mean weight, 1,400 gm)." | 3.65 | Prevention of apnea and bradycardia in low-birthweight infants. ( Gotay, F; Moylan, FM; Rogers, MC; Shannon, DC; Stein, IM; Todres, ID, 1975) |
| " The results are consonant with our concept of activation and recruitment of quiescent respiratory center neurones by somatic sensory stimulation, and they give fundamental support to the clinical observation of others that cutaneous stimulation is effective for the treatment of apnea of prematurity." | 3.65 | Cutaneous stimulation and generation of breathing in the fetus. ( Condorelli, S; Cosmi, EV; Scarpelli, EM, 1977) |
| "Five premature infants experiencing frequent episodes of apnea and bradycardia were treated with continuous positive airway pressure delivered by nasopharyngeal tube." | 3.65 | Prolonged apnea of prematurity: Treatment with continuous airway distending pressure delivered by nasopharyngeal tube. ( Boros, SJ; Reynolds, JW, 1976) |
| "4%) demonstrated apnea in association with RSV infection." | 3.65 | Apnea associated with respiratory syncytial virus infection in young infants. ( Bruhn, FW; McIntosh, K; Mokrohisky, ST, 1977) |
| " From the neurophysiological point of view, a review is also made of various therapeutical approaches for the prevention or reduction of apneas." | 3.65 | [Factors causing apneas in otherwise healthy newborns: a neurophysiological Concept (author's transl)]. ( Gabriel, M, 1977) |
| "The effectiveness of aminophylline in the treatment of apnea of prematurity was evaluated in 13 premature infants (mean birthweight, 1." | 3.65 | Treatment of apnea of prematurity with aminophylline. ( Bednarek, FJ; Roloff, DW, 1976) |
| "Respirations and apnea were recorded through an arterial catheter and observed simultaneously in 13 premature infants." | 3.65 | Apnea in premature infants: recording by arterial catheter. ( Belgaumkar, TK; Scott, KE, 1976) |
| "Twelve premature infants with primary apnea were treated with theophylline as an alternative to mechanical ventilation." | 3.65 | Treatment of severe apnea in prematures with orally administered theophylline. ( Shapiro, DL; Smith, B; Uauy, R; Warshaw, JB, 1975) |
| " These findings suggest that: (1) the peripheral chemo-receptors are active at least from 28 weeks of gestation and are probably not important in triggering periodic breathing or apnea in preterm infants, and (2) the preterm infant matures his response to hypoxia and is able to sustain hyperventilation with low oxygen by 18 days of age." | 3.65 | Chemoreceptor reflexes in preterm infants: I. The effect of gestational and postnatal age on the ventilatory response to inhalation of 100% and 15% oxygen. ( Brady, JP; de la Torre Verduzco, R; Rigatto, H, 1975) |
| "Two premature infants had frequent episodes of prolonged apnea." | 3.65 | Bradycardia preceding apneic attacks in low-birthweight infants. The relationship and management. ( Chen, JW; DuBrow, IW; Wong, PW, 1976) |
| " Fifteen of these infants had idiopathic apnea." | 3.65 | Urinary biogenic amines in idiopathic apnea of prematurity. ( Fanaroff, AA; Kattwinkel, J; Klaus, MH; Mars, H, 1976) |
| "If caffeine was found to have a greater effect, this would influence prescribing habits." | 2.69 | Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. ( Fang, S; Gamsu, HR; Greenough, A; Marsden, JT; Peters, TJ; Sherwood, RA, 1998) |
| "The incidence of inguinal hernia is higher in premature infants, particularly in low birth weight neonates." | 2.69 | Postoperative outcome in high-risk infants undergoing herniorrhaphy: comparison between spinal and general anaesthesia. ( Collins, G; Gaitini, L; Mogilner, G; Sabo, E; Somri, M; Vaida, S, 1998) |
| "Inguinal hernia is the most common condition requiring early surgery, appearing in 38% of infants whose birth weight is between 751 grams and 1000 grams." | 2.52 | Regional (spinal, epidural, caudal) versus general anaesthesia in preterm infants undergoing inguinal herniorrhaphy in early infancy. ( Badawi, N; Craven, PD; Foster, JP; Jones, LJ; Lakkundi, A, 2015) |
| "Caffeine citrate was used in extremely premature infants at younger gestation, at higher doses, and for longer durations than recommended on the drug label." | 1.51 | Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants. ( Bendel-Stenzel, E; Chhabra, R; Harper, B; Ku, L; Laughon, M; Moya, F; Payne, EH; Puia-Dumitrescu, M; Smith, PB; Soriano, A; Wade, KC; Zhao, J, 2019) |
| "To identify dosing strategies that will assure stable caffeine concentrations in preterm neonates despite changing caffeine clearance during the first 8 weeks of life." | 1.46 | Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates. ( Datta, AN; Jost, K; Koch, G; Pfister, M; Schulzke, SM; van den Anker, J, 2017) |
| "Doxapram treatment influences aEEG in preterm infants, showing higher percentages of continuous activity as well as more electrographic seizure activity and less sleep-wake cycling." | 1.40 | Amplitude-integrated electroencephalography shows that doxapram influences the brain activity of preterm infants. ( Berger, A; Czaba-Hnizdo, C; Klebermass-Schrehof, K; Olischar, M; Rona, Z; Weninger, M, 2014) |
| "Doxapram-treated infants were significantly younger and had a lower birth weight." | 1.39 | Doxapram and hypokalaemia in very preterm infants. ( Ferdynus, C; Fischer, C; Gouyon, JB; Semama, DS, 2013) |
| "Viral bronchiolitis is the most common lower respiratory tract infection in children less than 12 months of age." | 1.39 | Medical retrieval and needs of infants with bronchiolitis: an analysis by gestational age. ( Davis, PG; Fleming, PF; Kamlin, CO; Richards, S; Sokol, J; Stewart, M; Waterman, K, 2013) |
| "A discharge diagnosis of GERD was most common (n = 154, 49%); 138 (89%) were initially well appearing, 10 (6%) had in-hospital events, and only 20 (13%) had upper gastrointestinal series performed." | 1.38 | Apparent life-threatening event admissions and gastroesophageal reflux disease: the value of hospitalization. ( Bernard-Stover, L; Castillo, E; Doshi, A; Kuelbs, C; Stucky, E, 2012) |
| "To describe the occurrence of serious bacterial infections (SBIs) in well-appearing, afebrile infants aged 60 days or younger with an apparent life-threatening event (ALTE)." | 1.35 | Occurrence of serious bacterial infection in infants aged 60 days or younger with an apparent life-threatening event. ( Pitetti, RD; Zomorrodi, A; Zuckerbraun, NS, 2009) |
| "Apnoea, bradycardia and hypoxemia occur frequently in extremely preterm infants, yet there is little longitudinal data describing cardiorespiratory development in these infants." | 1.35 | Cardiorespiratory development in extremely preterm infants: vulnerability to infection and persistence of events beyond term-equivalent age. ( Herlenius, E; Hofstetter, AO; Katz-Salamon, M; Legnevall, L, 2008) |
| " A review of the literature reveals that when used in young infants brimonidine eye drops can potentially have toxic effects on the central nervous system (e." | 1.34 | [Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma]. ( Heimann, K; Hoernchen, H; Merz, U; Peschgens, T; Wenzl, T, 2007) |
| "Brain abscess and hypoxemia were thought to be serious complications resulting from CAPV and were successfully corrected by living donor liver transplantation at the age of 4 months." | 1.33 | Successful liver transplantation for congenital absence of the portal vein complicated by intrapulmonary shunt and brain abscess. ( Doi, H; Haga, H; Kamei, H; Kasahara, M; Ogawa, K; Ogura, Y; Ohnishi, Y; Tanaka, K; Ueda, M; Yoshitoshi, EY, 2005) |
| "Early grade 2-3 neonatal encephalopathy occurred with much the same frequency (0." | 1.33 | Can all neonatal resuscitation be managed by nurse practitioners? ( Chan, LC; Hey, E, 2006) |
| " The data were analysed for three dosage groups (<0." | 1.33 | Morphine-related apnoea in CPAP-treated preterm neonates. ( Enders, J; Gebauer, C; Knüpfer, M; Pulzer, F; Robel-Tillig, E, 2006) |
| " In this study various indices of HRV were compared pre- and postmethylxanthine dosing in 22 infants (aged 24-36 weeks)." | 1.29 | Heart rate variability in premature neonates pre-and postmethylxanthine administration. ( Kibblewhite, DP; Sleigh, JW, 1996) |
| "Airway obstruction is an important factor predisposing to the development of apnoea in preterm infants." | 1.28 | Site of upper airway obstruction in preterm infants with problematical apnoea. ( Milner, AD; Ruggins, NR, 1991) |
| "Caffeine led to an increase in the mean arterial blood pressure on the first 3 days of therapy, but the heart rate did not change." | 1.28 | Cardiovascular effects of caffeine therapy in preterm infants. ( Erickson, R; Sims, ME; Walther, FJ, 1990) |
| "Gastro-oesophageal reflux in very low birthweight infants was studied using a new 1 mm monocrystalline antimony oesophageal pH electrode." | 1.28 | Gastro-oesophageal reflux in preterm infants. ( Booth, IW; Durbin, GM; McNeish, AS; Morgan, ME; Newell, SJ, 1989) |
| "Doxapram infusion was given to five preterm infants in whom therapeutic concentrations of theophylline had failed to control episodes of apnoea." | 1.27 | Idiopathic apnoea of prematurity treated with doxapram and aminophylline. ( Alpan, G; Arad, I; Eyal, F; Patz, D; Sagi, E, 1984) |
| " Other pharmacokinetic indices, although variable, did not exhibit binomial distribution." | 1.27 | Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, GA, 1988) |
| "Caffeine was administered for 3." | 1.27 | Effect of caffeine on pneumogram and apnoea of infancy. ( Anwar, M; Graff, M; Hegyi, T; Hiatt, M; Mojica, N; Mondestin, H; Novo, R, 1986) |
| " Qualitative and quantitative differences in pharmacokinetics and pharmacodynamics of drugs should be considered before dosage regimens can be established." | 1.27 | [Peculiarities of drug therapy in childhood]. ( Kusenbach, G; Reinhardt, D, 1986) |
| " The elevated blood caffeine levels in breast-fed infants was not related to higher daily dosage of caffeine citrate (4." | 1.27 | Delay in caffeine elimination in breast-fed infants. ( Billon, B; Le Guennec, JC, 1987) |
| "Caffeine half-life was greatly increased in two infants who had cholestatic hepatitis secondary to prolonged parenteral alimentation and one infant who was breast-fed exclusively." | 1.27 | Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. ( Billon, B; Le Guennec, JC; Paré, C, 1985) |
| " At the moment, xanthines are the drugs of choice, since they are both effective and safe, provided dosage is adjusted to each patient." | 1.26 | [Drug treatment of apnoea in premature infants (author's transl)]. ( Klethi, J; Mack, G; Messer, J; Willard, D, 1981) |
| " Bioavailability up to 7 h after administration was determined from the serum concentration-time course." | 1.26 | Influence of food intake on bioavailability of theophylline in premature infants. ( Bergt, U; Heimann, G; Murgescu, J, 1982) |
| " The mean plasma half-live of theophylline was 22." | 1.26 | [Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981) |
| "Doxapram was detected by mass spectrometry for blood and plasma assays, and by flame ionisation for urine assays." | 1.26 | Quantitation of doxapram in blood, plasma and urine. ( Moore, RG; Nichol, H; Thomas, J; Vine, J, 1980) |
| "Caffeine was detectable in plasma at birth, and in preterm infants not receiving theophylline; plasma levels of caffeine tended to be similar to the levels in their mothers' milk." | 1.26 | Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. ( Brazier, JL; Renaud, H; Ribon, B; Salle, BL, 1979) |
| "Retrolental fibroplasia is a condition that principally affects low birth weight premature babies in whom oxygen therapy has not been adequately controlled." | 1.26 | [Present status of retrolental fibroplasia in France]. ( Bethenod, M; Gerhard, JP; Messer, J; Willard, D, 1979) |
| "), a value similar to that of children, but the half-life (30." | 1.26 | Pharmacokinetic aspects of theophylline in premature newborns. ( Aranda, JV; Loughnan, PM; Neims, AH; Parsons, WD; Sitar, DS, 1976) |
| "16% from Apnoe and approx." | 1.25 | [Infants of low birth weight after deliveries, morbidity and mortality (author's transl)]. ( Hohlweg-Majert, P; Kauert, S, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 296 (42.11) | 18.7374 |
| 1990's | 91 (12.94) | 18.2507 |
| 2000's | 127 (18.07) | 29.6817 |
| 2010's | 138 (19.63) | 24.3611 |
| 2020's | 51 (7.25) | 2.80 |
| Authors | Studies |
|---|---|
| Duchamp-Viret, P | 1 |
| Nguyen, HK | 1 |
| Maucort-Boulch, D | 1 |
| Remontet, L | 1 |
| Guyon, A | 1 |
| Franco, P | 1 |
| Cividjian, A | 1 |
| Thevenet, M | 1 |
| Iwaz, J | 1 |
| Galletti, S | 1 |
| Kassai, B | 1 |
| Cornaton, E | 1 |
| Plaisant, F | 1 |
| Claris, O | 1 |
| Gauthier-Moulinier, H | 1 |
| Bürgin, C | 1 |
| Simmen, P | 1 |
| Gupta, N | 1 |
| Suter, L | 1 |
| Kreuzer, S | 1 |
| Haeberlin, A | 1 |
| Schulzke, SM | 2 |
| Trachsel, D | 1 |
| Niederhauser, T | 1 |
| Jost, K | 2 |
| Saini, SS | 1 |
| Kumar, P | 2 |
| Pergolizzi, JV | 2 |
| Fort, P | 2 |
| Miller, TL | 2 |
| LeQuang, JA | 2 |
| Raffa, RB | 2 |
| Ariagno, S | 1 |
| Thorvilson, M | 1 |
| Andersen, L | 1 |
| Collura, C | 1 |
| Lim, K | 3 |
| Cramer, SJE | 2 |
| Te Pas, AB | 5 |
| Gale, TJ | 3 |
| Dargaville, PA | 3 |
| Varisco, G | 1 |
| Lensen, I | 1 |
| Kommers, D | 1 |
| Andriessen, P | 1 |
| Bovendeerd, P | 1 |
| van Pul, C | 1 |
| Yuan, Y | 1 |
| Yang, Y | 1 |
| Lei, X | 1 |
| Dong, W | 1 |
| Krajcar, N | 1 |
| Marić, LS | 1 |
| Roglić, S | 1 |
| Tešović, G | 1 |
| Kandpal, J | 1 |
| Priyadarshi, M | 1 |
| Chaurasia, S | 1 |
| Singh, P | 1 |
| Basu, S | 1 |
| Chavez, L | 1 |
| Bancalari, E | 9 |
| Xie, JB | 1 |
| Lin, XZ | 1 |
| Martin, RJ | 25 |
| Mitchell, LJ | 1 |
| MacFarlane, PM | 2 |
| Miao, Y | 1 |
| Zhou, Y | 1 |
| Zhao, S | 1 |
| Liu, W | 1 |
| Wang, A | 1 |
| Zhang, Y | 1 |
| Li, Y | 1 |
| Jiang, H | 1 |
| García-Robles, A | 1 |
| Solaz-García, Á | 1 |
| Verdú-Andrés, J | 1 |
| Andrés, JLP | 1 |
| Cañada-Martínez, AJ | 1 |
| Pericás, CC | 1 |
| Ponce-Rodriguez, HD | 1 |
| Vento, M | 1 |
| González, PS | 1 |
| Richmond, CM | 1 |
| Ring, F | 1 |
| Richmond, L | 1 |
| Rossouw, E | 1 |
| Ballard, E | 1 |
| Birch, P | 1 |
| Yee, AK | 2 |
| Siriwardhana, LS | 2 |
| Nixon, GM | 4 |
| Walter, LM | 2 |
| Wong, FY | 2 |
| Horne, RSC | 2 |
| Prakash, R | 2 |
| Bruschettini, M | 3 |
| Brattström, P | 1 |
| Russo, C | 1 |
| Onland, W | 4 |
| Davis, PG | 13 |
| Soll, R | 1 |
| Kuypers, KLAM | 1 |
| Hopman, A | 1 |
| Dekker, J | 1 |
| Visser, R | 1 |
| Hooper, SB | 2 |
| Schmidt, B | 13 |
| Gottlob, S | 1 |
| Gille, C | 1 |
| Poets, CF | 18 |
| Falsaperla, R | 1 |
| Vitaliti, G | 1 |
| Cimino, C | 1 |
| Catanzaro, S | 1 |
| Corsello, G | 1 |
| Maeda, T | 1 |
| Sekiguchi, K | 1 |
| Wasada, R | 1 |
| Ihara, K | 1 |
| Makarenko, VV | 1 |
| Peng, YJ | 1 |
| Khan, SA | 1 |
| Nanduri, J | 1 |
| Fox, AP | 1 |
| Prabhakar, NR | 1 |
| Rostas, SE | 1 |
| McPherson, C | 1 |
| Johansson, M | 2 |
| Juhl Jørgensen, K | 1 |
| Ji, D | 1 |
| Smith, PB | 2 |
| Clark, RH | 1 |
| Zimmerman, KO | 1 |
| Laughon, M | 2 |
| Ku, L | 2 |
| Greenberg, RG | 1 |
| Nylander Vujovic, S | 1 |
| Nava, C | 1 |
| Lavanga, M | 1 |
| Naulaers, G | 2 |
| Van Huffel, S | 1 |
| Wel, O | 1 |
| Caicedo, A | 1 |
| Deviaene, M | 1 |
| Moeyersons, J | 1 |
| Varon, C | 1 |
| Bollen, B | 1 |
| Jansen, K | 1 |
| Ortibus, E | 1 |
| Chung, J | 1 |
| Tran Lopez, K | 1 |
| Amendolia, B | 1 |
| Bhat, V | 1 |
| Nakhla, T | 1 |
| Slater-Myer, L | 1 |
| Saslow, J | 1 |
| Aghai, ZH | 1 |
| Alhersh, E | 1 |
| Abushanab, D | 1 |
| Al-Shaibi, S | 1 |
| Al-Badriyeh, D | 1 |
| He, T | 1 |
| Liao, ZC | 1 |
| Ding, Y | 1 |
| Wang, MJ | 1 |
| Li, W | 1 |
| Gan, JM | 1 |
| Yue, SJ | 1 |
| Liu, S | 1 |
| Zhang, X | 2 |
| Liu, Y | 1 |
| Yuan, X | 1 |
| Yang, L | 1 |
| Zhang, R | 1 |
| Wang, X | 1 |
| Xu, F | 1 |
| Zhu, C | 1 |
| Guo, A | 1 |
| Zhu, Z | 1 |
| Xue, J | 1 |
| Di, X | 1 |
| Fan, J | 1 |
| Huang, L | 1 |
| Zhao, P | 1 |
| Hu, X | 1 |
| Xie, H | 1 |
| Salaün, JP | 1 |
| de Queiroz, M | 1 |
| Orliaguet, G | 1 |
| Gileles-Hillel, A | 1 |
| Erlichman, I | 1 |
| Reiter, J | 1 |
| Eventov-Friedman, S | 1 |
| Synnes, A | 1 |
| Grunau, RE | 4 |
| Cheong, JLY | 2 |
| Doyle, LW | 12 |
| Saroha, V | 2 |
| Patel, RM | 2 |
| Eichenwald, EC | 6 |
| Ekhaguere, OA | 1 |
| Ayede, AI | 1 |
| Ezeaka, CV | 1 |
| Aranda, JV | 12 |
| Beharry, KD | 1 |
| Hartley, C | 1 |
| Baxter, L | 1 |
| Moultrie, F | 1 |
| Purdy, R | 1 |
| Bhatt, A | 1 |
| Rogers, R | 1 |
| Patel, C | 1 |
| Adams, E | 1 |
| Slater, R | 1 |
| Singh, M | 3 |
| Mukherjee, A | 1 |
| Sankhyan, N | 1 |
| Panigrahi, I | 1 |
| Sabsabi, B | 1 |
| Harrison, A | 1 |
| Banfield, L | 1 |
| Mukerji, A | 1 |
| Pournami, F | 1 |
| Prabhakar, J | 1 |
| Nandakumar, A | 1 |
| Nair, PMC | 1 |
| Jain, N | 1 |
| Engbers, AGJ | 1 |
| Völler, S | 1 |
| Knibbe, CAJ | 1 |
| Reiss, IKM | 1 |
| Koch, BCP | 1 |
| Flint, RB | 1 |
| Simons, SHP | 1 |
| Erickson, G | 1 |
| Dobson, NR | 2 |
| Hunt, CE | 4 |
| Conlon, S | 1 |
| Di Fiore, JM | 7 |
| Elmowafi, M | 1 |
| Mohsen, N | 1 |
| Nour, I | 2 |
| Nasef, N | 2 |
| Eastwood-Sutherland, C | 1 |
| Marshall, AP | 2 |
| Mohd Kori, AM | 1 |
| Van Rostenberghe, H | 1 |
| Ibrahim, NR | 1 |
| Yaacob, NM | 1 |
| Nasir, A | 1 |
| Sullivan, BA | 1 |
| Slevin, CC | 1 |
| Ahmad, SM | 1 |
| Sinkin, RA | 1 |
| Fairchild, KD | 2 |
| Roberts, RS | 9 |
| Anderson, PJ | 3 |
| Asztalos, EV | 3 |
| Costantini, L | 3 |
| Dewey, D | 2 |
| D'Ilario, J | 3 |
| Moddemann, D | 3 |
| Nelson, H | 2 |
| Ohlsson, A | 4 |
| Solimano, A | 4 |
| Tin, W | 5 |
| Shivakumar, M | 3 |
| Jayashree, P | 2 |
| Najih, M | 1 |
| Lewis, LES | 3 |
| Bhat Y, R | 1 |
| Kamath, A | 2 |
| Shashikala, - | 1 |
| Bhat, L | 1 |
| Bisht, S | 1 |
| Parga, JJ | 1 |
| Bhatt, RR | 1 |
| Kesavan, K | 2 |
| Sim, MS | 1 |
| Karp, HN | 1 |
| Harper, RM | 2 |
| Zeltzer, L | 1 |
| Goryniak, A | 1 |
| Szczęśniak, A | 1 |
| Śleboda, D | 1 |
| Dołęgowska, B | 1 |
| Ranganathan, S | 1 |
| Koch, G | 1 |
| Datta, AN | 1 |
| van den Anker, J | 1 |
| Pfister, M | 1 |
| O'Halloran, KD | 2 |
| McDonald, FB | 2 |
| Khurana, S | 1 |
| Sujith Kumar Reddy, GV | 1 |
| Ramesh Bhat, Y | 1 |
| Chalwadi, UK | 1 |
| Kalappanavar, NK | 1 |
| Simon Lewis, LE | 1 |
| Vliegenthart, R | 1 |
| Miedema, M | 1 |
| Hutten, GJ | 2 |
| van Kaam, AH | 4 |
| Dix, LML | 1 |
| van Bel, F | 2 |
| Baerts, W | 1 |
| Lemmers, PMA | 1 |
| Mürner-Lavanchy, IM | 1 |
| Ye, C | 1 |
| Miao, C | 1 |
| Yu, L | 1 |
| Dong, Z | 1 |
| Zhang, J | 1 |
| Mao, Y | 1 |
| Lu, X | 1 |
| Lyu, Q | 1 |
| Sharma, P | 2 |
| Davis, NL | 1 |
| Dempsey, EM | 1 |
| M, S | 1 |
| Nayak, K | 1 |
| Purkayastha, J | 1 |
| Scala, M | 2 |
| Seo, S | 1 |
| Lee-Park, J | 1 |
| McClure, C | 1 |
| Palafoutas, JJ | 1 |
| Abubakar, K | 1 |
| de Waal, CG | 1 |
| Kraaijenga, JV | 1 |
| de Jongh, FH | 1 |
| Gee, AH | 1 |
| Chang, J | 2 |
| Ghosh, J | 1 |
| Paydarfar, D | 4 |
| Álvarado Socarras, JL | 1 |
| Jain, VG | 1 |
| Jobe, A | 1 |
| Puia-Dumitrescu, M | 1 |
| Zhao, J | 1 |
| Soriano, A | 1 |
| Payne, EH | 1 |
| Harper, B | 1 |
| Bendel-Stenzel, E | 1 |
| Moya, F | 2 |
| Chhabra, R | 1 |
| Wade, KC | 1 |
| Ali, SK | 1 |
| Schutzman, DL | 1 |
| Salvador, A | 1 |
| Janeczko, M | 1 |
| Weisberg, L | 1 |
| Tran, N | 1 |
| Porat, R | 1 |
| Anderson, J | 1 |
| Noori, K | 1 |
| Morris, SA | 1 |
| Fischer, C | 1 |
| Ferdynus, C | 1 |
| Gouyon, JB | 1 |
| Semama, DS | 1 |
| Djeddi, D | 1 |
| Cantin, D | 1 |
| Samson, N | 1 |
| Tian, H | 1 |
| Praud, JP | 1 |
| Vergales, BD | 1 |
| Paget-Brown, AO | 1 |
| Lee, H | 1 |
| Guin, LE | 1 |
| Smoot, TJ | 1 |
| Rusin, CG | 1 |
| Clark, MT | 1 |
| Delos, JB | 1 |
| Lake, DE | 1 |
| Moorman, R | 1 |
| Kattwinkel, J | 6 |
| Elder, DE | 1 |
| Campbell, AJ | 1 |
| Galletly, D | 1 |
| Wilson, CG | 2 |
| Gauda, EB | 3 |
| Williamson, JR | 1 |
| Bliss, DW | 1 |
| Ozdemir, T | 1 |
| Arıkan, A | 1 |
| Abu Jawdeh, EG | 2 |
| Filippa, M | 1 |
| Devouche, E | 1 |
| Arioni, C | 1 |
| Imberty, M | 1 |
| Gratier, M | 1 |
| Chioukh, FZ | 1 |
| Ben Hmida, H | 1 |
| Ben Ameur, K | 1 |
| Toumi, A | 1 |
| Monastiri, K | 1 |
| Kumar, M | 3 |
| Chawla, R | 1 |
| Haloi, P | 1 |
| Laptook, AR | 1 |
| O'Riordan, M | 1 |
| Limrungsikul, A | 1 |
| Bandyopadhyay, A | 1 |
| Argus, BM | 1 |
| Nakad, PE | 1 |
| Supapannachart, S | 1 |
| Yunis, KA | 1 |
| Selbst, SM | 2 |
| Vatlach, S | 1 |
| Arand, J | 1 |
| Engel, C | 1 |
| Schoen, K | 1 |
| Yu, T | 1 |
| Stockmann, C | 1 |
| Spigarelli, MG | 1 |
| Sherwin, CM | 1 |
| Zhou, JJ | 1 |
| Zhang, P | 1 |
| Cheng, GQ | 1 |
| van Zanten, HA | 1 |
| Tan, RN | 1 |
| Thio, M | 1 |
| de Man-van Ginkel, JM | 1 |
| van Zwet, EW | 1 |
| Lopriore, E | 1 |
| Ulanovsky, I | 1 |
| Haleluya, NS | 1 |
| Blazer, S | 1 |
| Weissman, A | 1 |
| Czaba-Hnizdo, C | 1 |
| Olischar, M | 1 |
| Rona, Z | 1 |
| Weninger, M | 1 |
| Berger, A | 1 |
| Klebermass-Schrehof, K | 1 |
| Tong, X | 1 |
| Xue, X | 1 |
| Fu, J | 1 |
| Kreutzer, K | 1 |
| Bassler, D | 1 |
| Marcus, CL | 2 |
| Meltzer, LJ | 1 |
| Traylor, J | 1 |
| Dix, J | 1 |
| Asztalos, E | 2 |
| Opie, G | 1 |
| Biggs, SN | 1 |
| Narang, I | 1 |
| Bhattacharjee, R | 1 |
| Davey, M | 1 |
| Horne, RS | 1 |
| Cheshire, M | 1 |
| Gibbons, J | 1 |
| Bradford, R | 1 |
| Amin, SB | 3 |
| Bhutani, VK | 1 |
| Watchko, JF | 1 |
| Khan, SR | 1 |
| Gizzi, C | 1 |
| Montecchia, F | 1 |
| Panetta, V | 1 |
| Castellano, C | 1 |
| Mariani, C | 1 |
| Campelli, M | 1 |
| Papoff, P | 1 |
| Moretti, C | 2 |
| Agostino, R | 2 |
| Araujo, P | 1 |
| Tufik, S | 1 |
| Andersen, ML | 1 |
| Camargo, VC | 1 |
| Honorato da Silva, S | 1 |
| Freitas de Amorim, M | 1 |
| Nohama, P | 1 |
| Mohammed, S | 1 |
| Shabaan, AE | 1 |
| Shouman, B | 1 |
| Abdel-Hady, H | 1 |
| Duggan, EM | 1 |
| Patel, VP | 1 |
| Blakely, ML | 1 |
| Förster, KM | 1 |
| Immler, S | 1 |
| Ensslen, M | 1 |
| Flemmer, A | 1 |
| Schulze, A | 2 |
| von Poblotzki, M | 1 |
| Genzel-Boroviczény, O | 1 |
| Heinen, F | 1 |
| Hilgendorff, A | 1 |
| Jones, LJ | 1 |
| Craven, PD | 1 |
| Lakkundi, A | 1 |
| Foster, JP | 3 |
| Badawi, N | 1 |
| Gauda, E | 3 |
| MacFarlane, P | 2 |
| Smith, VC | 2 |
| Kelty-Stephen, D | 1 |
| Qureshi Ahmad, M | 1 |
| Mao, W | 2 |
| Cakert, K | 1 |
| Osborne, J | 1 |
| Ishihara, C | 1 |
| Ibara, S | 1 |
| Ohsone, Y | 1 |
| Kato, E | 1 |
| Tokuhisa, T | 1 |
| Yamamoto, Y | 1 |
| Maede, Y | 1 |
| Kuwahara, T | 1 |
| Minakami, H | 1 |
| Bilgin, H | 1 |
| Eren, A | 1 |
| Kara, S | 1 |
| Zhao, Y | 1 |
| Tian, X | 1 |
| Liu, G | 2 |
| Lista, G | 1 |
| Fabbri, L | 1 |
| Polackova, R | 1 |
| Kiechl-Kohlendorfer, U | 1 |
| Papagaroufalis, K | 1 |
| Saenz, P | 1 |
| Ferrari, F | 1 |
| Lasagna, G | 1 |
| Carnielli, VP | 1 |
| Molokhia, E | 1 |
| Perkins, A | 1 |
| McArdle, AJ | 1 |
| Mugisha, G | 1 |
| Birahinduka, D | 1 |
| Veit, L | 1 |
| Amberson, M | 1 |
| Freiberger, C | 1 |
| Montenegro, B | 1 |
| Mukhopadhyay, S | 1 |
| Rhein, LM | 1 |
| Ten Hove, CH | 2 |
| Vliegenthart, RJ | 2 |
| Brouwer, E | 1 |
| Rijken, M | 1 |
| van Wassenaer-Leemhuis, AG | 1 |
| Armanian, AM | 1 |
| Iranpour, R | 1 |
| Faghihian, E | 1 |
| Salehimehr, N | 1 |
| Morton, SU | 1 |
| Frank, P | 1 |
| Cordero, DM | 1 |
| Benharash, P | 1 |
| Kondo, T | 1 |
| Kondo, Y | 1 |
| Orita, Y | 1 |
| Mitarai, F | 1 |
| Ishitsuka, Y | 1 |
| Irikura, M | 1 |
| Shimodozono, Y | 1 |
| Douchi, T | 1 |
| Takeda, Y | 1 |
| Irie, T | 1 |
| Plumb, LA | 1 |
| Van't Hoff, W | 1 |
| Kleta, R | 1 |
| Reid, C | 1 |
| Ashton, E | 1 |
| Samuels, M | 1 |
| Bockenhauer, D | 1 |
| Greze, E | 1 |
| Benard, M | 1 |
| Hamon, I | 1 |
| Casper, C | 1 |
| Haddad, FE | 1 |
| Boutroy, MJ | 5 |
| Hascoët, JM | 2 |
| Chen, C | 1 |
| Shu, XX | 1 |
| Yang, XY | 1 |
| Shi, J | 1 |
| Tang, J | 1 |
| Mu, DZ | 1 |
| Maheux, A | 1 |
| Pladys, P | 1 |
| Laviolle, B | 1 |
| Ballout, RA | 1 |
| Kahale, LA | 1 |
| Badr, L | 1 |
| Ndour, D | 1 |
| Al-Saif, S | 1 |
| Alvaro, R | 4 |
| Manfreda, J | 2 |
| Kwiatkowski, K | 7 |
| Cates, D | 5 |
| Qurashi, M | 1 |
| Rigatto, H | 15 |
| Mimica, AF | 1 |
| dos Santos, AM | 1 |
| da Cunha, DH | 1 |
| Guinsburg, R | 1 |
| Bordin, JO | 1 |
| Chiba, A | 1 |
| Barros, MM | 1 |
| Kopelman, BI | 1 |
| Paul, K | 1 |
| Melichar, J | 1 |
| Miletín, J | 1 |
| Dittrichová, J | 1 |
| Abu-Shaweesh, JM | 4 |
| Corvaglia, L | 3 |
| Zama, D | 2 |
| Gualdi, S | 1 |
| Ferlini, M | 1 |
| Aceti, A | 3 |
| Faldella, G | 3 |
| Omari, TI | 1 |
| Al-Kindy, HA | 1 |
| Gélinas, JF | 1 |
| Hatzakis, G | 1 |
| Côté, A | 1 |
| Jasin, LR | 1 |
| Kern, S | 1 |
| Thompson, S | 1 |
| Walter, C | 1 |
| Rone, JM | 1 |
| Yohannan, MD | 1 |
| Soloveychik, V | 1 |
| Bin-Nun, A | 1 |
| Ionchev, A | 1 |
| Sriram, S | 1 |
| Meadow, W | 1 |
| Kim, J | 1 |
| Thornton, J | 1 |
| Eipe, N | 1 |
| Zuckerbraun, NS | 1 |
| Zomorrodi, A | 1 |
| Pitetti, RD | 1 |
| Pantalitschka, T | 1 |
| Sievers, J | 1 |
| Urschitz, MS | 1 |
| Herberts, T | 1 |
| Reher, C | 1 |
| Slocum, C | 2 |
| Arko, M | 3 |
| Di Fiore, J | 2 |
| Hibbs, AM | 3 |
| Silvestri, JM | 1 |
| Bakewell-Sachs, S | 1 |
| Medoff-Cooper, B | 1 |
| Escobar, GJ | 3 |
| Silber, JH | 1 |
| Lorch, SA | 3 |
| Nishiura, H | 1 |
| Kimura, A | 1 |
| Yamato, Y | 1 |
| Aoki, K | 1 |
| Inokuchi, T | 1 |
| Kurosawa, T | 1 |
| Matsuishi, T | 1 |
| Libby, A | 1 |
| Skouroliakou, M | 1 |
| Bacopoulou, F | 1 |
| Markantonis, SL | 1 |
| Haslam, R | 1 |
| Sinha, S | 1 |
| Moriette, G | 3 |
| Lescure, S | 1 |
| El Ayoubi, M | 1 |
| Lopez, E | 1 |
| Barak, S | 1 |
| Kushnir, A | 1 |
| Chulski, E | 1 |
| Miron, D | 1 |
| Henderson-Smart, DJ | 22 |
| Steer, PA | 5 |
| Herynk, B | 1 |
| Martin, R | 1 |
| Ohlin, A | 1 |
| Björkqvist, M | 1 |
| Montgomery, SM | 1 |
| Schollin, J | 1 |
| Winckworth, LC | 1 |
| Powell, E | 1 |
| Bloch-Salisbury, E | 1 |
| Hall, MH | 1 |
| Boyd, T | 1 |
| Bednarek, F | 1 |
| Beharry, K | 1 |
| Valencia, GB | 1 |
| Natarajan, G | 1 |
| Davis, J | 1 |
| Mathew, OP | 5 |
| De Paoli, AG | 4 |
| Dukhovny, D | 1 |
| Kok, JH | 1 |
| Kamholz, KL | 1 |
| Wang, N | 1 |
| Zupancic, JA | 3 |
| Mao, WY | 1 |
| Richardson, DK | 3 |
| McCormick, MC | 1 |
| Lee, SL | 1 |
| Gleason, JM | 1 |
| Sydorak, RM | 1 |
| Owen, LS | 1 |
| Morley, CJ | 2 |
| Dawson, JA | 1 |
| Davis, P | 3 |
| Peel, JL | 1 |
| Klein, M | 1 |
| Flanders, WD | 1 |
| Mulholland, JA | 1 |
| Freed, G | 1 |
| Tolbert, PE | 1 |
| Nunez, J | 1 |
| Cristofalo, E | 1 |
| McGinley, B | 1 |
| Katz, R | 1 |
| Glen, DR | 1 |
| Brockmann, PE | 1 |
| Clifford, V | 1 |
| Crawford, NW | 1 |
| Royle, J | 1 |
| Lazzaro, T | 1 |
| Danchin, M | 1 |
| Perrett, KP | 1 |
| Lee, KJ | 1 |
| Buttery, JP | 1 |
| Spizzichino, M | 2 |
| Mariani, E | 2 |
| Legnani, E | 2 |
| Srinivasan, L | 1 |
| Betts, KS | 1 |
| Brown, MK | 1 |
| DiBlasi, RM | 1 |
| Doheny, L | 1 |
| Hurwitz, S | 1 |
| Insoft, R | 1 |
| Ringer, S | 1 |
| Lahav, A | 1 |
| Doshi, A | 1 |
| Bernard-Stover, L | 1 |
| Kuelbs, C | 1 |
| Castillo, E | 1 |
| Stucky, E | 1 |
| Buijs, SC | 1 |
| Boersma, B | 1 |
| Raju, TN | 1 |
| Spitzer, AR | 4 |
| van Vonderen, JJ | 1 |
| Siew, ML | 1 |
| de Boer, MA | 1 |
| Walther, FJ | 2 |
| Shin, MS | 1 |
| Shim, JO | 1 |
| Moon, JS | 1 |
| Kim, HS | 1 |
| Ko, JS | 1 |
| Choi, JH | 2 |
| Seo, JK | 1 |
| Bredemeyer, SL | 1 |
| Cesar, K | 1 |
| Iolster, T | 1 |
| White, D | 1 |
| Latifi, S | 1 |
| Ribeiro, AP | 1 |
| Shirahata, M | 1 |
| Mason, A | 1 |
| Pichard, LE | 1 |
| Kostuk, EW | 1 |
| Chavez-Valdez, R | 1 |
| Bensouda, B | 1 |
| Tarazi, SE | 1 |
| Ali, N | 1 |
| Mandel, R | 1 |
| Sant'Anna, GM | 1 |
| Vagedes, J | 1 |
| Dietz, K | 1 |
| Picone, S | 1 |
| Bedetta, M | 1 |
| Paolillo, P | 1 |
| Martini, S | 1 |
| Battistini, B | 1 |
| Fleming, PF | 1 |
| Richards, S | 1 |
| Waterman, K | 1 |
| Kamlin, CO | 1 |
| Stewart, M | 1 |
| Sokol, J | 1 |
| Burnell, E | 1 |
| O'Brien, BJ | 1 |
| Weinstein, MC | 1 |
| Slack, MH | 1 |
| Schapira, C | 1 |
| Thwaites, RJ | 1 |
| Andrews, N | 1 |
| Schapira, D | 1 |
| MILLER, HC | 2 |
| BEHRLE, FC | 2 |
| SMULL, NW | 1 |
| KERR, M | 1 |
| GLEISS, J | 1 |
| TIZARD, JP | 1 |
| HAWORTH, JC | 1 |
| MCRAE, KN | 1 |
| REID, DH | 1 |
| TUNSTALL, ME | 1 |
| As-Sanie, S | 1 |
| Mercer, B | 1 |
| Moore, J | 1 |
| Tamim, H | 1 |
| Khogali, M | 1 |
| Beydoun, H | 1 |
| Melki, I | 1 |
| Yunis, K | 1 |
| Yamamoto, A | 1 |
| Yokoyama, N | 1 |
| Yonetani, M | 1 |
| Uetani, Y | 1 |
| Nakamura, H | 1 |
| Nakao, H | 1 |
| Baird, TM | 2 |
| Kabra, NS | 2 |
| Paes, B | 2 |
| McLemore, GL | 1 |
| Tolosa, J | 1 |
| Marston-Nelson, J | 1 |
| Kwak, D | 1 |
| Millar, D | 1 |
| Bohnhorst, B | 4 |
| Geuting, T | 1 |
| Peter, CS | 3 |
| Dördelmann, M | 2 |
| Wilken, B | 1 |
| Islam, SI | 1 |
| Ali, AS | 1 |
| Sheikh, AA | 1 |
| Fida, NM | 1 |
| Roll, C | 1 |
| Horsch, S | 1 |
| McNamara, DG | 1 |
| Anderson, BJ | 1 |
| Janvier, A | 1 |
| Khairy, M | 1 |
| Kokkotis, A | 1 |
| Cormier, C | 1 |
| Messmer, D | 1 |
| Barrington, KJ | 8 |
| Gill, D | 1 |
| Henderson-Smart, D | 1 |
| Steer, P | 7 |
| Haxhiu, MA | 1 |
| Marlier, L | 2 |
| Gaugler, C | 2 |
| Messer, J | 4 |
| Molloy, EJ | 1 |
| Smith, RK | 1 |
| Elias-Jones, AC | 1 |
| Charafeddine, L | 1 |
| Guillet, R | 1 |
| Schulzke, S | 1 |
| Heininger, U | 1 |
| Lücking-Famira, M | 1 |
| Fahnenstich, H | 1 |
| Bell, EF | 1 |
| Strauss, RG | 1 |
| Widness, JA | 1 |
| Mahoney, LT | 1 |
| Mock, DM | 1 |
| Seward, VJ | 1 |
| Cress, GA | 1 |
| Johnson, KJ | 1 |
| Kromer, IJ | 1 |
| Zimmerman, MB | 1 |
| Ohnishi, Y | 1 |
| Ueda, M | 1 |
| Doi, H | 1 |
| Kasahara, M | 1 |
| Haga, H | 1 |
| Kamei, H | 1 |
| Ogawa, K | 1 |
| Ogura, Y | 1 |
| Yoshitoshi, EY | 1 |
| Tanaka, K | 2 |
| Stokowski, LA | 1 |
| Chan, LC | 1 |
| Hey, E | 1 |
| Dani, C | 2 |
| Bertini, G | 2 |
| Pezzati, M | 1 |
| Pratesi, S | 2 |
| Filippi, L | 1 |
| Tronchin, M | 2 |
| Rubaltelli, FF | 2 |
| Whitehouse, M | 1 |
| Kimball, A | 1 |
| Rieger-Fackeldey, E | 1 |
| Hofmiller, A | 1 |
| del Moral, T | 1 |
| Finer, NN | 8 |
| Higgins, R | 1 |
| Lee, J | 1 |
| Robinson, JL | 1 |
| Spady, DW | 1 |
| Ducrocq, S | 2 |
| Biran-Mucignat, V | 2 |
| Lebas, F | 2 |
| Baudon, JJ | 2 |
| Gold, F | 2 |
| Boelle, PY | 1 |
| Enders, J | 2 |
| Gebauer, C | 2 |
| Pulzer, F | 2 |
| Robel-Tillig, E | 2 |
| Knüpfer, M | 2 |
| Coulter, DM | 1 |
| Hand, IL | 1 |
| Noble, LM | 1 |
| Greisen, G | 2 |
| Willwerth, BM | 1 |
| Harper, MB | 1 |
| Greenes, DS | 1 |
| Heimann, K | 1 |
| Peschgens, T | 1 |
| Merz, U | 1 |
| Hoernchen, H | 1 |
| Wenzl, T | 1 |
| Pillekamp, F | 1 |
| Hermann, C | 1 |
| Keller, T | 1 |
| von Gontard, A | 1 |
| Kribs, A | 1 |
| Roth, B | 1 |
| Daniels, H | 2 |
| Allegaert, K | 1 |
| Rayyan, M | 1 |
| Debeer, A | 1 |
| Devlieger, H | 1 |
| Orenstein, SR | 1 |
| Kachko, L | 1 |
| Simhi, E | 1 |
| Tzeitlin, E | 1 |
| Efrat, R | 1 |
| Tarabikin, E | 1 |
| Peled, E | 1 |
| Metzner, I | 1 |
| Katz, J | 1 |
| López Guinea, A | 1 |
| Casado Flores, J | 1 |
| Martín Sobrino, MA | 1 |
| Espínola Docio, B | 1 |
| de la Calle Cabrera, T | 1 |
| Serrano, A | 1 |
| García Teresa, MA | 1 |
| Stevenson, DK | 1 |
| Mishra, S | 1 |
| Agarwal, R | 1 |
| Jeevasankar, M | 1 |
| Aggarwal, R | 2 |
| Deorari, AK | 2 |
| Paul, VK | 2 |
| Hofstetter, AO | 1 |
| Legnevall, L | 1 |
| Herlenius, E | 1 |
| Katz-Salamon, M | 1 |
| Hoppenbrouwers, T | 4 |
| Hodgman, JE | 4 |
| Ramanathan, A | 1 |
| Dorey, F | 1 |
| Murphy, JJ | 1 |
| Swanson, T | 1 |
| Ansermino, M | 1 |
| Milner, R | 1 |
| Sankaran, K | 3 |
| Hindmarsh, KW | 3 |
| Watson, VG | 1 |
| Willard, D | 2 |
| Mack, G | 1 |
| Klethi, J | 1 |
| Bhat, AM | 3 |
| Scanlon, JW | 4 |
| Lavenstein, B | 3 |
| Chuang, L | 3 |
| Karoum, F | 3 |
| Jones, RA | 5 |
| Lukeman, D | 1 |
| Burnard, ED | 2 |
| Todd, DA | 1 |
| John, E | 1 |
| Haley, TJ | 1 |
| Hermier, M | 1 |
| Descos, B | 1 |
| Peters, KL | 3 |
| Duffley, LM | 1 |
| Coward, JH | 1 |
| Brady, JP | 5 |
| Gould, JB | 2 |
| Brown, LW | 1 |
| Weinberger, M | 1 |
| Sagi, E | 3 |
| Eyal, F | 3 |
| Alpan, G | 3 |
| Patz, D | 2 |
| Arad, I | 2 |
| Rosen, CL | 1 |
| Glaze, DG | 1 |
| Frost, JD | 1 |
| Gerhardt, T | 5 |
| Dulock, HL | 1 |
| Gregory, GA | 2 |
| Steward, DJ | 2 |
| Watanabe, K | 1 |
| Hakamada, S | 2 |
| Kuroyanagi, M | 1 |
| Yamazaki, T | 2 |
| Takeuchi, T | 1 |
| Sourgens, H | 1 |
| Staib, AH | 1 |
| Bielicki, M | 1 |
| von Loewenich, V | 1 |
| Outerbridge, EW | 3 |
| Trippenbach, T | 1 |
| François, J | 1 |
| Church, NR | 1 |
| Anas, NG | 1 |
| Hall, CB | 1 |
| Brooks, JG | 1 |
| Springer, C | 1 |
| Goder, K | 1 |
| Fesslová, V | 1 |
| Caccamo, ML | 3 |
| Salice, P | 1 |
| Marimi, A | 1 |
| Neu, J | 1 |
| Tivr, T | 1 |
| Lewis, J | 1 |
| Pettigrew, AG | 1 |
| Campbell, DJ | 1 |
| McCarthy, J | 3 |
| Hörnchen, H | 1 |
| Betz, R | 1 |
| Siller, V | 1 |
| Roebruck, P | 1 |
| Dransfield, DA | 2 |
| Fox, WW | 3 |
| Werthammer, J | 1 |
| Krasner, J | 1 |
| DiBenedetto, J | 1 |
| Stark, AR | 3 |
| Yeaton, HL | 1 |
| Mellish, RW | 1 |
| Avery, ME | 1 |
| Frantz, ID | 1 |
| Lönnerholm, G | 2 |
| Lindström, B | 2 |
| Paalzow, L | 1 |
| Sedin, G | 1 |
| Tudehope, D | 2 |
| Burke, J | 1 |
| Loadsman, T | 1 |
| Hargreaves, DB | 1 |
| Lealman, GT | 1 |
| Mulley, BA | 1 |
| Srinivasan, G | 1 |
| Singh, J | 1 |
| Cattamanchi, G | 1 |
| Yeh, TF | 2 |
| Pildes, RS | 1 |
| Southall, DP | 6 |
| Levitt, GA | 1 |
| Richards, JM | 2 |
| Kong, C | 1 |
| Farndon, PA | 1 |
| Alexander, JR | 1 |
| Wilson, AJ | 1 |
| Gunn, TR | 2 |
| Easdown, J | 1 |
| Suzuki, C | 1 |
| Saito, E | 1 |
| Takenouchi, S | 1 |
| Sakabe, M | 1 |
| Yamaguchi, F | 1 |
| Pörksen, C | 2 |
| Larsen, H | 1 |
| Hürter, P | 2 |
| Marzetti, G | 1 |
| Panero, A | 1 |
| Picece-Bucci, S | 1 |
| Mendicini, M | 1 |
| Colarizi, P | 1 |
| Bucci, G | 1 |
| Roberts, JL | 3 |
| Thach, BT | 9 |
| Tuck, SJ | 1 |
| Monin, P | 4 |
| Duvivier, C | 1 |
| May, T | 1 |
| Vert, P | 6 |
| Gorodischer, R | 1 |
| Karplus, M | 1 |
| Heimann, G | 1 |
| Murgescu, J | 1 |
| Bergt, U | 1 |
| Shankaran, S | 1 |
| Farooki, ZQ | 1 |
| Desai, R | 1 |
| Khanna, NN | 4 |
| Somani, SM | 5 |
| Boyer, A | 1 |
| Miller, J | 1 |
| Chua, C | 1 |
| Menke, JA | 1 |
| Berthou, F | 1 |
| Alix, D | 2 |
| Riche, C | 1 |
| Picart, D | 1 |
| Dreano, Y | 1 |
| Gouedard, H | 1 |
| Fisher, DM | 1 |
| Robinson, S | 1 |
| Perkett, EA | 1 |
| Vaughan, RL | 1 |
| Bada, HS | 3 |
| Marshall, TA | 1 |
| Tserng, KY | 1 |
| King, KC | 1 |
| Takieddine, FN | 1 |
| Cottancin, G | 1 |
| Sann, L | 1 |
| Bory, B | 1 |
| Bourgeois, J | 1 |
| Frederich, A | 3 |
| Baltassat, P | 3 |
| Bethenod, M | 4 |
| Korner, AF | 2 |
| Smith, ML | 1 |
| Milner, AD | 11 |
| Murat, I | 2 |
| Blin, MC | 1 |
| Couchard, M | 1 |
| Flouvat, B | 2 |
| De Gamarra, E | 2 |
| Relier, JP | 2 |
| Dreyfus-Brisac, C | 1 |
| Vyas, H | 1 |
| Hopkin, IE | 3 |
| Saint Martin, J | 1 |
| Riechert, M | 2 |
| Lipowsky, G | 1 |
| Stöckl, H | 1 |
| Stiegler, H | 1 |
| Gupta, JM | 2 |
| Mercer, HP | 1 |
| Koo, WW | 1 |
| Boon, AW | 1 |
| Saunders, RA | 1 |
| Lau, KC | 1 |
| Shinebourne, EA | 2 |
| Richards, J | 1 |
| Brown, DJ | 1 |
| Johnston, PG | 1 |
| de Swiet, M | 1 |
| Nichol, H | 1 |
| Vine, J | 1 |
| Thomas, J | 1 |
| Moore, RG | 1 |
| Barr, PA | 1 |
| O'Loughlin, EV | 1 |
| Anderson, DG | 1 |
| Lagercrantz, H | 2 |
| Rane, A | 1 |
| Tunell, R | 1 |
| Philip, AG | 2 |
| Milsap, RL | 1 |
| Krauss, AN | 3 |
| Auld, PA | 3 |
| Hilligoss, DM | 1 |
| Jusko, WJ | 2 |
| Koup, JR | 3 |
| Giacoia, G | 2 |
| Nelson, RM | 1 |
| Resnick, MB | 1 |
| Holstrum, WJ | 1 |
| Eitzman, DV | 1 |
| Baumgart, S | 2 |
| Engle, WD | 1 |
| Langman, CB | 1 |
| Polin, RA | 1 |
| Floberg, S | 1 |
| Hiatt, IM | 3 |
| Hegyi, T | 5 |
| Indyk, L | 1 |
| Dangman, BC | 1 |
| James, LS | 1 |
| Bell, C | 1 |
| Dubose, R | 1 |
| Seashore, J | 1 |
| Touloukian, R | 1 |
| Rosen, C | 1 |
| Oh, TH | 2 |
| Hughes, CW | 1 |
| Mooney, S | 1 |
| O'Connor, TZ | 1 |
| Koons, AH | 2 |
| Mojica, N | 2 |
| Jadeja, N | 1 |
| Ostfeld, B | 1 |
| Hiatt, M | 2 |
| Sontheimer, D | 1 |
| Fischer, CB | 1 |
| Scheffer, F | 1 |
| Kaempf, D | 1 |
| Linderkamp, O | 4 |
| Lundstrøm, KE | 1 |
| Larsen, PB | 2 |
| Brendstrup, L | 2 |
| Skov, L | 2 |
| Stebbens, VA | 1 |
| Richard, D | 1 |
| Flachs, H | 1 |
| Stute, H | 1 |
| Greiner, B | 1 |
| Alvarez, J | 2 |
| Derleth, DP | 1 |
| Jirapaet, K | 1 |
| Rao, R | 1 |
| Narang, A | 2 |
| Roux, A | 1 |
| Ansermino, JM | 1 |
| Frawley, GP | 1 |
| Carden, JR | 1 |
| Gonzalez, MT | 1 |
| Sherwood, JB | 1 |
| Brion, LP | 1 |
| Schulman, M | 1 |
| Ramaekers, VT | 1 |
| Casaer, P | 1 |
| Cabal, LA | 3 |
| Tan, L | 1 |
| Kalapurackal, M | 1 |
| Topalovski, M | 1 |
| Yang, SS | 1 |
| Boonpasat, Y | 1 |
| Sizun, J | 1 |
| Soupre, D | 1 |
| Giroux, JD | 1 |
| Legrand, MC | 1 |
| Demazure, M | 1 |
| Chastel, C | 1 |
| Hammerman, C | 1 |
| Zangen, D | 1 |
| Haga, S | 1 |
| Shima, T | 1 |
| Momose, K | 1 |
| Andoh, K | 1 |
| Hoshi, K | 1 |
| Hashimoto, Y | 1 |
| Berul, CI | 1 |
| Fajardo, C | 1 |
| Wong, A | 1 |
| Sidhu, J | 1 |
| Triggs, E | 1 |
| Charles, B | 1 |
| Gray, P | 1 |
| Cowley, D | 1 |
| Malviya, S | 2 |
| Swartz, J | 2 |
| Lerman, J | 2 |
| Duc, G | 3 |
| Bucher, HU | 2 |
| Spinillo, A | 1 |
| Capuzzo, E | 1 |
| Stronati, M | 1 |
| Iasci, A | 1 |
| Ometto, A | 1 |
| Solerte, L | 1 |
| Calhoun, LK | 1 |
| Agwunobi, J | 1 |
| Abedin, M | 1 |
| Young, M | 1 |
| Beeram, M | 1 |
| Sinkford, S | 1 |
| Watkin, SL | 1 |
| Spencer, SA | 1 |
| Pryce, A | 1 |
| Zia Haider, A | 1 |
| Al-Saedi, S | 1 |
| Kibblewhite, DP | 1 |
| Sleigh, JW | 1 |
| al-Omran, A | 1 |
| al-Alaiyan, S | 1 |
| Aina, A | 1 |
| Jenni, OG | 1 |
| von Siebenthal, K | 1 |
| Wolf, M | 1 |
| Keel, M | 1 |
| Darnall, RA | 1 |
| Nattie, C | 1 |
| Robinson, M | 1 |
| Botham, SJ | 1 |
| Isaacs, D | 1 |
| Torres, C | 1 |
| Holditch-Davis, D | 1 |
| O'Hale, A | 1 |
| D'Auria, J | 1 |
| Gaultier, C | 1 |
| Hannam, S | 1 |
| Ingram, DM | 1 |
| Fang, S | 1 |
| Sherwood, RA | 1 |
| Gamsu, HR | 1 |
| Marsden, JT | 1 |
| Peters, TJ | 1 |
| Greenough, A | 1 |
| De Villiers, GS | 1 |
| Walele, A | 1 |
| Van der Merwe, PL | 1 |
| Kalis, NN | 1 |
| Ravet, F | 1 |
| François, G | 1 |
| Somri, M | 1 |
| Gaitini, L | 1 |
| Vaida, S | 1 |
| Collins, G | 1 |
| Sabo, E | 1 |
| Mogilner, G | 1 |
| Lin, CH | 1 |
| Wang, ST | 1 |
| Lin, YJ | 1 |
| Kunst, G | 1 |
| Holle, R | 1 |
| Motsch, J | 1 |
| Martin, E | 1 |
| Mukhopadhyay, K | 1 |
| Chakraborty, S | 1 |
| Mittal, BR | 1 |
| Urlesberger, B | 1 |
| Kaspirek, A | 1 |
| Pichler, G | 1 |
| Müller, W | 2 |
| Freed, GE | 1 |
| Meny, RG | 1 |
| Darraj, S | 1 |
| Sindel, BD | 1 |
| Winkubourne, B | 1 |
| Rickards, AL | 1 |
| Kelly, EA | 1 |
| Ford, GW | 1 |
| Davis, NM | 1 |
| Callanan, C | 1 |
| Subhani, M | 1 |
| Katz, S | 1 |
| DeCristofaro, JD | 1 |
| Osborn, DA | 4 |
| Subramanian, P | 1 |
| Ahn, HW | 1 |
| Shin, WG | 1 |
| Park, KJ | 1 |
| Suh, OK | 1 |
| Reali, MF | 1 |
| Wiechmann, L | 1 |
| Martelli, E | 1 |
| Bhatia, J | 1 |
| Lemyre, B | 2 |
| Stalker, DJ | 1 |
| Hoch, B | 1 |
| Bernhard, M | 1 |
| Courtney, SE | 1 |
| Pyon, KH | 1 |
| Saslow, JG | 1 |
| Arnold, GK | 1 |
| Pandit, PB | 1 |
| Habib, RH | 1 |
| Kajiwara, M | 1 |
| Itahashi, K | 1 |
| Fujimura, M | 1 |
| Sreenan, C | 1 |
| Lemke, RP | 1 |
| Hudson-Mason, A | 1 |
| Osiovich, H | 1 |
| Bauer, J | 1 |
| Maier, K | 1 |
| Hentschel, R | 1 |
| Al-Aif, S | 1 |
| Donzelli, G | 1 |
| Lowry, JA | 1 |
| Jarrett, RV | 1 |
| Wasserman, G | 1 |
| Pettett, G | 1 |
| Kauffman, RE | 1 |
| Merchant, JR | 1 |
| Worwa, C | 1 |
| Porter, S | 1 |
| Coleman, JM | 2 |
| deRegnier, RA | 1 |
| William, JM | 1 |
| Stoddart, PA | 1 |
| Williams, SA | 1 |
| Wolf, AR | 1 |
| Blackwell, M | 1 |
| Lloyd, JS | 1 |
| Tran, T | 1 |
| Wilker, RE | 1 |
| Subramaniam, P | 1 |
| Arko, MK | 1 |
| Miller, MJ | 4 |
| Krauss, A | 1 |
| Betkerur, A | 1 |
| Zadell, A | 1 |
| Kenney, SR | 1 |
| Lee, BP | 1 |
| Singhal, A | 1 |
| Sprodowski, N | 1 |
| Silny, J | 1 |
| Tan, K | 1 |
| Rich, W | 2 |
| O'Donnell, J | 1 |
| Barshop, BA | 1 |
| Ackley, HA | 1 |
| Dutta, S | 1 |
| Theobald, K | 1 |
| Botwinski, C | 1 |
| Albanna, S | 1 |
| McWilliam, P | 1 |
| Gannon, BA | 1 |
| Hochwald, C | 1 |
| Kennedy, K | 1 |
| Davi, MJ | 1 |
| Simons, KJ | 1 |
| Simons, FE | 1 |
| Seshia, MM | 1 |
| Bory, C | 2 |
| Porthault, M | 2 |
| Royer, RJ | 2 |
| Royer-Morrot, MJ | 2 |
| Gabriel, M | 5 |
| Albani, M | 4 |
| Lee, AF | 1 |
| James, O | 1 |
| Sander, L | 1 |
| Teager, H | 1 |
| Fineberg, N | 1 |
| Solomon, GE | 1 |
| Michael, CF | 1 |
| Shannon, DC | 2 |
| Gotay, F | 2 |
| Stein, IM | 1 |
| Rogers, MC | 1 |
| Todres, ID | 1 |
| Moylan, FM | 1 |
| Sham, B | 1 |
| Messerly, AM | 1 |
| Reynolds, EO | 2 |
| Schulte, FJ | 3 |
| Frisch, H | 2 |
| Schabel, F | 1 |
| Zieglauer, H | 1 |
| Haffner, B | 1 |
| Haberfellner, H | 1 |
| Roos, R | 1 |
| Metrakos, K | 1 |
| Riley, P | 1 |
| Willis, D | 1 |
| Bartel, J | 1 |
| Turmen, T | 2 |
| Cook, CE | 1 |
| Gorman, W | 1 |
| Collinge, JM | 1 |
| Loughnan, PM | 2 |
| Aldridge, A | 1 |
| Neims, AH | 2 |
| Baillie, E | 1 |
| Brazier, JL | 1 |
| Renaud, H | 1 |
| Ribon, B | 1 |
| Salle, BL | 1 |
| King, DM | 1 |
| Heeley, AF | 1 |
| Kuzemko, JA | 3 |
| Harkavy, KL | 1 |
| Jose, P | 1 |
| Javorka, K | 1 |
| Tomori, Z | 1 |
| Zavarská, L | 1 |
| Tin, AA | 1 |
| Pagani, G | 1 |
| Raponi, S | 1 |
| Petrone, M | 1 |
| Olson, RJ | 1 |
| Bromberg, BB | 1 |
| Zimmerman, TJ | 1 |
| Costalos, C | 1 |
| Houlsby, WT | 1 |
| Manchett, P | 1 |
| Lloyd, DJ | 2 |
| Louridas, TA | 1 |
| Edel'shteĭn, EA | 1 |
| Bondarenko, ES | 1 |
| Mumladze, TA | 1 |
| Scarpelli, EM | 1 |
| Condorelli, S | 1 |
| Cosmi, EV | 1 |
| Neese, AL | 1 |
| Soyka, LF | 1 |
| Gerhard, JP | 1 |
| Mercer, H | 1 |
| Guilleminault, C | 1 |
| Van den Hoed, J | 1 |
| Baldwin, RB | 1 |
| Witolla, C | 1 |
| Latini, R | 2 |
| Assael, BM | 2 |
| Bonati, M | 1 |
| Gerna, M | 2 |
| Mandelli, M | 2 |
| Marini, A | 2 |
| Sereni, F | 2 |
| Tognoni, G | 2 |
| Eisenberg, W | 1 |
| Holzgraefe, E | 1 |
| Naim, M | 1 |
| Dietrich, J | 1 |
| Reidenberg, M | 1 |
| Drayer, DE | 1 |
| Irnberger, E | 1 |
| Hart, BA | 1 |
| Boros, SJ | 1 |
| Reynolds, JW | 1 |
| Ehlers, H | 1 |
| Bernsau, I | 1 |
| Menke, J | 1 |
| Bruhn, FW | 1 |
| Mokrohisky, ST | 1 |
| McIntosh, K | 1 |
| Nobel, PA | 1 |
| Light, GS | 1 |
| Ekert, WD | 1 |
| Apitz, J | 1 |
| König, C | 1 |
| Schenck, HW | 1 |
| Storrs, CN | 1 |
| Katona, PG | 2 |
| Durand, D | 1 |
| Stern, K | 1 |
| Fleming, DG | 1 |
| Sitar, DS | 1 |
| Parsons, WD | 1 |
| Deutsch, ME | 1 |
| Fich, CF | 1 |
| Frederiksen, PS | 1 |
| Kamper, J | 1 |
| Friis-Hansen, B | 1 |
| Bednarek, FJ | 1 |
| Roloff, DW | 1 |
| Rosenfeld, CR | 1 |
| Hodr, R | 1 |
| Nikl, J | 1 |
| Dupont, C | 1 |
| Belgaumkar, TK | 1 |
| Scott, KE | 1 |
| Rowe, JC | 1 |
| Belenky, DA | 1 |
| Flanagan, WJ | 1 |
| Pawlowski, P | 1 |
| Venzmer, J | 1 |
| Wiedersberg, H | 1 |
| Nearman, HS | 1 |
| Fanaroff, AA | 2 |
| Klaus, MH | 2 |
| Roberton, NR | 1 |
| Smith, MA | 1 |
| Lucey, JF | 1 |
| Uauy, R | 1 |
| Shapiro, DL | 1 |
| Smith, B | 1 |
| Warshaw, JB | 1 |
| de la Torre Verduzco, R | 2 |
| Morens, DM | 1 |
| Hohlweg-Majert, P | 1 |
| Kauert, S | 1 |
| DuBrow, IW | 1 |
| Chen, JW | 1 |
| Wong, PW | 1 |
| Mars, H | 1 |
| Ferrari, B | 1 |
| Tonni, G | 1 |
| Luzietti, R | 1 |
| Ciarlini, G | 1 |
| Vadora, E | 1 |
| Merialdi, A | 1 |
| Merchant, RH | 1 |
| Sakhalkar, VS | 1 |
| Ashavaid, TF | 1 |
| Upton, CJ | 4 |
| Stokes, GM | 4 |
| Evans, JC | 1 |
| Romagnoli, C | 1 |
| De Carolis, MP | 1 |
| Muzii, U | 1 |
| Zecca, E | 1 |
| Tortorolo, G | 1 |
| Chiarotti, M | 1 |
| De Giovanni, N | 1 |
| Carnevale, A | 1 |
| Melone, JH | 1 |
| Schwartz, MZ | 1 |
| Tyson, KR | 1 |
| Marr, CC | 1 |
| Greenholz, SK | 1 |
| Taub, JE | 1 |
| Hough, VJ | 1 |
| Samuels, MP | 1 |
| Kobayashi, K | 1 |
| Katayama, M | 1 |
| Miyasaka, K | 1 |
| Bairam, A | 3 |
| Faulon, M | 1 |
| van den Anker, JN | 1 |
| Jongejan, HT | 1 |
| Sauer, PJ | 1 |
| Sasidharan, P | 1 |
| Heimler, R | 1 |
| Cooney, S | 1 |
| Dhillon, S | 1 |
| Bennett, G | 1 |
| Trehane, C | 1 |
| Bifano, EM | 1 |
| Smith, F | 1 |
| Borer, J | 1 |
| Graff, M | 2 |
| Soriano, C | 1 |
| Rovell, K | 1 |
| Ruggins, NR | 2 |
| Kwiatkowski, KA | 1 |
| Hasan, SU | 2 |
| Cates, DB | 2 |
| Webster, AC | 1 |
| McKishnie, JD | 1 |
| Kenyon, CF | 1 |
| Marshall, DG | 1 |
| Tashiro, C | 1 |
| Matsui, Y | 1 |
| Nakano, S | 1 |
| Ueyama, H | 1 |
| Nishimura, M | 1 |
| Oka, N | 1 |
| Rodríguez-Palomares, C | 1 |
| Udaeta-Mora, E | 1 |
| González-Treviño, J | 1 |
| Juárez-Olguín, H | 1 |
| Calderón-Mandujano, B | 1 |
| Prado-Serrano, A | 1 |
| Belmont-Gómez, A | 1 |
| Tay-Uyboco, J | 1 |
| Seifert, B | 1 |
| Aujard, Y | 1 |
| Gonzalez, F | 2 |
| McCulloch, KM | 1 |
| Kelly, DH | 1 |
| Morisot, C | 1 |
| Simoens, C | 1 |
| Trublin, F | 1 |
| Lhermitte, M | 2 |
| Gremillet, C | 1 |
| Robert, MH | 1 |
| Lequien, P | 2 |
| Taylor, RH | 1 |
| Welborn, LG | 2 |
| Hannallah, RS | 1 |
| Higgins, T | 1 |
| Fink, R | 2 |
| Luban, N | 1 |
| Davies, AM | 1 |
| Koenig, JS | 1 |
| Menon, A | 1 |
| Pickens, DL | 3 |
| Jolley, SG | 1 |
| Halpern, CT | 1 |
| Sterling, CE | 1 |
| Feldman, BH | 1 |
| Erickson, R | 1 |
| Sims, ME | 2 |
| Ryan, CA | 1 |
| Van de Bor, M | 1 |
| Stijnen, T | 1 |
| Baan, J | 1 |
| Ruys, JH | 1 |
| Kriter, KE | 1 |
| Blanchard, J | 1 |
| Ross, MP | 1 |
| Christensen, RD | 1 |
| Rothstein, G | 1 |
| Koenig, JM | 1 |
| Simmons, MA | 1 |
| Noble, NA | 1 |
| Kimura, RE | 1 |
| Flood, E | 1 |
| Schefft, GL | 1 |
| Storch, GA | 1 |
| DeMaio, JG | 1 |
| Harris, MC | 1 |
| Deuber, C | 1 |
| Noerr, B | 1 |
| Closa, RM | 1 |
| Tarres Roure, A | 1 |
| Gómez Papi, A | 1 |
| Casasin Edo, T | 1 |
| Daga, SR | 2 |
| Joseph, B | 1 |
| Kinikar, N | 1 |
| Newell, SJ | 1 |
| Booth, IW | 1 |
| Morgan, ME | 1 |
| Durbin, GM | 1 |
| McNeish, AS | 1 |
| Watcha, MF | 1 |
| Gunter, JB | 1 |
| Yang, S | 1 |
| Cannon, RA | 1 |
| Purohit, DM | 1 |
| Ellison, RC | 1 |
| Zierler, S | 1 |
| Miettinen, OS | 1 |
| Nadas, AS | 1 |
| Mecrow, IK | 1 |
| Goldie, BP | 1 |
| Davidson, S | 1 |
| Gil-Ad, I | 1 |
| Rogovin, H | 1 |
| Laron, Z | 1 |
| Reisner, SH | 1 |
| Cattarossi, L | 1 |
| Colacino, V | 1 |
| Janes, A | 1 |
| LoGreco, P | 1 |
| Rubini, S | 1 |
| Zilli, M | 1 |
| Macagno, F | 1 |
| Gupta, P | 1 |
| Barton, J | 1 |
| Graff, MA | 1 |
| Novo, RP | 1 |
| Smith, C | 1 |
| Zapanta, V | 1 |
| Diaz, M | 1 |
| Carlo, WA | 3 |
| Torok-Both, G | 1 |
| Jamali, F | 2 |
| Coutts, RT | 2 |
| Itani, Y | 1 |
| Fujioka, M | 1 |
| Nishimura, G | 1 |
| Niitsu, N | 1 |
| Oono, T | 1 |
| Pons, G | 1 |
| Carrier, O | 1 |
| Richard, MO | 1 |
| Rey, E | 1 |
| d'Athis, P | 1 |
| Moran, C | 1 |
| Badoual, J | 1 |
| Olive, G | 1 |
| Torok-Both, GA | 1 |
| Muttitt, SC | 1 |
| Tierney, AJ | 1 |
| Tsang, RC | 1 |
| Mimouni, F | 1 |
| Caddell, JL | 2 |
| Rennie, JM | 1 |
| South, M | 1 |
| Schefft, G | 1 |
| Wilschanski, M | 1 |
| Kaplan, M | 1 |
| Vohr, BR | 1 |
| Chen, A | 1 |
| Garcia Coll, C | 1 |
| Oh, W | 1 |
| Beaudry, MA | 1 |
| Bradley, JM | 1 |
| Gramlich, LM | 1 |
| LeGatt, D | 1 |
| Hageman, JR | 1 |
| Holmes, D | 1 |
| Suchy, S | 1 |
| Saigal, S | 1 |
| Watts, J | 1 |
| Campbell, D | 1 |
| Badonnel, Y | 1 |
| Houdret, N | 1 |
| Broly, F | 1 |
| Roussel, P | 1 |
| Carpentier, C | 1 |
| Zaoui, C | 1 |
| Ginoza, GW | 1 |
| Strauss, AA | 1 |
| Iskra, MK | 1 |
| Modanlou, HD | 1 |
| Rose, SJ | 1 |
| Duffty, P | 1 |
| Sacré, L | 1 |
| Vandenplas, Y | 1 |
| Ramirez, N | 1 |
| Ruttimann, UE | 1 |
| Guzzetta, P | 1 |
| Epstein, BS | 1 |
| Lee, D | 1 |
| Caces, R | 1 |
| Frank, M | 1 |
| Hayakawa, F | 1 |
| Kuno, K | 1 |
| Nakashima, T | 1 |
| Miyachi, Y | 1 |
| Cater, G | 1 |
| Shaffer, S | 1 |
| Hall, RT | 1 |
| McCulloch, K | 1 |
| Vidyasagar, D | 1 |
| Zouari, A | 1 |
| Dehan, M | 1 |
| Magny, JF | 1 |
| Saby, MA | 1 |
| Ropert, JC | 1 |
| Gabilan, JC | 1 |
| Anwar, M | 1 |
| Mondestin, H | 1 |
| Novo, R | 1 |
| Reinhardt, D | 1 |
| Kusenbach, G | 1 |
| Le Guennec, JC | 2 |
| Billon, B | 2 |
| Yau, G | 1 |
| Rambhatla, S | 1 |
| Cabal, L | 1 |
| Wu, PY | 1 |
| Donovan, EF | 1 |
| Butcher-Puech, MC | 1 |
| Holley, D | 1 |
| Lacey, JL | 1 |
| Edwards, DA | 1 |
| Durand, M | 1 |
| Georgie, S | 1 |
| Barberis, C | 1 |
| Field, D | 1 |
| Lyon, AJ | 1 |
| McIntosh, N | 1 |
| Glick, B | 1 |
| Peleg, O | 1 |
| Dgani, Y | 1 |
| Steinmann, J | 1 |
| Albrecht, K | 1 |
| Brouard, C | 1 |
| Pajot, N | 1 |
| Walti, H | 1 |
| Ment, LR | 1 |
| Scott, DT | 1 |
| Ehrenkranz, RA | 1 |
| Duncan, CC | 1 |
| Boldrini, A | 1 |
| Biver, P | 1 |
| Fantoni, M | 1 |
| Lenzoni, N | 1 |
| Cipolloni, C | 1 |
| Fisher, JB | 1 |
| Edgren, BE | 1 |
| Mammel, MC | 1 |
| Beilin, B | 1 |
| Vatashsky, E | 1 |
| Aronson, HB | 1 |
| Weinstock, M | 1 |
| Perlman, JM | 1 |
| Volpe, JJ | 1 |
| Paré, C | 1 |
| Caro, CG | 2 |
| Bloice, JA | 2 |
| Wick, H | 1 |
| Schmitt, H | 1 |
| Lewin, JE | 1 |
| Blake, AM | 1 |
| Langham, J | 1 |
| Collins, LM | 1 |
| Higgs, SC | 1 |
| Malan, AF | 1 |
| De Heese, HV | 1 |
| Rosegger, H | 1 |
| Kreissel, M | 1 |
| Buckfield, PM | 2 |
| Ahlström, H | 1 |
| Smith, PC | 1 |
| Smith, NT | 1 |
| Malcolm, DS | 1 |
| Riegel, K | 1 |
| Welsch, H | 1 |
| Sahn, DJ | 1 |
| Friedman, WF | 1 |
| Thomas, DB | 1 |
| Koppe, JG | 1 |
| Rietveld, HJ | 1 |
| de Wilde, TW | 1 |
| Thibeault, DW | 1 |
| Gershanik, JJ | 1 |
| Levkoff, AH | 1 |
| Duncan, R | 1 |
| Deuel, RK | 1 |
| Paala, J | 1 |
| Alden, ER | 1 |
| Kalina, RE | 1 |
| Hodson, WA | 1 |
| Murphy, DA | 1 |
| Outerbridge, E | 1 |
| Stern, L | 1 |
| Karn, GM | 1 |
| Jegier, W | 1 |
| Rosales, J | 1 |
| Sueishi, K | 1 |
| Watanabe, T | 1 |
| Shin, H | 1 |
| Vogtmann, C | 1 |
| Böttcher, H | 1 |
| Raue, W | 1 |
| Picton-Warlow, CG | 1 |
| Caldera, R | 1 |
| Rossier, A | 1 |
| Mushin, A | 1 |
| Robinson, R | 1 |
| Brüster, H | 1 |
| Wirtz, P | 1 |
| Jürgens, U | 1 |
| Perlstein, PH | 1 |
| Edwards, NK | 1 |
| Sutherland, JM | 1 |
| Sinclair, JC | 1 |
| Diekmann, L | 1 |
| Pickard, RE | 1 |
| Oropeza, G | 1 |
| Cohn, R | 1 |
| Sunshine, P | 1 |
| Wigger, HJ | 1 |
| Tang, P | 1 |
| Barry, H | 1 |
| Daily, WJ | 1 |
| Klaus, M | 1 |
| Meyer, HB | 1 |
| McNamara, JJ | 1 |
| Harkins, GA | 1 |
| Bacola, E | 1 |
| De Schweinitz, L | 1 |
| Mira, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "PREMODEUR. Odors to Insufflate Life. Implementation of a Controlled Olfactory Sensorial Method to Decrease Apneas in Premature Newborns. Proof of Concept Study. Latin-square Open Study With Blind Evaluation of Primary Outcome."[NCT02851979] | 60 participants (Anticipated) | Interventional | 2018-11-09 | Recruiting | |||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| The SSSH's: SNOO Smart Sleeper Use in Post-Operative Infants With Congenital Heart[NCT04534335] | 11 participants (Actual) | Observational | 2020-02-04 | Completed | |||
| Womb Recordings and Respiratory Control Maturation in Neonates[NCT05298748] | 34 participants (Anticipated) | Interventional | 2022-09-16 | Recruiting | |||
| Effect of Three Different Sensory Interventions on Pain Level During Heel Blood Collection in Term Infant: A Randomized Controlled Study[NCT05526378] | 120 participants (Actual) | Interventional | 2022-12-22 | Completed | |||
| Effects of Early Vocal Contact (EVC) in the Neonatal Intensive Care Unit: A Multi-centre, Randomized Clinical Trial[NCT04759573] | 80 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | |||
| Pilot Study to Evaluate the Benefits of Preterm Newborn Exposition to a Maternal Voice and Heardbeat Recording During Hospital Stay[NCT04757012] | 32 participants (Anticipated) | Interventional | 2022-04-19 | Recruiting | |||
| Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357] | Phase 3 | 201 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Noninvasive NAVA Versus NIPPV in Low Birthweight Premature Infants[NCT03137225] | 1 participants (Actual) | Interventional | 2017-04-15 | Terminated (stopped due to Insufficient resources available to complete the study) | |||
| Application of Modified Intubation-surfactant-extubation (InSurE) Technique in Preterm Neonates With Respiratory Distress Syndrome[NCT03989960] | 120 participants (Anticipated) | Interventional | 2018-08-01 | Active, not recruiting | |||
| Short Term Effects of Synchronized vs. Non-synchronized NIPPV in Preterm Infants: Study Protocol for an Unmasked Randomized Crossover Trial.[NCT03289936] | 30 participants (Anticipated) | Interventional | 2020-11-16 | Recruiting | |||
| High Versus Low Dose Caffeine as Respiratory Stimulant in Preterm Infants[NCT04144712] | Phase 1 | 80 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| Apneic Oxygenation to Prevent Oxygen Desaturation During Intubation in the NICU[NCT05451953] | 110 participants (Anticipated) | Interventional | 2022-07-21 | Recruiting | |||
| Stochastic Resonance Mattress (Physiological Interventions) and Biomarkers for Enhancing Neonatal Health[NCT01643057] | 36 participants (Actual) | Observational | 2012-07-31 | Completed | |||
| Caffeine for Late Preterm Infants: A Double Blind Randomized Controlled Trial[NCT06026163] | Phase 2/Phase 3 | 134 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| The Effect of Standardizing the Definition and Approach to a Clinically Significant Cardiopulmonary Event in Infants Less Than 30 Weeks on Length of Stay[NCT03414671] | 160 participants (Actual) | Observational | 2018-06-01 | Completed | |||
| Dexmedetomidine for LISA Procedure in Preterm Infants: a Pilot Study[NCT04820101] | 40 participants (Anticipated) | Interventional | 2021-05-15 | Not yet recruiting | |||
| Effect of Early Use of Caffeine Citrate in Preterm Neonates Needing Respiratory Support.[NCT04001712] | Phase 3 | 54 participants (Actual) | Interventional | 2019-04-05 | Completed | ||
| WAVE Trial in Premature Infants With Apnea of Prematurity Using a Simple, Non-invasive Vibratory Device to Study the Effectiveness in Supporting Breathing and General Stability[NCT04528030] | 17 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | |||
| Neuromodulation of Limb Proprioceptive Afferents Using a Vibratory Device to Decrease Apnea, Intermittent Hypoxia and Bradycardia of Prematurity.[NCT02641249] | 19 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| Evaluation of Dosing Chart Taking Into Account Age and Gender for Calculating the First Dose of Doxapram in Premature Infants[NCT00389909] | Phase 4 | 85 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| High Flow Nasal Cannula vs Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation[NCT01270581] | 7 participants (Actual) | Interventional | 2010-07-31 | Terminated (stopped due to lack of sufficient enrollment) | |||
| A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473] | Phase 4 | 24 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| Effects of Vanilla on Hypoxic Intermittent Events in Premature Infants[NCT02630147] | 32 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Feasibility and Safety of Duodenal Feeds in Very Low Birth Weight Infants[NCT04246333] | 30 participants (Anticipated) | Interventional | 2020-08-07 | Recruiting | |||
| Structure & Function of Dopaminergic Brain Networks Following Postnatally-Occurring Hypoxic Insults[NCT03407729] | 21 participants (Actual) | Observational | 2018-06-08 | Completed | |||
| Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants[NCT02293824] | 50 participants (Anticipated) | Observational | 2014-12-31 | Completed | |||
| Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study[NCT02726178] | Phase 2 | 56 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Randomized Trial of Liberal Versus Restrictive Guidelines for Red Blood Cell Transfusion in Preterm Infants[NCT00369005] | 100 participants | Interventional | 1992-12-31 | Completed | |||
| Effects of Non-nutritive Sucking on Gastroesophageal Reflux, Apneas and Bradycardias in Symptomatic Preterm Infants.[NCT02023216] | 30 participants (Actual) | Observational | 2013-05-31 | Completed | |||
| A Randomized Controlled Trial of Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Pressure as a Primary Mode for Respiratory Distress Syndrome in Preterm Infants[NCT00821119] | 200 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia[NCT04447989] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-05-27 | Recruiting | ||
| Comparison of CPAP and NIPPV as a Mode of Non-invasive Respiratory Support for Neonates in a Level III NICU[NCT03347136] | 80 participants (Actual) | Interventional | 2015-01-10 | Completed | |||
| Comparing Regional Ventilation in Neonates With Different Delivery Systems of Continuous Positive Airway Pressure[NCT06038565] | 20 participants (Anticipated) | Interventional | 2023-10-18 | Recruiting | |||
| Comparison of Humidified High Flow Nasal Cannula to Nasal Continuous Positive Airway Pressure for Non-Invasive Respiratory Support in Neonates[NCT00609882] | 420 participants (Actual) | Interventional | 2007-12-31 | Completed | |||
| Adaptive Dynamic Inspiratory Nasal Apparatus (ADINA): Comparison to High Flow Nasal Cannula (HFNC)[NCT03171129] | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| Post-extubation High-flow Nasal Oxygen vs. Conventional Oxygen in Patients Recovered From Acute Hypoxemic Respiratory Failure for Preventing Extubation Failure[NCT03361683] | 127 participants (Actual) | Interventional | 2017-10-01 | Completed | |||
| Comparison of High Flow Nasal Cannula Therapy to Nasal Oxygen (O2) as a Treatment for Obstructive Sleep Apnea (OSA) in Infants[NCT02858154] | 9 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Observational, Cross-over Study of the Positive Distending Pressure Generated by Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure[NCT00356668] | Phase 3 | 16 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Continuous Versus Intermittent Bolus Feeding in Very Preterm Infants - Effects on Respiratory Morbidity: A Multicentre Randomised Controlled Clinical Trial[NCT03961139] | 150 participants (Anticipated) | Interventional | 2019-12-03 | Recruiting | |||
| Correlation Between Carnitine Deficiency and Hypoglycemic Events in Type I Diabetes; Effects of Carnitine Supplementation on Hypoglycemic Events in Type I Diabetes[NCT00351234] | 200 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| Effects on Coordination of Sucking, Swallowing and Breathing Process of a Valved Feeding System in Late-preterm Newborns. The Safe Oral Feeding Trial (SOFT)[NCT04400175] | 40 participants (Actual) | Interventional | 2020-12-01 | Completed | |||
| Comparison Between NAVA and PSV in Neurocritical Patients: a Pilot Study[NCT03721354] | 20 participants (Anticipated) | Interventional | 2018-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The total number of bradycardia episodes to <100 bpm lasting >5 seconds/episode will be compared during periods of vibration (intervention) to periods of no vibrations (no intervention). (NCT02641249)
Timeframe: 12 hours of intervention/12 hours of no intervention
| Intervention | bradycardias (Mean) |
|---|---|
| No Vibration | 50.53 |
| Vibration | 14.93 |
The total number of intermittent hypoxic episodes to <90% (pulse oximetry) lasting >5 seconds/episode will be compared during periods of vibration (intervention) to periods of no vibrations (no intervention). (NCT02641249)
Timeframe: 12 hours of intervention/12 hours of no intervention
| Intervention | IH events (Mean) |
|---|---|
| No Vibration | 151.67 |
| Vibration | 109.67 |
The total number of apneas/breathing pauses will be compared during periods of vibration (intervention) to periods of no vibrations (no intervention). (NCT02641249)
Timeframe: 12 hours of intervention/12 hours of no intervention
| Intervention | breathing pauses (Mean) |
|---|---|
| No Vibration | 284.13 |
| Vibration | 174.27 |
Number per hour of oxygen saturation < 90% for at least 5 seconds (NCT02630147)
Timeframe: 12 hour period of recording on the night 1 and 3 of each participants, in which they are exposed to vanilla or no vanilla odor
| Intervention | Number of events (Mean) |
|---|---|
| Night-vanilla | 51.7 |
| Night-no Vanilla | 56.9 |
Mean value of oxygen saturation (%) (NCT02630147)
Timeframe: 12 hour period of recording on the night 1 and 3 of each participants, in which they are exposed to vanilla or no vanilla odor
| Intervention | % of SpO2 (Mean) |
|---|---|
| Night-vanilla | 98 |
| Night-no Vanilla | 97.5 |
Percentage time in overall duration of oxygen saturation under 90% (NCT02630147)
Timeframe: 12 hour period of recording on the night 1 and 3 of each participants, in which they are exposed to vanilla or no vanilla odor
| Intervention | % of overall time (Mean) |
|---|---|
| Night-vanilla | 1.8 |
| Night-no Vanilla | 2.2 |
"Percent of time of the recording spent in periodic breathing or in apnea.~A periodic beathing epoch was defined as a series of 3 episodes or more of apneas lasting at least 3 seconds and separated by less than 20 seconds of normal breathing~Apneas were defined as the absence of respiratory movements for at least 20 seconds or for at least 2 breathing cycles with a decrease of at least 3% in SpO2" (NCT02630147)
Timeframe: 12 hour period of recording on the night 1 and 3 of each participants, in which they are exposed to vanilla or no vanilla odor
| Intervention | % of overall time (Mean) |
|---|---|
| Night-vanilla | 12.2 |
| Night-no Vanilla | 8.7 |
Percent of time of the recording spent in apnea (NCT02630147)
Timeframe: 12 hour period of recording on the night 1 and 3 of each participants, in which they are exposed to vanilla or no vanilla odor
| Intervention | % of overall time (Mean) |
|---|---|
| Night-vanilla | 0.99 |
| Night-no Vanilla | 1.02 |
Measured using the grooved pegboard task (number of seconds required to place 25 pegs using the dominant hand) (NCT03407729)
Timeframe: 20 minutes
| Intervention | seconds (Mean) |
|---|---|
| Post-hypoxic Former Preterm | 102.11 |
| Healthy Term-born Children | 82.71 |
Subjects in each group were evaluated for changes in functional connectivity between the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA), as evaluated by functional magnetic resonance imaging blood oxygen level dependent (fMRI-BOLD), using whole brain analysis. The measurement is increase/decrease of MRI signal intensity in a given region, thresholded at p <0.05, summarized into a value representing 'size of region of increase' or 'size of region of decrease' after subjects' scans were combined/mapped onto a standard MNI brain. Only clusters of over 50 voxels were included, and the size of the region is reported in voxel size. The averaged brains for prematurely born fMRI was subtracted from the full term treatment for each group, and then these averaged differences were subtracted from each other. While other areas of the brain met threshold criteria in the analysis, only brain regions innervated by primary or collateral dopaminergic pathways are reported. (NCT03407729)
Timeframe: 30 minutes
| Intervention | Cluster size (voxels) (Number) | |
|---|---|---|
| Left thalamus | Left middle temporal gyrus | |
| Healthy Term-born Children | 358 | 75 |
| Post-hypoxic Former Preterm | 310 | 95 |
Assessment of dopaminergic circuits originating in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA). Includes right and left nucleus accumbens, right and left mamillary body, right and left hippocampus. Measured using Magnetic Resonance T1-weighted magnetization prepared rapid gradient echo (MPRAGE) scans with three-dimensional volumetrics analysis (NCT03407729)
Timeframe: 30 minutes
| Intervention | mm^3 (Mean) | |||||
|---|---|---|---|---|---|---|
| left nucleus accumbens | right nucleus accumbens | left mamillary body | right mamillary body | left hippocampus | right hippocampus | |
| Healthy Term-born Children | 175.93 | 192.78 | 54.78 | 44.70 | 3419.48 | 4241.03 |
| Post-hypoxic Former Preterm | 148.90 | 177.25 | 89.34 | 67.78 | 2741.09 | 3329.34 |
Immunization with the pentavalent vaccine Diphtheria-Tetanus-Acellular pertussis-Inactivated poliomyelitis-Haemophilus influenzae type b (DTPa-IPV-Hib) at two months of age is known to be associated with cardio-respiratory events (CRE), in 11 to 47% of preterm infants.It is considered that the immature brainstem respiratory control of preterms make them more vulnerable to the inflammatory reaction caused by immunization. We hypothesized that post-immunization CRE are correlated with inflammatory reaction. The primary objective was to examine the impact of endogenous PG inhibition on the occurrence of CRE following the first dose of pentavalent vaccine in preterm infants born < 32 weeks gestation. Total CRE was expressed as the average number of events (desaturation + apneas + bradycardia) / 24 hours. Δ Total CRE / patient / 24 hours was defined as the difference between the average number of events / 24 hours observed before vs. after immunization for each patient. (NCT02726178)
Timeframe: the mean of CRE occured in the 48h after immunization minus the base line CRE : mesured 24h before immunization
| Intervention | events/patient/24hours (Mean) |
|---|---|
| Advil® Pediatric Drops for Infants | 0.1 |
| Control | 5.4 |
The secondary objective was to identify predictive factors of occurrence of CRE in preterm infants after immunization through the analysis of their HRV. Two annotated polysomnographies were performed for all patients with an AURA PSG GRASS ambulatory and wireless system. Each polysomnography had a duration of 2.5 hours: the first was conducted on enrolment (the day before immunization), and the second was conducted 18 to 24 hours after immunization : we compared the mean of the datas of polysomnographies after to those before immunization. (NCT02726178)
Timeframe: 72 h
| Intervention | msec (Mean) |
|---|---|
| Advil® Pediatric Drops for Infants | -10 |
| Control | -8 |
The incidence of bronchopulmonary dysplasia was calculated based on the number of infants surviving to 36 weeks postmenstrual age and diagnosed with bronchopulmonary dysplasia, according to the definiton of bronchopulmonary dysplasia currently used in the neonatal Unit. (NCT00821119)
Timeframe: at 36 weeks gestational age
| Intervention | participants (Number) |
|---|---|
| NCPAP | 20 |
| NIPPV | 22 |
The primary outcome of the study was the need for intubation within the first 72 hours (h) of life.The need for intubation was made by the attending neonatologist, according to the strict protocol of intubation for ventilation, used in the neonatal Unit (NCT00821119)
Timeframe: first 3 days of life(72hours)
| Intervention | participants (Number) |
|---|---|
| NCPAP | 34 |
| NIPPV | 25 |
number of participants that needed endotracheal ventilation (failed non invasive ventilation) in the first 72 hours of life (NCT00821119)
Timeframe: first 72 hs of life
| Intervention | participants (Number) |
|---|---|
| NCPAP | 34 |
| NIPPV | 25 |
All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive low flow oxygen by nasal cannula. (NCT02858154)
Timeframe: end of visit (12 hours)
| Intervention | events/hour (Mean) | |
|---|---|---|
| AHI from diagnostic sleep study | AHI from improvement in OSA with low flow oxygen by nasal cannula | |
| Average AHI Diagnostic Study Compared to Average AHI With Improvement in OSA With Low Flow Oxygen | 13.44 | 4.9 |
AHI will be compared from diagnostic sleep study to average AHI with improvement in OSA with HFNC (NCT02858154)
Timeframe: End of visit (12 hours)
| Intervention | events/hour (Mean) | |
|---|---|---|
| AHI on diagnostic study | AHI with improvement in OSA with HFNC | |
| Average AHI Diagnostic Sleep Study Compared to Average AHI With Improvement in OSA With HFNC | 15.6 | 5.12 |
123 reviews available for apnea and Infant, Premature, Diseases
| Article | Year |
|---|---|
Sensory stimulation for apnoea mitigation in preterm infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intermittent Positiv | 2022 |
Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved.
Topics: Animals; Apnea; Bronchopulmonary Dysplasia; Caffeine; Humans; Infant, Newborn; Infant, Premature; In | 2022 |
Caffeine: Some of the Evidence behind Its Use and Abuse in the Preterm Infant.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2022 |
[Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity].
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa | 2022 |
Apnea of prematurity and sudden infant death syndrome.
Topics: Apnea; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Sudden Infan | 2022 |
Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.
Topics: Aminophylline; Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases | 2022 |
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Humans; Infant; Infant, Extremely Premature; Inf | 2023 |
Apnea events in neonatal age: A case report and literature review.
Topics: Anticonvulsants; Apnea; Autonomic Nervous System Diseases; Bradycardia; Cyanosis; Diagnosis, Differe | 2019 |
Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine.
Topics: Airway Extubation; Apnea; Caffeine; Central Nervous System; Central Nervous System Stimulants; Dose- | 2019 |
Confounding biases in studies on early- versus late-caffeine in preterm infants: a systematic review.
Topics: Apnea; Caffeine; Drug Administration Schedule; Humans; Infant; Infant, Newborn; Infant, Premature; I | 2020 |
Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intensive | 2020 |
Development: Epidemiology and management of postoperative apnoea in premature and term newborns.
Topics: Apnea; Bradycardia; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; | 2020 |
[APNEA OF PREMATURITY - PATHOPHYSIOLOGY, TREATMENT & PROGNOSIS].
Topics: Apnea; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Intensive Care Units, | 2020 |
Neurodevelopmental outcomes after neonatal caffeine therapy.
Topics: Animals; Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; D | 2020 |
Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose?
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Dose-Response Relationsh | 2020 |
National and international guidelines for neonatal caffeine use: Are they evidenced-based?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Evidence-Based Medicine; Humans; Infan | 2020 |
Nasal Intermittent Positive Pressure Ventilation versus Continuous Positive Airway Pressure and Apnea of Prematurity: A Systematic Review and Meta-Analysis.
Topics: Apnea; Continuous Positive Airway Pressure; Female; Humans; Infant, Newborn; Infant, Premature; Infa | 2022 |
Immature control of breathing and apnea of prematurity: the known and unknown.
Topics: Apnea; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Infant, Prematu | 2021 |
High versus standard dose caffeine for apnoea: a systematic review.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Dose-Response Relati | 2018 |
Caffeine: an evidence-based success story in VLBW pharmacotherapy.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, Patent; Enterocolitis, Necrot | 2018 |
Is early caffeine therapy safe and effective for ventilated preterm infants?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2019 |
Current definitions for neonatal apnoea: are they evidence based?
Topics: Apnea; Biomarkers; Evidence-Based Medicine; Heart Rate; Humans; Infant, Newborn; Infant, Premature; | 2013 |
Apnea of prematurity.
Topics: Afferent Pathways; Airway Obstruction; Apnea; Bradycardia; Bronchodilator Agents; Carbon Dioxide; Co | 2012 |
Apnea of prematurity--perfect storm.
Topics: Apnea; Humans; Infant; Infant, Premature; Infant, Premature, Diseases | 2013 |
Forecasting respiratory collapse: theory and practice for averting life-threatening infant apneas.
Topics: Apnea; Forecasting; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Predict | 2013 |
Neonatal apnea and gastroesophageal reflux (GER): is there a problem?
Topics: Apnea; Esophageal pH Monitoring; Esophageal Sphincter, Lower; Gastroesophageal Reflux; Humans; Hydro | 2013 |
Neurologic and metabolic issues in moderately preterm, late preterm, and early term infants.
Topics: Apnea; Central Nervous System; Feeding Behavior; Gestational Age; Humans; Hypothermia, Induced; Infa | 2013 |
Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Drug Monitoring; Humans; Infant, Prema | 2014 |
[Advance in researches on neonatal humidified high flow nasal cannulae].
Topics: Apnea; Catheters; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant, Premature; I | 2013 |
Caffeine for apnea of prematurity: a neonatal success story.
Topics: Animals; Apnea; Birth Weight; Caffeine; Cost-Benefit Analysis; Drug Costs; Gestational Age; Humans; | 2014 |
Apnea in acute bilirubin encephalopathy.
Topics: Apnea; Bilirubin; Gestational Age; Humans; Hyperbilirubinemia, Neonatal; Infant, Newborn; Infant, Pr | 2014 |
Inguinal hernia repair in premature infants: more questions than answers.
Topics: Apnea; Bradycardia; Hernia, Inguinal; Herniorrhaphy; Humans; Infant, Newborn; Infant, Premature; Inf | 2015 |
Regional (spinal, epidural, caudal) versus general anaesthesia in preterm infants undergoing inguinal herniorrhaphy in early infancy.
Topics: Anesthesia, Conduction; Anesthesia, Epidural; Anesthesia, General; Anesthesia, Spinal; Apnea; Bradyc | 2015 |
Cardiorespiratory events in preterm infants: etiology and monitoring technologies.
Topics: Apnea; Blood Gas Analysis; Bradycardia; Female; Gestational Age; Humans; Hypoxia; Infant; Infant, Ne | 2016 |
Cardiorespiratory events in preterm infants: interventions and consequences.
Topics: Animals; Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Continuous Positive Airway | 2016 |
Treatment options for apnoea of prematurity.
Topics: Apnea; Disease Management; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2016 |
Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
Topics: Apnea; Caffeine; Doxapram; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infa | 2017 |
Body positioning for spontaneously breathing preterm infants with apnoea.
Topics: Apnea; Bradycardia; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Oxygen | 2017 |
[Gastroesophageal reflux in premature: a case report].
Topics: Apnea; Bradycardia; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2016 |
Neonatal apnea: what's new?
Topics: Apnea; Continuous Positive Airway Pressure; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant | 2008 |
Indications for home apnea monitoring (or not).
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Monitoring, Ambulato | 2009 |
Spinal anesthesia in preterm infant undergoing herniorrhaphy.
Topics: Anesthesia, Spinal; Anesthetics, Local; Apnea; Bradycardia; Comorbidity; Hernia, Inguinal; Humans; I | 2009 |
[Apnea of prematurity: what's new?].
Topics: Apnea; Bradycardia; Brain Damage, Chronic; Bronchopulmonary Dysplasia; Caffeine; Central Nervous Sys | 2010 |
Interventions for apnoea of prematurity: a personal view.
Topics: Amino Acids; Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant, | 2010 |
Caffeine versus theophylline for apnea in preterm infants.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; | 2010 |
Question 1 Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Developmental Disabilities; | 2010 |
Caffeine impact on neonatal morbidities.
Topics: Animals; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premat | 2010 |
Apnea of prematurity: pathogenesis and management strategies.
Topics: Apnea; Arrhythmias, Cardiac; Brain Stem; Caffeine; Central Nervous System Stimulants; Continuous Pos | 2011 |
Methylxanthine treatment for apnoea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2010 |
Prophylactic methylxanthine for prevention of apnoea in preterm infants.
Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Humans; Hypoxia; Infant, Newborn; I | 2010 |
Myth: gastroesophageal reflux is a pathological entity in the preterm infant.
Topics: Apnea; Failure to Thrive; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature; Infan | 2011 |
Mechanical ventilation of the premature neonate.
Topics: Apnea; High-Frequency Ventilation; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2011 |
Developmental physiology of late and moderate prematurity.
Topics: Apnea; Gestational Age; Humans; Hypoglycemia; Hypothermia; Infant, Newborn; Infant, Premature; Infan | 2012 |
Evidence-based methylxanthine use in the NICU.
Topics: Apnea; Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Evidence-Based Medicine; Humans; Infan | 2012 |
Body positioning for spontaneously breathing preterm infants with apnoea.
Topics: Apnea; Bradycardia; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient | 2012 |
Carotid chemoreceptor development and neonatal apnea.
Topics: Animals; Animals, Newborn; Apnea; Carotid Body; Humans; Infant, Newborn; Infant, Premature, Diseases | 2013 |
Inflammation in the carotid body during development and its contribution to apnea of prematurity.
Topics: Animals; Apnea; Carotid Body; Humans; Hypoxia; Infant, Newborn; Infant, Premature; Infant, Premature | 2013 |
Caffeine citrate: when and for how long. A literature review.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Humans; Infant, Newborn; Infant, Prema | 2012 |
Gastroesophageal reflux: a critical review of its role in preterm infants.
Topics: Animals; Apnea; Cattle; Diagnosis, Differential; Failure to Thrive; Gastroesophageal Reflux; Humans; | 2004 |
Apnoea of prematurity.
Topics: Apnea; Continuous Positive Airway Pressure; Humans; Hypercapnia; Hypoxia; Infant, Newborn; Infant, P | 2004 |
Role of carnitine supplementation in apnea of prematurity: a systematic review.
Topics: Apnea; Carnitine; Dietary Supplements; Humans; Infant, Newborn; Infant, Premature, Diseases; Length | 2004 |
Maturation of peripheral arterial chemoreceptors in relation to neonatal apnoea.
Topics: Apnea; Arteries; Carotid Body; Chemoreceptor Cells; Dopamine; Humans; Hypoxia; Incidence; Infant, Ne | 2004 |
Clinical correlates, natural history and outcome of neonatal apnoea.
Topics: Apnea; Bradycardia; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Sudden | 2004 |
Controversies surrounding xanthine therapy.
Topics: Adenosine; Apnea; Central Nervous System Stimulants; Heart Rate; Humans; Infant, Newborn; Infant, Pr | 2004 |
Methylxanthines for the treatment of apnea associated with bronchiolitis and anesthesia.
Topics: Anesthesia, General; Apnea; Bronchiolitis; Caffeine; Clinical Trials as Topic; Humans; Infant; Infan | 2004 |
Doxapram treatment for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2004 |
Carnitine supplementation for preterm infants with recurrent apnea.
Topics: Apnea; Carnitine; Dietary Supplements; Humans; Infant, Newborn; Infant, Premature; Infant, Premature | 2004 |
Role of inhibitory neurotransmitter interactions in the pathogenesis of neonatal apnea: implications for management.
Topics: Animals; Animals, Newborn; Apnea; Bicuculline; Female; gamma-Aminobutyric Acid; Humans; Infant, Newb | 2004 |
Does gastroesophageal reflux cause apnea in preterm infants?
Topics: Apnea; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2005 |
Control of breathing and neonatal apnea.
Topics: Apnea; Bradycardia; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant, Premature; | 2005 |
A primer on Apnea of prematurity.
Topics: Apnea; Central Nervous System Stimulants; Combined Modality Therapy; Continuity of Patient Care; Dru | 2005 |
Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.
Topics: Aging; Apnea; Blindness; Cerebral Palsy; Cognition Disorders; Deafness; Follow-Up Studies; Humans; I | 2005 |
Continuous positive airway pressure: early, late, or stay with synchronized intermittent mandatory ventilation?
Topics: Apnea; Bronchopulmonary Dysplasia; Continuous Positive Airway Pressure; Gestational Age; Humans; Inf | 2006 |
Ontogeny of autonomic regulation in late preterm infants born at 34-37 weeks postmenstrual age.
Topics: Apnea; Bradycardia; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2006 |
[Sensory stimulations for the treatment of idiopathic apneas of prematurity].
Topics: Acoustic Stimulation; Apnea; Bradycardia; Humans; Infant; Infant, Newborn; Infant, Premature; Infant | 2007 |
Infant apnea and gastroesophageal reflux: a critical review and framework for further investigation.
Topics: Apnea; Esophageal Sphincter, Lower; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Infant | 2007 |
Apnea in the newborn.
Topics: Apnea; Bronchodilator Agents; Central Nervous System Stimulants; Diagnosis, Differential; Drug Thera | 2008 |
Metabolism and pharmacokinetics of theophylline in human neonates, children, and adults.
Topics: Adult; Age Factors; Apnea; Asthma; Biotransformation; Bradycardia; Caffeine; Child; Female; Half-Lif | 1983 |
[Gastroesophageal reflux and respiratory manifestations].
Topics: Airway Obstruction; Apnea; Bronchopneumonia; Child; Child, Preschool; Chronic Disease; Gastroesophag | 1983 |
Sudden infant death syndrome: the physician's dilemma.
Topics: Age Factors; Airway Obstruction; Apnea; Brain Diseases; Endocrine System Diseases; Growth; Humans; H | 1983 |
Home monitoring of the high-risk infant.
Topics: Airway Obstruction; Apnea; Female; Gastroesophageal Reflux; Home Nursing; Humans; Infant; Infant, Ne | 1984 |
The pharmacology and therapeutic use of theophylline.
Topics: Acute Disease; Adolescent; Adult; Apnea; Asthma; Bronchodilator Agents; Chemistry, Pharmaceutical; C | 1984 |
Pharmacologic management of apnea of prematurity.
Topics: Apnea; Bronchodilator Agents; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature, | 1996 |
Early disturbances in cardiorespiratory control.
Topics: Animals; Apnea; Central Nervous System; Emergencies; Humans; Hypoventilation; Infant; Infant, Newbor | 1997 |
[Follow-up of the premature infant: prevention of severe diseases and sudden death. Role of polysomnography].
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Polysomn | 1998 |
Doxapram treatment for apnea in preterm infants.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Respirator | 2000 |
Doxapram versus methylxanthine for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2000 |
Caffeine versus theophylline for apnea in preterm infants.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; | 2000 |
Kinesthetic stimulation for preventing apnea in preterm infants.
Topics: Apnea; Beds; Humans; Infant Equipment; Infant, Newborn; Infant, Premature; Infant, Premature, Diseas | 2000 |
Kinesthetic stimulation for treating apnea in preterm infants.
Topics: Apnea; Beds; Humans; Infant Equipment; Infant, Newborn; Infant, Premature; Infant, Premature, Diseas | 2000 |
Kinesthetic stimulation versus theophylline for apnea in preterm infants.
Topics: Apnea; Beds; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infant, | 2000 |
Continuous positive airway pressure versus theophylline for apnea in preterm infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Positive-Pressure Re | 2000 |
Postoperative caffeine for preventing apnea in preterm infants.
Topics: Anesthesia, General; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; In | 2000 |
Methylxanthine treatment for apnea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2000 |
Prophylactic methylxanthine for preventing of apnea in preterm infants.
Topics: Apnea; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infant, Premat | 2000 |
Current options in the management of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Prema | 2000 |
Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intermittent Positiv | 2000 |
Doxapram versus methylxanthine for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2000 |
Methylxanthine treatment for apnea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2001 |
Prophylactic caffeine to prevent postoperative apnea following general anesthesia in preterm infants.
Topics: Anesthesia, General; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; In | 2001 |
Doxapram treatment for apnea in preterm infants.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Respirator | 2001 |
Continuous positive airway pressure versus theophylline for apnea in preterm infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Positive-Pressure Re | 2001 |
Apnea in the newborn.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; In | 2001 |
Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intermittent Positiv | 2002 |
Apnea of prematurity: diagnosis, implications for care, and pharmacologic management.
Topics: Apnea; Combined Modality Therapy; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premat | 2000 |
Theophylline or caffeine: which is best for apnea of prematurity?
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2000 |
Kinesthetic stimulation for preventing apnea in preterm infants.
Topics: Apnea; Beds; Humans; Infant Equipment; Infant, Newborn; Infant, Premature; Infant, Premature, Diseas | 2002 |
Apnea.
Topics: Apnea; Blood Pressure; Bradycardia; Electroencephalography; Heart Rate; Humans; Infant, Newborn; Inf | 1977 |
[Drug therapy of patent ductus arteriosus in premature and newborn infants].
Topics: Apnea; Aspirin; Chloroquine; Digitalis Glycosides; Ductus Arteriosus, Patent; Humans; Indomethacin; | 1978 |
Apnea and periodic breathing.
Topics: Apnea; Carbon Dioxide; Cheyne-Stokes Respiration; Humans; Hypoxia; Infant, Newborn; Infant, Prematur | 1977 |
Methylxanthines in apnea of prematurity.
Topics: Apnea; Caffeine; Hemodynamics; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Respi | 1979 |
Neurodevelopmental outcome in infants with apnea.
Topics: Apnea; Brain Diseases; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Sudden Infant D | 1992 |
Apnea of prematurity.
Topics: Apnea; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Sudden Infant Death | 1992 |
Pathophysiology of apnoea in preterm infants.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Larynx; Pharynx; Positive-Pre | 1991 |
Management of apnea in infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Xanthines | 1989 |
Caffeine: a new look at an age-old drug.
Topics: Apnea; Arteriosclerosis; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Neoplasms | 1988 |
Pathogenesis of apnea in preterm infants.
Topics: Apnea; Carbon Dioxide; Chemoreceptor Cells; Humans; Infant, Newborn; Infant, Premature, Diseases; Me | 1986 |
Reply to an editorial concerning magnesium therapy in premature infants with apnea neonatorum.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Magnesium | 1988 |
Principles of neonatal assisted ventilation.
Topics: Airway Resistance; Apnea; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Dis | 1986 |
Perioperative care of the surgical neonate.
Topics: Adaptation, Physiological; Apnea; Bacterial Infections; Body Temperature Regulation; Cardiovascular | 1985 |
Sleep apnea in infancy and childhood.
Topics: Apnea; Child; Child, Preschool; Eating; Epilepsy; Gastroesophageal Reflux; Heart Rate; Humans; Hypov | 1985 |
[Urgent care for the high-risk newborn infant].
Topics: Apgar Score; Apnea; Birth Weight; Blood Transfusion; Edema; Erythroblastosis, Fetal; Female; Humans; | 1973 |
Difficulties in distinguishing cardiac from pulmonary disease in the neonate.
Topics: Apnea; Arteriovenous Malformations; Carbon Dioxide; Cardiovascular System; Cyanosis; Diagnosis, Diff | 1973 |
73 trials available for apnea and Infant, Premature, Diseases
| Article | Year |
|---|---|
Protocol of controlled odorant stimulation for reducing apnoeic episodes in premature newborns: a randomised open-label Latin-square study with independent evaluation of the main endpoint (PREMODEUR).
Topics: Apnea; Child; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Inten | 2021 |
'Propped and prone' positioning reduces respiratory events in spontaneously breathing preterm infants: A randomised triple crossover study.
Topics: Apnea; Cross-Over Studies; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2023 |
Randomized Controlled Trial on the Effects of Morning versus Evening Primary Vaccination on Episodes of Hypoxemia and Bradycardia in Very Preterm Infants.
Topics: Apnea; Bradycardia; Female; Gestational Age; Humans; Hypoxia; Infant; Infant, Extremely Premature; I | 2019 |
[Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial].
Topics: Apnea; Caffeine; Citrates; Double-Blind Method; Humans; Infant; Infant, Newborn; Infant, Premature; | 2020 |
Early application of caffeine improves white matter development in very preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child Development; Diffusion Tensor Imaging; Fem | 2020 |
Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant, Newborn; Infant, Prematu | 2021 |
Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Ox | 2022 |
A Randomized Controlled Trial Comparing Two Doses of Caffeine for Apnoea in Prematurity.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2021 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial.
Topics: Aminophylline; Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male | 2017 |
Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
Topics: Aminophylline; Apnea; Caffeine; Child Development; Cognition Disorders; Developmental Disabilities; | 2017 |
Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child; Child Development; Double-Blind Method; F | 2018 |
Acute hemodynamic effects of methylxanthine therapy in preterm neonates: Effect of variations in subgroups.
Topics: Aminophylline; Apnea; Caffeine; Dose-Response Relationship, Drug; Echocardiography; Female; Gestatio | 2019 |
Live maternal speech and singing have beneficial effects on hospitalized preterm infants.
Topics: Adult; Apnea; Bayes Theorem; Biomarkers; Bradycardia; Female; Heart Rate; Hospitalization; Humans; H | 2013 |
Live maternal speech and singing have beneficial effects on hospitalized preterm infants.
Topics: Adult; Apnea; Bayes Theorem; Biomarkers; Bradycardia; Female; Heart Rate; Hospitalization; Humans; H | 2013 |
Live maternal speech and singing have beneficial effects on hospitalized preterm infants.
Topics: Adult; Apnea; Bayes Theorem; Biomarkers; Bradycardia; Female; Heart Rate; Hospitalization; Humans; H | 2013 |
Live maternal speech and singing have beneficial effects on hospitalized preterm infants.
Topics: Adult; Apnea; Bayes Theorem; Biomarkers; Bradycardia; Female; Heart Rate; Hospitalization; Humans; H | 2013 |
Live maternal speech and singing have beneficial effects on hospitalized preterm infants.
Topics: Adult; Apnea; Bayes Theorem; Biomarkers; Bradycardia; Female; Heart Rate; Hospitalization; Humans; H | 2013 |
Live maternal speech and singing have beneficial effects on hospitalized preterm infants.
Topics: Adult; Apnea; Bayes Theorem; Biomarkers; Bradycardia; Female; Heart Rate; Hospitalization; Humans; H | 2013 |
Live maternal speech and singing have beneficial effects on hospitalized preterm infants.
Topics: Adult; Apnea; Bayes Theorem; Biomarkers; Bradycardia; Female; Heart Rate; Hospitalization; Humans; H | 2013 |
Live maternal speech and singing have beneficial effects on hospitalized preterm infants.
Topics: Adult; Apnea; Bayes Theorem; Biomarkers; Bradycardia; Female; Heart Rate; Hospitalization; Humans; H | 2013 |
Live maternal speech and singing have beneficial effects on hospitalized preterm infants.
Topics: Adult; Apnea; Bayes Theorem; Biomarkers; Bradycardia; Female; Heart Rate; Hospitalization; Humans; H | 2013 |
The effects of caffeine on heart rate variability in newborns with apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Heart Rate; Humans; Infant, Newborn; Inf | 2014 |
Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age.
Topics: Actigraphy; Apnea; Caffeine; Central Nervous System Stimulants; Child; Child, Preschool; Double-Blin | 2014 |
Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Infant, Premature; Infant, Premature, Diseas | 2015 |
Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Infant, Premature; Infant, Premature, Diseas | 2015 |
Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Infant, Premature; Infant, Premature, Diseas | 2015 |
Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Infant, Premature; Infant, Premature, Diseas | 2015 |
Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Infant, Premature; Infant, Premature, Diseas | 2015 |
Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Infant, Premature; Infant, Premature, Diseas | 2015 |
Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Infant, Premature; Infant, Premature, Diseas | 2015 |
Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Infant, Premature; Infant, Premature, Diseas | 2015 |
Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Infant, Premature; Infant, Premature, Diseas | 2015 |
High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial.
Topics: Airway Extubation; Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relat | 2015 |
Stochastic Resonance Effects on Apnea, Bradycardia, and Oxygenation: A Randomized Controlled Trial.
Topics: Apnea; Beds; Bradycardia; Cross-Over Studies; Female; Humans; Hypoxia; Infant, Newborn; Infant, Prem | 2015 |
Effects of infant flow Bi-NCPAP on apnea of prematurity.
Topics: Adult; Apnea; Continuous Positive Airway Pressure; Female; Follow-Up Studies; Humans; Infant; Infant | 2016 |
[Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants].
Topics: Apnea; Birth Weight; Caffeine; Citrates; Female; Gestational Age; Humans; Infant, Newborn; Infant, P | 2016 |
Caffeine Administration to Prevent Apnea in Very Premature Infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Female; Gestational Age; Hu | 2016 |
Neuromodulation of Limb Proprioceptive Afferents Decreases Apnea of Prematurity and Accompanying Intermittent Hypoxia and Bradycardia.
Topics: Afferent Pathways; Apnea; Birth Weight; Bradycardia; Extremities; Female; Gestational Age; Humans; H | 2016 |
Neuromodulation of Limb Proprioceptive Afferents Decreases Apnea of Prematurity and Accompanying Intermittent Hypoxia and Bradycardia.
Topics: Afferent Pathways; Apnea; Birth Weight; Bradycardia; Extremities; Female; Gestational Age; Humans; H | 2016 |
Neuromodulation of Limb Proprioceptive Afferents Decreases Apnea of Prematurity and Accompanying Intermittent Hypoxia and Bradycardia.
Topics: Afferent Pathways; Apnea; Birth Weight; Bradycardia; Extremities; Female; Gestational Age; Humans; H | 2016 |
Neuromodulation of Limb Proprioceptive Afferents Decreases Apnea of Prematurity and Accompanying Intermittent Hypoxia and Bradycardia.
Topics: Afferent Pathways; Apnea; Birth Weight; Bradycardia; Extremities; Female; Gestational Age; Humans; H | 2016 |
Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial.
Topics: Apnea; Double-Blind Method; Doxapram; Female; Humans; Infant; Infant, Newborn; Infant, Premature; In | 2016 |
A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Bronchodilator Agents; Carbon Dioxide; Humans; Infant, Newborn; I | 2008 |
A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Bronchodilator Agents; Carbon Dioxide; Humans; Infant, Newborn; I | 2008 |
A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Bronchodilator Agents; Carbon Dioxide; Humans; Infant, Newborn; I | 2008 |
A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Bronchodilator Agents; Carbon Dioxide; Humans; Infant, Newborn; I | 2008 |
Randomised crossover trial of four nasal respiratory support systems for apnoea of prematurity in very low birthweight infants.
Topics: Apnea; Birth Weight; Continuous Positive Airway Pressure; Cross-Over Studies; Female; Gestational Ag | 2009 |
Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Drug Therapy, Combination | 2009 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Sodium Alginate (Gaviscon®) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants.
Topics: Alginates; Aluminum Hydroxide; Apnea; Drug Combinations; Female; Gastroesophageal Reflux; Glucuronic | 2011 |
Exposure to biological maternal sounds improves cardiorespiratory regulation in extremely preterm infants.
Topics: Acoustic Stimulation; Adult; Apnea; Bradycardia; Female; Heart; Humans; Infant, Extremely Premature; | 2012 |
Randomized, controlled trial of oral creatine supplementation (not effective) for apnea of prematurity.
Topics: Apnea; Bradycardia; Creatine; Double-Blind Method; Humans; Hypoxia; Infant, Newborn; Infant, Prematu | 2004 |
Pharmacokinetics of theophylline in preterm neonates during the first month of life.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Female; Humans; Infant, Newborn; Infant, Premature; Inf | 2004 |
Effect of doxapram on cerebral blood flow velocity in preterm infants.
Topics: Anterior Cerebral Artery; Apnea; Blood Flow Velocity; Cerebrovascular Circulation; Doxapram; Female; | 2004 |
Olfactory stimulation prevents apnea in premature newborns.
Topics: Apnea; Aromatherapy; Bradycardia; Caffeine; Central Nervous System Stimulants; Combined Modality The | 2005 |
Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants.
Topics: Anemia; Apnea; Blood Donors; Brain Damage, Chronic; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; | 2005 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
An evaluation of theophylline for idiopathic apnea of infancy.
Topics: Apnea; Birth Weight; Clinical Trials as Topic; Humans; Infant; Infant, Newborn; Infant, Premature, D | 1984 |
Apnoea of immaturity. 1. A controlled trial of theophylline and face mask continuous positive airways pressure.
Topics: Apnea; Clinical Trials as Topic; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, P | 1982 |
A controlled trial of a regularly cycled oscillating waterbed and a non-oscillating waterbed in the prevention of apnoea in the preterm infant.
Topics: Apnea; Beds; Clinical Trials as Topic; Humans; Infant, Newborn; Infant, Premature, Diseases; Random | 1981 |
The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Prospective Studies; Recurren | 1981 |
Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline.
Topics: Aminophylline; Analysis of Variance; Apnea; Caffeine; Cerebrovascular Circulation; Humans; Infant, N | 1995 |
Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates.
Topics: Apnea; Bradycardia; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Prematur | 1995 |
The effect of vertical pulsating stimulation on apnea of prematurity.
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Male; Physic | 1993 |
Erythropoietin levels during theophylline treatment in premature infants.
Topics: Apnea; Erythropoietin; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Theo | 1994 |
Effect of nursing in the head elevated tilt position (15 degrees) on the incidence of bradycardic and hypoxemic episodes in preterm infants.
Topics: Apnea; Bradycardia; Cross-Over Studies; Female; Humans; Hypoxia; Infant, Newborn; Infant, Premature; | 1997 |
Effect of standard rest periods on apnea and weight gain in preterm infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Neonatal Nursing; Re | 1997 |
Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants.
Topics: Anemia; Apnea; Caffeine; Erythropoietin; Humans; Infant, Newborn; Infant, Premature; Infant, Prematu | 1998 |
Postoperative outcome in high-risk infants undergoing herniorrhaphy: comparison between spinal and general anaesthesia.
Topics: Anesthesia, General; Anesthesia, Spinal; Apnea; Bradycardia; Hernia, Inguinal; Humans; Infant, Newbo | 1998 |
Efficacy of nasal intermittent positive pressure ventilation in treating apnea of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intermittent Positiv | 1998 |
The proportion of high risk preterm infants with postoperative apnea and bradycardia is the same after general and spinal anesthesia.
Topics: Anesthesia, General; Anesthesia, Spinal; Anesthetics, Inhalation; Anesthetics, Local; Apnea; Bradyca | 1999 |
Apnoea of prematurity and changes in cerebral oxygenation and cerebral blood volume.
Topics: Analysis of Variance; Apnea; Blood Volume; Brain; Female; Humans; Infant, Newborn; Infant, Premature | 1999 |
Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants.
Topics: Apnea; Birth Weight; Bradycardia; Caffeine; Doxapram; Drug Resistance; Gestational Age; Humans; Hypo | 1999 |
Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment.
Topics: Aminophylline; Apnea; Birth Weight; Blood Flow Velocity; Blood Volume; Caffeine; Central Nervous Sys | 2000 |
Central apnoea and endogenous prostaglandins in neonates.
Topics: Apnea; Bradycardia; Chromatography, Gas; Data Interpretation, Statistical; Dinoprostone; Electrocard | 2000 |
Lung recruitment and breathing pattern during variable versus continuous flow nasal continuous positive airway pressure in premature infants: an evaluation of three devices.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Lung Compliance; Nos | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
Post-operative recovery after inguinal herniotomy in ex-premature infants: comparison between sevoflurane and spinal anaesthesia.
Topics: Anesthesia, Spinal; Anesthetics, Inhalation; Anesthetics, Local; Apnea; Bradycardia; Bupivacaine; He | 2001 |
Gastroesophageal reflux and apnea of prematurity: no temporal relationship.
Topics: Apnea; Comorbidity; Female; Gastroesophageal Reflux; Gestational Age; Heart Arrest; Humans; Infant; | 2002 |
Role of L-carnitine in apnea of prematurity: a randomized, controlled trial.
Topics: Aminophylline; Apnea; Carnitine; Dietary Supplements; Humans; Infant, Newborn; Infant, Premature, Di | 2002 |
A randomized, controlled, double-blind trial comparing two loading doses of aminophylline.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Double-Blind Method; Female; Humans; Infant, Newborn; I | 2002 |
Theophylline pharmacokinetics in premature infants with apnea.
Topics: Apnea; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Infant, Low Birth Wei | 1976 |
Apnea of prematurity. Comparative therapeutic effects of cutaneous stimulation and nasal continuous positive airway pressure.
Topics: Apnea; Birth Weight; Cyanosis; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases | 1975 |
Prophylactic theophylline infusion for prevention of apnea of prematurity.
Topics: Aminophylline; Apnea; Birth Weight; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, | 1992 |
Nasal intermittent positive-pressure ventilation offers no advantages over nasal continuous positive airway pressure in apnea of prematurity.
Topics: Apnea; Carbon Dioxide; Humans; Infant, Newborn; Infant, Premature, Diseases; Intermittent Positive-P | 1989 |
A randomized trial to develop criteria for administering erythrocyte transfusions to anemic preterm infants 1 to 3 months of age.
Topics: Anemia, Neonatal; Apnea; Blood Transfusion; Bradycardia; Erythrocyte Transfusion; Erythropoiesis; He | 1989 |
Magnesium therapy in premature neonates with apnea neonatorum.
Topics: Apnea; Clinical Trials as Topic; Double-Blind Method; Humans; Infant, Newborn; Infant, Premature, Di | 1988 |
Randomized clinical trial of an oscillating air mattress in preterm infants: effect on apnea, growth, and development.
Topics: Air; Apnea; Beds; Birth Weight; Body Weight; Bradycardia; Child Behavior; Child Development; Clinica | 1986 |
Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant.
Topics: Apnea; Caffeine; Double-Blind Method; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseas | 1987 |
Limitations of theophylline in the treatment of apnea of prematurity.
Topics: Apnea; Clinical Trials as Topic; Humans; Infant, Newborn; Infant, Premature, Diseases; Random Alloca | 1985 |
Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study.
Topics: Aminophylline; Apnea; Double-Blind Method; Doxapram; Drug Resistance; Drug Therapy, Combination; Hum | 1985 |
Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Tachycardia; Theophylline | 1985 |
A comparison of oral feeding and total parenteral nutrition in infants of very low birthweight.
Topics: Amino Acids; Apnea; Birth Weight; Cholesterol; Clinical Trials as Topic; Enteral Nutrition; Female; | 1974 |
507 other studies available for apnea and Infant, Premature, Diseases
| Article | Year |
|---|---|
Multichannel esophageal signals to monitor respiratory rate in preterm infants.
Topics: Apnea; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; | 2022 |
Caffeine Duration for Apnea of Prematurity: All Bets Are Off!
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2021 |
The limited management options for apnoea of prematurity.
Topics: Apnea; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2022 |
Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant; Infant, Newborn; Infant, | 2022 |
The epidemiology of apnoea of prematurity.
Topics: Apnea; Female; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Prematur | 2022 |
The effect of apnea length on vital parameters in apnea of prematurity - Hybrid observations from clinical data and simulation in a mathematical model.
Topics: Apnea; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Infant, Prematu | 2022 |
Among Young Infants With Uncomplicated COVID-19: Should We Broaden Diagnostic Tests for Infectious Causes of Apnea?
Topics: Apnea; COVID-19; Diagnostic Tests, Routine; Humans; Infant; Infant, Newborn; Infant, Premature; Infa | 2022 |
Postvaccination Apnea in Extremely-Low-Birth-Weight Infants.
Topics: Apnea; Humans; Infant; Infant, Extremely Low Birth Weight; Infant, Newborn; Infant, Premature, Disea | 2022 |
[Expert consensus on the diagnosis and management of apnea of prematurity (2022)].
Topics: Apnea; Consensus; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infant, Pre | 2022 |
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa | 2022 |
Periodic breathing in clinically stable very preterm infants.
Topics: Apnea; Female; Fetal Growth Retardation; Gestational Age; Humans; Hypoxia; Infant; Infant, Newborn; | 2023 |
Periodic breathing in clinically stable very preterm infants.
Topics: Apnea; Female; Fetal Growth Retardation; Gestational Age; Humans; Hypoxia; Infant; Infant, Newborn; | 2023 |
Periodic breathing in clinically stable very preterm infants.
Topics: Apnea; Female; Fetal Growth Retardation; Gestational Age; Humans; Hypoxia; Infant; Infant, Newborn; | 2023 |
Periodic breathing in clinically stable very preterm infants.
Topics: Apnea; Female; Fetal Growth Retardation; Gestational Age; Humans; Hypoxia; Infant; Infant, Newborn; | 2023 |
It is time for a rethink about caffeine therapy for apnoea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas | 2023 |
Effect of initial and subsequent mask applications on breathing and heart rate in preterm infants at birth.
Topics: Apnea; Bradycardia; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Prematur | 2023 |
Caffeine for Apnea of Prematurity: Too Much or Too Little of a Good Thing.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas | 2023 |
Caffeine not associated with irritable behaviour in very low-birth-weight infants.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Female; Hu | 2019 |
Long-term facilitation of catecholamine secretion from adrenal chromaffin cells of neonatal rats by chronic intermittent hypoxia.
Topics: Adrenal Medulla; Animals; Animals, Newborn; Apnea; Catecholamines; Chromaffin Cells; Chronic Disease | 2019 |
Is earlier better when it comes giving caffeine to preterm infants or are we risking unnecessary treatment and serious harm?
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2020 |
Wide variation in caffeine discontinuation timing in premature infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Cohort Studies; Combined Modality Ther | 2020 |
The implementation of an apnea-based perinatal stress calculator.
Topics: Apnea; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Inte | 2019 |
Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range?
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Re | 2022 |
Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea.
Topics: Apnea; Asian People; Caffeine; Central Nervous System Stimulants; Citrates; Female; Humans; Infant, | 2020 |
Childhood respiratory outcomes after neonatal caffeine therapy.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Child; Citrates; Duc | 2020 |
When to start and stop caffeine and why respiratory status matters.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Humans; Hypoxia; Infant; Infant, Newbo | 2020 |
Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa.
Topics: Africa South of the Sahara; Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Costs and | 2020 |
Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationship, Drug; Huma | 2020 |
Predicting severity of adverse cardiorespiratory effects of morphine in premature infants: a post hoc analysis of Procedural Pain in Premature Infants trial data.
Topics: Analgesics, Opioid; Apnea; Data Analysis; Heart Rate; Humans; Infant, Newborn; Infant, Premature; In | 2021 |
Recurrent Apnea in an Infant - Think Beyond the Usual.
Topics: Apnea; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Sleep Apnea Syndromes | 2021 |
The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age.
Topics: Apnea; Caffeine; Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2021 |
Are we over-treating hypoxic spells in preterm infants?
Topics: Apnea; Caffeine; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Dis | 2021 |
Limitations of thoracic impedance monitoring for central apnoea detection in preterm infants.
Topics: Apnea; Electric Impedance; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2021 |
Achievement of maturational milestones among very low birth weight infants.
Topics: Apnea; Birth Weight; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Infant, Very Low | 2022 |
Unique Way of Peripheral Stimulation for Recurrent Apnea in a Preterm Neonate.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Recurrence | 2017 |
A prospective observational cohort study of exposure to womb-like sounds to stabilize breathing and cardiovascular patterns in preterm neonates.
Topics: Apnea; Bradycardia; Cohort Studies; Female; Heart Rate; Humans; Hypoxia; Infant, Newborn; Infant, Pr | 2018 |
A prospective observational cohort study of exposure to womb-like sounds to stabilize breathing and cardiovascular patterns in preterm neonates.
Topics: Apnea; Bradycardia; Cohort Studies; Female; Heart Rate; Humans; Hypoxia; Infant, Newborn; Infant, Pr | 2018 |
A prospective observational cohort study of exposure to womb-like sounds to stabilize breathing and cardiovascular patterns in preterm neonates.
Topics: Apnea; Bradycardia; Cohort Studies; Female; Heart Rate; Humans; Hypoxia; Infant, Newborn; Infant, Pr | 2018 |
A prospective observational cohort study of exposure to womb-like sounds to stabilize breathing and cardiovascular patterns in preterm neonates.
Topics: Apnea; Bradycardia; Cohort Studies; Female; Heart Rate; Humans; Hypoxia; Infant, Newborn; Infant, Pr | 2018 |
[Apnea of prematurity - characteristic and treatment].
Topics: Apnea; Humans; Hypoxia; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2017 |
Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Female; Follow-Up Studies; Humans; Infant, Newbo | 2017 |
Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationsh | 2017 |
Pharmacotherapies for apnoea of prematurity: time to pause and consider targeted sex-specific strategies?
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male | 2018 |
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity: Few Concerns.
Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2017 |
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity: Few Concerns: Author's Reply.
Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2017 |
Effects of caffeine on the preterm brain: An observational study.
Topics: Apnea; Brain; Caffeine; Electroencephalography; Gestational Age; Humans; Infant, Newborn; Infant, Pr | 2018 |
Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit.
Topics: Aminophylline; Apnea; Birth Weight; Female; Gestational Age; Humans; Infant; Infant, Newborn; Infant | 2019 |
Post-discharge outcomes of failed car seat tolerance screens: A case-control and follow-up study.
Topics: Apnea; Bradycardia; Case-Control Studies; Child Restraint Systems; Contraindications; Female; Follow | 2018 |
The unfortunate tale of immature respiratory control superimposed on an immature lung.
Topics: Apnea; Bronchopulmonary Dysplasia; Continuous Positive Airway Pressure; History, 20th Century; Histo | 2018 |
Caffeine therapy for apnoea of prematurity: Wake up to the fact that sex matters.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Retrospective Studies; Sex Ch | 2018 |
Effect of reading to preterm infants on measures of cardiorespiratory stability in the neonatal intensive care unit.
Topics: Apnea; Bradycardia; Female; Heart Rate; Humans; Infant, Newborn; Infant, Premature; Infant, Prematur | 2018 |
Doxapram Treatment and Diaphragmatic Activity in Preterm Infants.
Topics: Apnea; Birth Weight; Diaphragm; Doxapram; Electromyography; Female; Gestational Age; Humans; Infant, | 2019 |
Bayesian Online Changepoint Detection Of Physiological Transitions.
Topics: Apnea; Bayes Theorem; Bradycardia; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Prema | 2018 |
Caffeine use in preterm infants: from magic to uncertainty.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2018 |
Self-reported Quality of Life at Middle School Age in Survivors of Very Preterm Birth: Results From the Caffeine for Apnea of Prematurity Trial.
Topics: Apnea; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Child; Female; Follow-Up S | 2019 |
Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Ductus Arteriosus, Paten | 2019 |
Physiological instability after respiratory pauses in preterm infants.
Topics: Apnea; Bradycardia; Heart Rate; Humans; Hypoxia; Infant, Newborn; Infant, Premature; Infant, Prematu | 2019 |
A comparison of the infant car seat challenge and the polysomnogram at the time of hospital discharge.
Topics: Apnea; Bradycardia; Child Restraint Systems; Female; Humans; Hypoxia; Infant, Newborn; Infant, Prema | 2013 |
Apnoea after the 2-month immunisation in extremely preterm infants: what happens with the 4-month immunisation?
Topics: Apnea; Humans; Immunization; Infant, Extremely Premature; Infant, Newborn; Infant, Premature, Diseas | 2013 |
Doxapram and hypokalaemia in very preterm infants.
Topics: Analysis of Variance; Apnea; Diuretics; Doxapram; Female; Furosemide; Humans; Hypokalemia; Infant, E | 2013 |
Absence of effect of nasal continuous positive airway pressure on the esophageal phase of nutritive swallowing in newborn lambs.
Topics: Animals; Animals, Newborn; Apnea; Bottle Feeding; Continuous Positive Airway Pressure; Deglutition; | 2013 |
Accurate automated apnea analysis in preterm infants.
Topics: Algorithms; Apnea; Diagnosis, Computer-Assisted; Electrocardiography; Humans; Infant, Newborn; Infan | 2014 |
Postoperative apnea after inguinal hernia repair in formerly premature infants: impacts of gestational age, postconceptional age and comorbidities.
Topics: Age Factors; Apnea; Female; Gestational Age; Hernia, Inguinal; Humans; Infant, Newborn; Infant, Prem | 2013 |
[Saccharomyces cerevisiae fungemia in a premature neonate treated receiving probiotics].
Topics: Antifungal Agents; Apnea; Candidemia; Catheter-Related Infections; Diagnosis, Differential; Equipmen | 2013 |
The use of caffeine for the treatment of apnea of prematurity and bradycardia in a holoprosencephalic child with cleft lip and palate.
Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Citrates; Cleft Lip; Cleft Palate; | 2013 |
Methylxanthine use for apnea of prematurity among an international cohort of neonatologists.
Topics: Apnea; Australia; Caffeine; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; | 2013 |
Pediatric emergency medicine: legal briefs.
Topics: Adolescent; Ambulances; Amputation, Surgical; Apnea; Blindness; Brain Damage, Chronic; Child; Child, | 2013 |
Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity.
Topics: Apnea; Caffeine; Chemistry, Pharmaceutical; Citrates; Drug-Related Side Effects and Adverse Reaction | 2014 |
The risk for hyperoxaemia after apnoea, bradycardia and hypoxaemia in preterm infants.
Topics: Apnea; Bradycardia; Continuous Positive Airway Pressure; Female; Gestational Age; Humans; Hyperoxia; | 2014 |
Amplitude-integrated electroencephalography shows that doxapram influences the brain activity of preterm infants.
Topics: Apnea; Brain; Doxapram; Electroencephalography; Female; Gestational Age; Humans; Infant, Newborn; In | 2014 |
[Exploring the clinical significance of continuously measuring apparent diffusion coefficient values in the preterm infants with punctate white matter damage by applying diffusion weighted imaging].
Topics: Apnea; Birth Weight; Brain; Brain Diseases; Case-Control Studies; Diffusion Magnetic Resonance Imagi | 2014 |
Former preterm infants, caffeine was good for you, but now beware of snoring!
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal | 2014 |
Neonatal caffeine therapy and sleep: important findings to guide new approaches and reduce concerns.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal | 2014 |
Reply: neonatal caffeine therapy and sleep: important findings to guide new approaches and reduce concerns.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal | 2014 |
Instrumentation for the detection and interruption of apnea episodes for premature newborn.
Topics: Apnea; Female; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2014 |
[Indications and concept of follow-up care of home-monitoring for premature and risk infants].
Topics: Apnea; Bradycardia; Cooperative Behavior; Diagnosis, Differential; Germany; Guideline Adherence; Hom | 2015 |
Apnea of Prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient Discharge | 2016 |
Apnea of Prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient Discharge | 2016 |
Apnea of Prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient Discharge | 2016 |
Apnea of Prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient Discharge | 2016 |
Apnea of Prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient Discharge | 2016 |
Apnea of Prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient Discharge | 2016 |
Apnea of Prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient Discharge | 2016 |
Apnea of Prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient Discharge | 2016 |
Apnea of Prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Patient Discharge | 2016 |
Gaviscon and domperidon responsive apnea episodes associated with gastro-esophageal reflux disease in twins.
Topics: Alginates; Aluminum Hydroxide; Antacids; Antiemetics; Apnea; Diseases in Twins; Domperidone; Drug Co | 2015 |
The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Citrates; Europe; Female; Humans; Infant, Newborn; Infa | 2016 |
Home apnea monitors--when to discontinue use.
Topics: Apnea; Brief, Resolved, Unexplained Event; Humans; Infant, Newborn; Infant, Premature; Infant, Prema | 2015 |
QUESTION 2: Vaccinating preterm infants in resource-poor settings: what is the incidence of apnoea, bradycardia and need for respiratory support?
Topics: Apnea; Bradycardia; Gestational Age; Humans; Immunization Schedule; Incidence; Infant; Infant, Newbo | 2016 |
Diagnostic Evaluation and Home Monitor Use in Late Preterm to Term Infants With Apnea, Bradycardia, and Desaturations.
Topics: Adult; Apnea; Boston; Bradycardia; Female; Gestational Age; Humans; Infant, Extremely Low Birth Weig | 2016 |
Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Central Nervous System Stimulants; Child Development; Doxapram; D | 2016 |
Predictive Factors for Efficacy and Safety of Prophylactic Theophylline for Extubation in Infants with Apnea of Prematurity.
Topics: Airway Extubation; Apnea; Bronchodilator Agents; Female; Gestational Age; Humans; Infant, Newborn; I | 2016 |
Renal apnoea: extreme disturbance of homoeostasis in a child with Bartter syndrome type IV.
Topics: Amiloride; Apnea; Bartter Syndrome; Diuretics, Potassium Sparing; Female; Homeostasis; Humans; Infan | 2016 |
[Current research status of drug therapy for apnea of prematurity].
Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2016 |
Caffeine for apnea in bronchiolitis.
Topics: Apnea; Bronchiolitis; Caffeine; Humans; Infant, Premature; Infant, Premature, Diseases | 2017 |
A very strict guideline reduces the number of erythrocyte transfusions in preterm infants.
Topics: Apnea; Cerebral Hemorrhage; Cohort Studies; Erythrocyte Transfusion; Female; Gestational Age; Guidel | 2008 |
Differential diagnosis of apneas in preterm infants.
Topics: Apgar Score; Apnea; Arousal; Birth Weight; Diagnosis, Differential; Electrocardiography; Electroence | 2009 |
Gastro-oesophageal reflux increases the number of apnoeas in very preterm infants.
Topics: Apnea; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, P | 2009 |
Apnea-associated reduction in lower esophageal sphincter tone in premature infants.
Topics: Apnea; Deglutition; Esophageal Motility Disorders; Esophageal Sphincter, Lower; Humans; Infant, Newb | 2009 |
Risk factors for extreme events in infants hospitalized for apparent life-threatening events.
Topics: Airway Obstruction; Apnea; Canada; Cohort Studies; Comorbidity; Cyanosis; Female; Gestational Age; H | 2009 |
Subcutaneous scalp emphysema, pneumo-orbitis and pneumocephalus in a neonate on high humidity high flow nasal cannula.
Topics: Apnea; Continuous Positive Airway Pressure; Humans; Infant, Extremely Low Birth Weight; Infant, Newb | 2008 |
Acute hemodynamic effects of caffeine administration in premature infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Hemodynamics; Humans; Infant, Newborn; | 2009 |
Spinal anesthesia for the premature infant: is this really the answer to avoiding postoperative apnea?
Topics: Anesthesia, General; Anesthesia, Spinal; Apnea; Clinical Protocols; Hernia, Inguinal; Humans; Infant | 2009 |
Occurrence of serious bacterial infection in infants aged 60 days or younger with an apparent life-threatening event.
Topics: Airway Obstruction; Apnea; Bacteremia; Bacterial Infections; Bacteriuria; Cerebrospinal Fluid; Comor | 2009 |
Apnea, bradycardia and desaturation in preterm infants before and after feeding.
Topics: Apnea; Blood Gas Analysis; Bradycardia; Cohort Studies; Female; Gastroesophageal Reflux; Humans; Inf | 2009 |
Pediatric emergency medicine: legal briefs.
Topics: Abdomen, Acute; Accidents, Traffic; Adolescent; Aortic Aneurysm, Abdominal; Aortic Rupture; Apnea; B | 2009 |
Infant functional status: the timing of physiologic maturation of premature infants.
Topics: Apnea; Child Development; Gestational Age; Hot Temperature; Humans; Infant Care; Infant, Newborn; In | 2009 |
Developmental pattern of urinary bile acid profile in preterm infants.
Topics: Apgar Score; Apnea; Bile Acids and Salts; Birth Weight; Female; Gas Chromatography-Mass Spectrometry | 2010 |
Influenza A/H1N1 virus in very low-birth-weight premature infant: case report.
Topics: Antiviral Agents; Apnea; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Dise | 2010 |
Characterization of cardiorespiratory events following gastroesophageal reflux in preterm infants.
Topics: Apnea; Bradycardia; Cardiography, Impedance; Female; Gastroesophageal Reflux; Humans; Infant, Newbor | 2010 |
Clinical signs and CRP values associated with blood culture results in neonates evaluated for suspected sepsis.
Topics: Apnea; Blood Pressure; Bradycardia; C-Reactive Protein; Feeding Behavior; Female; Gestational Age; H | 2010 |
Heritability of apnea of prematurity: a retrospective twin study.
Topics: Apnea; Diseases in Twins; Female; Genetic Predisposition to Disease; Humans; Infant, Newborn; Infant | 2010 |
Economic evaluation of caffeine for apnea of prematurity.
Topics: Apnea; Caffeine; Cost-Benefit Analysis; Female; Humans; Infant, Newborn; Infant, Premature, Diseases | 2011 |
Variation in diagnosis of apnea in moderately preterm infants predicts length of stay.
Topics: Apnea; Female; Forecasting; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; L | 2011 |
A critical review of premature infants with inguinal hernias: optimal timing of repair, incarceration risk, and postoperative apnea.
Topics: Apnea; Birth Weight; Comorbidity; Elective Surgical Procedures; Female; General Surgery; Gestational | 2011 |
Effects of non-synchronised nasal intermittent positive pressure ventilation on spontaneous breathing in preterm infants.
Topics: Apnea; Birth Weight; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Infant, Pr | 2011 |
Archimedes: Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb | 2011 |
Ambient air pollution and apnea and bradycardia in high-risk infants on home monitors.
Topics: Air Pollutants; Apnea; Bradycardia; Confidence Intervals; Female; Georgia; Home Care Services; Human | 2011 |
Temporal association of polysomnographic cardiorespiratory events with GER detected by MII-pH probe in the premature infant at term.
Topics: Apnea; Electric Impedance; Esophageal pH Monitoring; Fundoplication; Gastroesophageal Reflux; Gestat | 2011 |
Recurrent apnoea post immunisation: Informing re-immunisation policy.
Topics: Apnea; Bradycardia; Female; Gestational Age; Humans; Immunization; Immunization Schedule; Infant; In | 2011 |
Epidemiology of apnea and bradycardia resolution in premature infants.
Topics: Age Factors; Apnea; Bradycardia; Cohort Studies; Female; Humans; Infant, Newborn; Infant, Premature; | 2011 |
Ambient air pollution and infant health: home monitors make cardiorespiratory connections.
Topics: Air Pollutants; Apnea; Bradycardia; Female; Humans; Infant, Premature, Diseases; Male; Monitoring, P | 2011 |
Apparent life-threatening event admissions and gastroesophageal reflux disease: the value of hospitalization.
Topics: Airway Obstruction; Apnea; California; Consciousness Disorders; Cyanosis; Disease Management; Emerge | 2012 |
[Cardiorespiratory events after first immunization in premature infants: a prospective cohort study].
Topics: Apnea; Bradycardia; Cohort Studies; Diphtheria-Tetanus-acellular Pertussis Vaccines; Diphtheria-Teta | 2012 |
Effects of naloxone on the breathing pattern of a newborn exposed to maternal opiates.
Topics: Analgesics, Opioid; Anesthetics, Intravenous; Apnea; Female; Humans; Infant, Newborn; Infant, Premat | 2012 |
Impedance-pH monitoring and conventional pH monitoring are complementary methods to detect association between gastroesophageal reflux and apnea-related symptoms in preterm infants and neonates.
Topics: Apnea; Electric Impedance; Esophageal pH Monitoring; Female; Gastric Acidity Determination; Gastroes | 2012 |
Caffeine as treatment for bronchiolitis-related apnoea.
Topics: Apnea; Bronchiolitis; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Prematur | 2012 |
Episodes of apnea, desaturation and bradycardia and the development of necrotizing enterocolitis in preterm infants: a case-control study.
Topics: Apnea; Bradycardia; Case-Control Studies; Enteral Nutrition; Enterocolitis, Necrotizing; Female; Hum | 2013 |
Averaging time, desaturation level, duration and extent.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Oximetry; Oxygen; Pr | 2013 |
A thickened formula does not reduce apneas related to gastroesophageal reflux in preterm infants.
Topics: Apnea; Female; Gastroesophageal Reflux; Gestational Age; Humans; Hydrogen-Ion Concentration; Infant | 2013 |
Gastroesophageal reflux and apnea of prematurity--coincidence, not causation. Commentary on L. Corvaglia et Al.: A thickened formula does not reduce apneas related to gastroesophageal reflux in preterm infants (Neonatology 2013;103;98-102).
Topics: Apnea; Female; Gastroesophageal Reflux; Humans; Infant Formula; Infant, Premature; Infant, Premature | 2013 |
Medical retrieval and needs of infants with bronchiolitis: an analysis by gestational age.
Topics: Apnea; Australia; Bronchiolitis; Cohort Studies; Female; Gestational Age; Health Services Needs and | 2013 |
Monitoring apnea of prematurity: validity of nursing documentation and bedside cardiorespiratory monitor.
Topics: Apnea; Bradycardia; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2013 |
Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity.
Topics: Apnea; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Health Care Costs; H | 2003 |
Apnea, sudden infant death syndrome, and home monitoring.
Topics: Apnea; Bradycardia; Evidence-Based Medicine; Home Nursing; Humans; Hypoxia; Infant; Infant, Newborn; | 2003 |
Acellular pertussis and meningococcal C vaccines: cardio-respiratory events in preterm infants.
Topics: Apnea; Bradycardia; Diphtheria-Tetanus-acellular Pertussis Vaccines; Humans; Infant, Newborn; Infant | 2003 |
Severe apnea and irregular respiratory rhythms among premature infants; a clinical and laboratory study.
Topics: Apnea; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Respiration | 1959 |
HYPERBARIC OXYGEN IN THE TREATMENT OF APNOEA NEONATORUM.
Topics: Apnea; Asphyxia Neonatorum; Atmospheric Pressure; Blood; Humans; Hyperbaric Oxygenation; Infant; Inf | 1964 |
[CONTRIBUTION TO GAS ANALYTICAL DIAGNOSIS OF RESPIRATORY DISORDER IN PREMATURE NEWBORN INFANTS].
Topics: Acidosis; Apnea; Blood Gas Analysis; Humans; Hyaline Membrane Disease; Infant; Infant, Newborn; Infa | 1964 |
INDICATIONS FOR OXYGEN THERAPY IN THE NEWBORN.
Topics: Apnea; Asphyxia Neonatorum; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Oxygen; Ox | 1964 |
THE NEUROLOGICAL AND DEVELOPMENTAL EFFECTS OF NEONATAL HYPOGLYCEMIA: A FOLLOW-UP OF 22 CASES.
Topics: Apnea; Cyanosis; Diabetes Mellitus; Female; Follow-Up Studies; Growth; Humans; Hypoglycemia; Infant; | 1965 |
RECURRENT NEONATAL APNOEA.
Topics: Apnea; Blood Gas Analysis; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Prema | 1965 |
The association between respiratory distress and nonpulmonary morbidity at 34 to 36 weeks' gestation.
Topics: Apnea; Bradycardia; Case-Control Studies; Ethnicity; Female; Gestational Age; Humans; Infant, Newbor | 2003 |
Consanguinity and apnea of prematurity.
Topics: Adult; Apgar Score; Apnea; Chi-Square Distribution; Consanguinity; Cross-Sectional Studies; Educatio | 2003 |
Evaluation of change of cerebral circulation by SpO2 in preterm infants with apneic episodes using near infrared spectroscopy.
Topics: Apnea; Blood Volume; Cerebrovascular Circulation; Humans; Infant, Newborn; Infant, Premature, Diseas | 2003 |
Apnea is associated with neurodevelopmental impairment in very low birth weight infants.
Topics: Apnea; Child Development; Communication; Developmental Disabilities; Female; Follow-Up Studies; Huma | 2004 |
Apnea is associated with neurodevelopmental impairment in very low birth weight infants.
Topics: Apnea; Child Development; Communication; Developmental Disabilities; Female; Follow-Up Studies; Huma | 2004 |
Apnea is associated with neurodevelopmental impairment in very low birth weight infants.
Topics: Apnea; Child Development; Communication; Developmental Disabilities; Female; Follow-Up Studies; Huma | 2004 |
Apnea is associated with neurodevelopmental impairment in very low birth weight infants.
Topics: Apnea; Child Development; Communication; Developmental Disabilities; Female; Follow-Up Studies; Huma | 2004 |
Bradycardia and desaturation during skin-to-skin care: no relationship to hyperthermia.
Topics: Apnea; Body Temperature; Bradycardia; Female; Heart Rate; Humans; Incubators, Infant; Infant; Infant | 2004 |
Risk of life threatening apnoea after immunisation.
Topics: Apnea; Humans; Immunization; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2005 |
Transient bilirubin encephalopathy and apnea of prematurity in 28 to 32 weeks gestational age infants.
Topics: Apnea; Bilirubin; Evoked Potentials, Auditory, Brain Stem; Gestational Age; Humans; Infant, Newborn; | 2005 |
Apnoea and bradycardia in preterm infants following immunisation with pentavalent or hexavalent vaccines.
Topics: Apnea; Bradycardia; Diphtheria-Tetanus-Pertussis Vaccine; Female; Haemophilus Vaccines; Hepatitis B | 2005 |
Successful liver transplantation for congenital absence of the portal vein complicated by intrapulmonary shunt and brain abscess.
Topics: Abnormalities, Multiple; Anti-Bacterial Agents; Apnea; Atrophy; Birth Weight; Brain; Brain Abscess; | 2005 |
Can all neonatal resuscitation be managed by nurse practitioners?
Topics: Apnea; Brain Diseases; Clinical Competence; Hospital Mortality; Humans; Hypovolemia; Infant, Newborn | 2006 |
Brain hemodynamic effects of doxapram in preterm infants.
Topics: Apnea; Birth Weight; Blood Flow Velocity; Brain; Case-Control Studies; Doxapram; Gestational Age; Hu | 2006 |
Apnea is not prolonged by acid gastroesophageal reflux in preterm infants.
Topics: Apnea; Esophageal pH Monitoring; Gastroesophageal Reflux; Heart Rate; Humans; Infant, Newborn; Infan | 2005 |
Apnea is not prolonged by acid gastroesophageal reflux in preterm infants.
Topics: Apnea; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2005 |
Antecedents of respiratory pauses in extremely low birth weight infants supported by proportional assist ventilation.
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infant, Very | 2006 |
Caffeine for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newb | 2006 |
Summary proceedings from the apnea-of-prematurity group.
Topics: Apnea; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2006 |
Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants.
Topics: Alberta; Apnea; Birth Weight; Body Weight; Bradycardia; Child, Hospitalized; Cohort Studies; Diphthe | 2006 |
[Caffeine citrate utilization for treatment of apnea in French neonatal units].
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationship, Drug; Drug | 2006 |
[Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate].
Topics: Ambulatory Care; Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Citrates; Continu | 2006 |
Morphine-related apnoea in CPAP-treated preterm neonates.
Topics: Analgesics, Opioid; Apnea; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant, Pre | 2006 |
Caffeine for apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Diuresis; Growth; Humans; Infant, Low Birth Weig | 2006 |
Caffeine for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, P | 2006 |
Brain monitoring in the neonate--the Rationale.
Topics: Apnea; Brain; Brain Ischemia; Electrocardiography; Electroencephalography; Fetal Monitoring; Humans; | 2006 |
Identifying hospitalized infants who have bronchiolitis and are at high risk for apnea.
Topics: Age Factors; Apnea; Bronchiolitis; Cohort Studies; Databases, Factual; Female; Gestational Age; Huma | 2006 |
[Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma].
Topics: Antihypertensive Agents; Apnea; Brimonidine Tartrate; Cataract; Female; Glaucoma; Humans; Infant, Ne | 2007 |
Factors influencing apnea and bradycardia of prematurity - implications for neurodevelopment.
Topics: Apnea; Bradycardia; Developmental Disabilities; Female; Follow-Up Studies; Gestational Age; Hospital | 2007 |
Cardiorespiratory events recorded on home monitors: the effect of prematurity on later serious events.
Topics: Age Factors; Apnea; Bradycardia; Follow-Up Studies; Home Care Services; Humans; Infant; Infant, Newb | 2007 |
Spinal anesthesia in neonates and infants - a single-center experience of 505 cases.
Topics: Anesthesia, Spinal; Anesthetics, Local; Apnea; Body Weight; Bradycardia; Bupivacaine; Female; Gestat | 2007 |
[Severe bronchiolitis. Epidemiology and clinical course of 284 patients].
Topics: Age Factors; Apnea; Bronchiolitis, Viral; Child, Preschool; Humans; Infant; Infant, Newborn; Infant, | 2007 |
On the caffeination of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb | 2007 |
Cardiorespiratory development in extremely preterm infants: vulnerability to infection and persistence of events beyond term-equivalent age.
Topics: Apnea; Bradycardia; Female; Heart; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Premature; Infa | 2008 |
ACOG Committee Opinion No. 404 April 2008. Late-preterm infants.
Topics: Apnea; Body Temperature; Gestational Age; Humans; Infant Mortality; Infant, Newborn; Infant, Prematu | 2008 |
Extreme and conventional cardiorespiratory events and epidemiologic risk factors for SIDS.
Topics: Apnea; Bradycardia; Case-Control Studies; Circadian Rhythm; Cohort Studies; Female; Humans; Infant; | 2008 |
The frequency of apneas in premature infants after inguinal hernia repair: do they need overnight monitoring in the intensive care unit?
Topics: Apnea; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Comorbidity; Ductus Arteriosus, Patent; Fema | 2008 |
Analgosedation with low-dose morphine for preterm infants with CPAP: risks and benefits.
Topics: Analgesics, Opioid; Apnea; Conscious Sedation; Continuous Positive Airway Pressure; Female; Heart Ra | 2008 |
Plasma beta-endorphin concentration in infants with apneic spells.
Topics: Apnea; beta-Endorphin; Bradycardia; Endorphins; Humans; Hypotension; Infant, Newborn; Infant, Premat | 1984 |
[Drug treatment of apnoea in premature infants (author's transl)].
Topics: Apnea; Chemoreceptor Cells; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Neurotra | 1981 |
Study of neurotransmitters in premature infants with or without apnea of prematurity.
Topics: Apnea; Biogenic Amines; Homovanillic Acid; Humans; Infant, Newborn; Infant, Premature; Infant, Prema | 1982 |
Effect of theophylline on neurotransmitters in preterm infants with apnea.
Topics: Apnea; Biogenic Amines; Catecholamines; Homovanillic Acid; Humans; Infant, Newborn; Infant, Prematur | 1983 |
Apnoea of immaturity. 2. Mortality and handicap.
Topics: Apnea; Disabled Persons; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Intellectual | 1982 |
Beta-endorphin levels in newborn cerebrospinal fluid.
Topics: Apnea; beta-Endorphin; Endorphins; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Prema | 1982 |
Idiopathic apnoea of prematurity treated with doxapram and aminophylline.
Topics: Aminophylline; Apnea; Carbon Dioxide; Doxapram; Drug Therapy, Combination; Female; Humans; Infant, N | 1984 |
Hypoxemia associated with feeding in the preterm infant and full-term neonate.
Topics: Apnea; Bottle Feeding; Bradycardia; Carbon Dioxide; Female; Humans; Hypoxia; Infant; Infant, Newborn | 1984 |
Apnea of prematurity: I. Lung function and regulation of breathing.
Topics: Apnea; Carbon Dioxide; Evaluation Studies as Topic; Humans; Infant, Newborn; Infant, Premature, Dise | 1984 |
Monitoring apnea in premature newborns: how effective are conventional techniques?
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physiologic | 1983 |
Life-threatening perioperative apnea in the ex-"premie".
Topics: Anesthesia; Apnea; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; | 1983 |
Electroencephalographic study of intraventricular hemorrhage in the preterm newborn.
Topics: Apnea; Cerebral Hemorrhage; Electroencephalography; Humans; Infant, Newborn; Infant, Premature, Dise | 1983 |
T4 levels in methylxanthine-treated premature newborns.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Retrospective Studies; Theoph | 1983 |
Interaction of caffeine and continuous distending airway pressure in neonatal apnea.
Topics: Apnea; Caffeine; Combined Modality Therapy; Humans; Infant, Newborn; Infant, Premature, Diseases; Lu | 1983 |
Risk factors for retrolental fibroplasia.
Topics: Apnea; Exchange Transfusion, Whole Blood; Humans; Hyaline Membrane Disease; Infant, Newborn; Infant, | 1983 |
Respiratory syncytial virus-related apnea in infants. Demographics and outcome.
Topics: Apnea; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Male | 1984 |
Doxapram in the treatment of idiopathic apnea of prematurity unresponsive to aminophylline.
Topics: Aminophylline; Apnea; Doxapram; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature, Dise | 1984 |
Apnea of prematurity: II. Respiratory reflexes.
Topics: Air Pressure; Airway Obstruction; Apnea; Esophagus; Humans; Infant, Newborn; Infant, Premature, Dise | 1984 |
Assessment of cardiovascular effects to theophylline in premature newborns by means of serial echocardiography.
Topics: Apnea; Echocardiography; Hemodynamics; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophy | 1984 |
Prolonged intermittent positive pressure ventilation by nasal prongs in apnea of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Intermittent Positive-Pressure Ventilat | 1982 |
Apnea.
Topics: Apnea; Carbon Dioxide; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseas | 1982 |
Clinical apnea and brain-stem neural function in preterm infants.
Topics: Apnea; Brain Stem; Evoked Potentials, Auditory; Gestational Age; Humans; Infant, Newborn; Infant, Pr | 1983 |
Effects of aminophylline on respiratory center and reflex activity in premature infants with apnea.
Topics: Aminophylline; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Reflex; Respiration; Res | 1983 |
Microprocessor-based long term cardiorespirography. I. Heart rate changes and apneic attacks.
Topics: Apnea; Computers; Electrocardiography; Heart Rate; Humans; Infant, Newborn; Infant, Newborn, Disease | 1983 |
Episodic airway obstruction in premature infants.
Topics: Airway Obstruction; Apnea; Asphyxia Neonatorum; Bradycardia; Humans; Infant, Newborn; Infant, Premat | 1983 |
Apnea monitoring by acoustic detection of airflow.
Topics: Acoustics; Apnea; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Phys | 1983 |
Cerebrospinal fluid concentration of biogenic amine metabolites in idiopathic apnea of prematurity.
Topics: Apnea; Glycols; Homovanillic Acid; Humans; Infant, Newborn; Infant, Premature, Diseases; Methoxyhydr | 1983 |
Resolution of prolonged neonatal apnea with hernia repair.
Topics: Apnea; Hernia, Inguinal; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Male | 1983 |
To breathe or not to breathe--what have we learned about apneic spells and sudden infant death?
Topics: Apnea; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Respiration; Sudden Infant Deat | 1983 |
Plasma theophylline and caffeine and plasma clearance of theophylline during theophylline treatment in the first year of life.
Topics: Apnea; Caffeine; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1983 |
Syndrome of inappropriate antidiuretic hormone (SIADH) secretion in a preterm infant who was receiving oral theophylline.
Topics: Administration, Oral; Apnea; Female; Humans; Inappropriate ADH Syndrome; Infant, Newborn; Infant, Pr | 1983 |
Plasma xanthine levels in premature infants treated for apnoea with theophylline.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Xanth | 1983 |
Plasma glucose changes in preterm infants during oral theophylline therapy.
Topics: Apnea; Blood Glucose; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1983 |
Undetected episodes of prolonged apnea and severe bradycardia in preterm infants.
Topics: Aminophylline; Apnea; Bradycardia; Electrocardiography; Female; Heart Rate; Humans; Infant; Infant, | 1983 |
Risk factors in retrolental fibroplasia.
Topics: Apnea; Birth Weight; Follow-Up Studies; Gestational Age; Humans; Infant, Newborn; Infant, Newborn, D | 1980 |
[Nursing report. Naso-oral suction in premature infants--a method acceptable to the child and not likely to cause apnea or bradycardia].
Topics: Apnea; Bradycardia; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Mouth; | 1981 |
[Cardiorespirographic studies in prematures with apnea and bradycardia during spontaneous breathing and CPAP-therapy (author's transl)].
Topics: Apnea; Asphyxia Neonatorum; Bradycardia; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Dis | 1980 |
Prolonged intermittent positive pressure ventilation by nasal prongs in intractable apnea of prematurity.
Topics: Apnea; Blood Gas Analysis; Female; Follow-Up Studies; Humans; Infant, Newborn; Infant, Premature, Di | 1981 |
Pharyngeal airway obstruction in preterm infants during mixed and obstructive apnea.
Topics: Airway Obstruction; Apnea; Catheterization; Humans; Infant, Newborn; Infant, Premature, Diseases; Ph | 1982 |
The efficacy of theophylline in premature infants with mixed and obstructive apnea and apnea associated with pulmonary and neurologic disease.
Topics: Airway Obstruction; Apnea; Cerebral Hemorrhage; Humans; Hyaline Membrane Disease; Infant, Newborn; I | 1982 |
Effect of a rocking bed on apnoea of prematurity.
Topics: Apnea; Beds; Bradycardia; Humans; Incubators, Infant; Infant; Infant, Newborn; Infant, Premature, Di | 1982 |
Pharmacokinetic aspects of caffeine in premature infants with apnoea.
Topics: Apnea; Caffeine; Female; Half-Life; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Ki | 1982 |
Influence of food intake on bioavailability of theophylline in premature infants.
Topics: Apnea; Biological Availability; Food; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Pr | 1982 |
beta-hemolytic streptococcal infection appearing as persistent fetal circulation.
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Male | 1982 |
Cross validation of serum to saliva relationships of caffeine, theophylline and total methylxanthines in neonates.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Saliva; Theophylline; Xanthin | 1982 |
[Use of caffeine in the treatment of apnea in premature infants].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Time | 1982 |
Additional causes of postoperative complications in premature infants.
Topics: Apnea; Humans; Hypoxia; Infant, Newborn; Infant, Premature, Diseases; Postoperative Complications; W | 1982 |
Evidence for a laryngeal chemoreflex in some human preterm infants.
Topics: Apnea; Deglutition; Humans; Infant, Newborn; Infant, Premature, Diseases; Larynx; Reflex; Sodium Chl | 1982 |
Caffeine and theophylline: serum/CSF correlation in premature infants.
Topics: Apnea; Blood-Brain Barrier; Caffeine; Chromatography, Liquid; Humans; Infant, Newborn; Infant, Prema | 1980 |
Functional residual capacity and oxygen tension in apnea of prematurity.
Topics: Apnea; Functional Residual Capacity; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; L | 1981 |
Theophylline metabolism in premature infants.
Topics: Aminophylline; Apnea; Biotransformation; Gas Chromatography-Mass Spectrometry; Humans; Infant, Newbo | 1981 |
[Apnea and theophylline in the premature infant. Clinical and pharmacokinetic study in 32 premature infants].
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline | 1981 |
What we don't know about water beds and apneic preterm infants.
Topics: Apnea; Beds; Bradycardia; Humans; Infant, Newborn; Infant, Premature, Diseases | 1981 |
Bradycardia and associated respiratory changes in neonates.
Topics: Apnea; Bradycardia; Humans; Infant, Newborn; Infant, Premature, Diseases; Movement; Respiration | 1981 |
Relationship between apnoea and bradycardia in preterm infants.
Topics: Apnea; Bradycardia; Humans; Infant, Newborn; Infant, Premature, Diseases; Pulmonary Ventilation; Sle | 1981 |
[Apnea in premature infants. Current therapy (author's transl)].
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Respiratory Therapy; Xanthines | 1981 |
[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Protein Binding; Th | 1981 |
Theophylline in treatment of apnoea of prematurity.
Topics: Apnea; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1981 |
Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Regression Analysis; Saliva; | 1980 |
Upper airways obstruction and apnoea in preterm babies.
Topics: Airway Obstruction; Apnea; Esophagus; Functional Residual Capacity; Humans; Infant; Infant, Newborn; | 1980 |
An explanation for failure of impedance apnoea alarm systems.
Topics: Apnea; Diagnostic Errors; Electrocardiography; Female; Humans; Infant; Infant, Newborn; Infant, Newb | 1980 |
24-hour tape recordings of ECG and respiration in the newborn infant with findings related to sudden death and unexplained brain damage in infancy.
Topics: Apnea; Arrhythmias, Cardiac; Bradycardia; Brain Damage, Chronic; Electrocardiography; Female; Heart | 1980 |
Quantitation of doxapram in blood, plasma and urine.
Topics: Apnea; Doxapram; Flame Ionization; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Infant, | 1980 |
Bacterial infection in preterm infants during xanthine therapy for idiopathic apnoea of prematurity.
Topics: Aminophylline; Apnea; Bacterial Infections; Female; Humans; Infant, Newborn; Infant, Premature, Dise | 1980 |
Plasma concentration-effect relationship of theophylline in treatment of apnea in preterm infants.
Topics: Apnea; Gestational Age; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Re | 1980 |
Neonatal inguinal hernia and recurrent apnea.
Topics: Apnea; Hernia, Inguinal; Humans; Infant, Newborn; Infant, Premature, Diseases; Male | 1980 |
Oxygen consumption in apneic premature infants after low-dose theophylline.
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Consumption; Theop | 1980 |
Factors affecting theophylline pharmacokinetics in premature infants with apnea.
Topics: Age Factors; Apnea; Body Weight; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinet | 1980 |
Developmental outcome of premature infants treated with theophylline.
Topics: Apnea; Growth; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1980 |
Monitoring radiant power in the critically ill newborn under a radiant warmer.
Topics: Apnea; Body Temperature Regulation; Critical Care; Dehydration; Humans; Infant, Newborn; Infant, Pre | 1980 |
Simultaneous determination of theophylline and caffeine after extractive alkylation in small volumes of plasma by gas chromatography--mass spectrometry.
Topics: Alkylation; Apnea; Caffeine; Gas Chromatography-Mass Spectrometry; Humans; Infant, Newborn; Infant, | 1980 |
Continuous monitoring of PO2 during apnea of prematurity.
Topics: Apnea; Heart Rate; Humans; Hypoxia; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature, Di | 1981 |
Improved understanding of respiratory control--implications for the treatment of apnoea.
Topics: Apnea; Chemoreceptor Cells; Humans; Infant, Newborn; Infant, Premature, Diseases; Respiration; Respi | 1995 |
Infant apnea detection after herniorrhaphy.
Topics: Apnea; Elective Surgical Procedures; Hernia, Inguinal; Humans; Infant, Newborn; Infant, Premature, D | 1995 |
Neurodevelopmental outcome of infants with apnea of infancy.
Topics: Apnea; Cerebral Palsy; Child, Preschool; Developmental Disabilities; Female; Follow-Up Studies; Huma | 1993 |
Pitfalls in respiratory monitoring of premature infants during kangaroo care.
Topics: Apnea; Electrodes; Heart Rate; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseas | 1995 |
Prolonged episodes of hypoxemia in preterm infants undetectable by cardiorespiratory monitors.
Topics: Apnea; Bradycardia; Female; Heart Rate; Humans; Hypoxia; Infant, Newborn; Infant, Premature; Infant, | 1995 |
Effect of blood transfusion on cardiorespiratory abnormalities in preterm infants.
Topics: Apnea; Erythrocyte Transfusion; Heart Rate; Humans; Infant; Infant, Low Birth Weight; Infant, Newbor | 1995 |
Induction of mixed apneas by inhalation of 100% oxygen in preterm infants.
Topics: Apnea; Electromyography; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; O | 1994 |
Treatment of apnea of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Positive-Pressure Respiration; Primidon | 1994 |
Theophylline infusion for prevention of apnea of prematurity.
Topics: Apnea; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, Intravenous | 1993 |
Plasma cholinesterase deficiency in a premature neonate.
Topics: Anesthesia, Intravenous; Apnea; Cholinesterases; Humans; Infant, Newborn; Infant, Premature; Infant, | 1994 |
Suxamethonium-induced prolonged apnoea in a premature neonate.
Topics: Anesthesia, Intravenous; Apnea; Cerebrospinal Fluid Shunts; Cholinesterases; Homozygote; Humans; Hyd | 1994 |
Cerebral hyperperfusion following episodes of bradycardia in the preterm infant.
Topics: Apnea; Blood Flow Velocity; Blood Gas Monitoring, Transcutaneous; Blood Pressure; Bradycardia; Brain | 1993 |
Episodes of bradycardia during early infancy in the term-born and preterm infant.
Topics: Age Factors; Apnea; Bradycardia; Female; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premat | 1993 |
Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity.
Topics: Apnea; beta-Endorphin; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Xanthine; Xan | 1993 |
Listeriosis of the placenta: clinicopathologic study of seven cases.
Topics: Adolescent; Adult; Apnea; Bacteremia; Female; Fetal Diseases; Humans; Hyaline Membrane Disease; Infa | 1993 |
Nasal colonization with coronavirus and apnea of the premature newborn.
Topics: Apnea; Coronaviridae; Coronaviridae Infections; Cross Infection; Humans; Infant, Newborn; Infant, Pr | 1993 |
Indomethacin and apnea of prematurity.
Topics: Aminophylline; Apnea; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Premature, D | 1993 |
[Postoperative apnea in preterm infants after inguinal herniorrhaphy].
Topics: Apnea; Hernia, Inguinal; Humans; Infant, Newborn; Infant, Premature, Diseases; Japan; Postoperative | 1993 |
Higher adenosine dosage required for supraventricular tachycardia in infants treated with theophylline.
Topics: Adenosine; Apnea; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Tachycardia, Paroxys | 1993 |
The incidence of obstructive apneas in preterm infants with and without bronchopulmonary dysplasia.
Topics: Apnea; Bronchopulmonary Dysplasia; Heart Rate; Humans; Incidence; Infant, Newborn; Infant, Premature | 1993 |
Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach.
Topics: Aminophylline; Apnea; Caffeine; Electric Impedance; Female; Humans; Infant, Newborn; Infant, Prematu | 1993 |
Are all preterm infants younger than 60 weeks postconceptual age at risk for postanesthetic apnea?
Topics: Age Factors; Anesthesia Recovery Period; Anesthesia, General; Apnea; Bradycardia; Humans; Infant, Ne | 1993 |
Aminophylline versus caffeine citrate...
Topics: Aminophylline; Apnea; Bradycardia; Caffeine; Cardiotonic Agents; Citrates; Clinical Trials as Topic; | 1995 |
Early neonatal complications after elective preterm delivery in hypertensive pregnancies.
Topics: Acidosis; Adult; Apnea; Bradycardia; Case-Control Studies; Cerebral Hemorrhage; Female; Fetal Growth | 1995 |
Impact of theophylline use in Wolff-Parkinson-White syndrome.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Cardiotonic Agents; Electrocardiography; Humans; Infant | 1996 |
Temporal relationship between pauses in nasal airflow and desaturation in preterm infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Oximetry; Oxygen; Ox | 1996 |
Low baseline oxygenation predisposes preterm infants to mixed apneas during inhalation of 100% oxygen.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Oxygen; Oxygen Inhalation Therapy; Slee | 1996 |
Heart rate variability in premature neonates pre-and postmethylxanthine administration.
Topics: Apnea; Autonomic Nervous System; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; X | 1996 |
Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline in preterm infants.
Topics: Administration, Oral; Aminophylline; Apnea; Birth Weight; Bronchodilator Agents; Gestational Age; Hu | 1997 |
Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks.
Topics: Apnea; Bradycardia; Gestational Age; Hospitalization; Humans; Incidence; Infant, Newborn; Infant, Pr | 1997 |
Margin of safety for discharge after apnea in preterm infants.
Topics: Apnea; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Infant, Premature, Dise | 1997 |
Incidence of apnoea and bradycardia in preterm infants following DTPw and Hib immunization: a prospective study.
Topics: Apnea; Birth Weight; Bradycardia; Diphtheria-Tetanus-Pertussis Vaccine; Female; Haemophilus Vaccines | 1997 |
A possible role for the Hering-Breuer deflation reflex in apnea of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Reflex; Respiratory | 1998 |
Second-degree atrioventricular heart block after doxapram administration.
Topics: Apnea; Doxapram; Female; Heart Block; Humans; Hyaline Membrane Disease; Infant, Newborn; Infant, Pre | 1998 |
[Treatment of apnea in prematurity].
Topics: Apnea; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infa | 1998 |
Gastroesophageal reflux and pulmonary complication in a neonate.
Topics: Antiemetics; Apnea; Cisapride; Follow-Up Studies; Gastroesophageal Reflux; Gastrointestinal Agents; | 1998 |
Apnea of prematurity and risk for sudden infant death syndrome.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physiologic; Risk Factors; | 1999 |
Methylxanthine therapy in premature infants: sound practice, disaster, or fruitless byway?
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Xanthines | 1999 |
Neonatal apnea casebook. Gastroesophageal reflux (GER)-associated apnea.
Topics: Apnea; Female; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature; Infant, Prematur | 1999 |
Methylxanthines and sensorineural outcome at 14 years in children < 1501 g birthweight.
Topics: Adolescent; Apnea; Bronchodilator Agents; Cerebral Palsy; Child Development; Developmental Disabilit | 2000 |
Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature; Infant, Pr | 2000 |
Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea.
Topics: Aminophylline; Apnea; Caffeine; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Inf | 1999 |
Apnoea following immunisation in premature infants.
Topics: Apnea; Diphtheria-Tetanus-Pertussis Vaccine; Humans; Immunization; Infant, Newborn; Infant, Prematur | 2000 |
Low-dose doxapram therapy for idiopathic apnea of prematurity.
Topics: Apnea; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature; Infant, Prem | 2001 |
Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea.
Topics: Apnea; Body Weight; Caffeine; Energy Metabolism; Humans; Infant, Newborn; Infant, Premature, Disease | 2001 |
Inhalation of low (0.5%-1.5%) CO2 as a potential treatment for apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Birth Weight; Carbon Dioxide; Gestational Age; Humans; Infant, Ne | 2001 |
Inhalation of low (0.5%-1.5%) CO2 as a potential treatment for apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Birth Weight; Carbon Dioxide; Gestational Age; Humans; Infant, Ne | 2001 |
Inhalation of low (0.5%-1.5%) CO2 as a potential treatment for apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Birth Weight; Carbon Dioxide; Gestational Age; Humans; Infant, Ne | 2001 |
Inhalation of low (0.5%-1.5%) CO2 as a potential treatment for apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Birth Weight; Carbon Dioxide; Gestational Age; Humans; Infant, Ne | 2001 |
[Evaluation of cerebral oxygenation in newborns with prematurity apnea: new frequency domain NIR oximeter].
Topics: Apnea; Brain; Humans; Infant, Newborn; Infant, Premature, Diseases; Oxygen; Spectroscopy, Near-Infra | 2000 |
Theophylline toxicokinetics in premature newborns.
Topics: Apnea; Bronchodilator Agents; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Infant, N | 2001 |
Respiratory instability of term and near-term healthy newborn infants in car safety seats.
Topics: Apnea; Bradycardia; Equipment Design; Female; Gestational Age; Humans; Incidence; Infant Equipment; | 2001 |
Inter-neonatal intensive care unit variation in discharge timing: influence of apnea and feeding management.
Topics: Age Factors; Apnea; Birth Weight; Body Temperature Regulation; Bradycardia; Child Development; Feedi | 2001 |
Cardiorespiratory events in preterm infants referred for apnea monitoring studies.
Topics: Apnea; Bradycardia; Heart Rate; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2001 |
Apnea, bradycardia and thrombocytopenia in a premature infant.
Topics: Animals; Apnea; Babesia; Babesiosis; Bradycardia; Erythrocytes; Humans; Infant, Newborn; Infant, Pre | 2001 |
Apnea at discharge and gastro-esophageal reflux in the preterm infant.
Topics: Apnea; Bronchodilator Agents; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature; I | 2002 |
Respiratory instability of term and near-term healthy newborn infants in car safety seats.
Topics: Apnea; Bradycardia; Humans; Incidence; Infant Equipment; Infant, Newborn; Infant, Premature, Disease | 2002 |
High-flow nasal cannula versus nasal continuous positive airway pressure in the management of apnea of prematurity.
Topics: Apnea; Catheterization; Humans; Infant, Newborn; Infant, Premature, Diseases; Positive-Pressure Resp | 2002 |
Physiologic changes induced by theophylline in the treatment of apnea in preterm infants.
Topics: Apnea; Blood; Carbon Dioxide; Female; Functional Residual Capacity; Humans; Hydrogen-Ion Concentrati | 1978 |
Continuous positive airway pressure in recurrent apnoea.
Topics: Apnea; Humans; Hyaline Membrane Disease; Infant, Newborn; Infant, Premature, Diseases; Positive-Pres | 1976 |
Management of apnoea of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Methods; Respiratory Care Units | 1977 |
Biotransformation of theophylline to caffeine in premature newborn.
Topics: Administration, Oral; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature | 1978 |
Sleep apnoea syndromes.
Topics: Apnea; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Premature, Diseases; Oxygen; Respiration; S | 1979 |
Methylation of theophylline to caffeine in premature infants.
Topics: Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Methylatio | 1979 |
Cardiac slowing and respiratory arrest in preterm infants.
Topics: Apnea; Bradycardia; Humans; Infant, Newborn; Infant, Premature, Diseases; Sleep; Sleep, REM | 1976 |
The sleep state characteristics of apnea during infancy.
Topics: Aging; Apnea; Diseases in Twins; Female; Gestational Age; Humans; Infant; Infant, Newborn; Infant, P | 1977 |
Sleep state, apnea and bradycardia in pre-term infants.
Topics: Apnea; Birth Weight; Bradycardia; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Infan | 1977 |
Rapid eye movement sleep, apnea, and cardiac slowing influenced by phenobarbital administration in the neonate.
Topics: Apnea; Female; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Phenobarbital | 1977 |
Congenital infection in the premature infant: trials and tribulations.
Topics: Anemia, Hemolytic; Apnea; Cytomegalovirus Infections; Diagnosis, Differential; Female; Humans; Hypox | 1977 |
Prevention of apnea and bradycardia in low-birthweight infants.
Topics: Apnea; Birth Weight; Bradycardia; Carbon Dioxide; Female; Humans; Hydrogen-Ion Concentration; Infant | 1975 |
Apnea in the premature infant: an overview of causes and treatment.
Topics: Anemia, Neonatal; Apnea; Body Temperature; Central Nervous System; Diagnosis, Differential; Humans; | 1978 |
Hypoxia in the newborn infant.
Topics: Apnea; Asphyxia Neonatorum; Blood Circulation; Humans; Hyaline Membrane Disease; Hypoxia; Infant, Ne | 1977 |
[Artificial ventilation of preterm and term infants (author's transl)].
Topics: Apnea; Humans; Hyaline Membrane Disease; Infant, Newborn; Infant, Newborn, Diseases; Infant, Prematu | 1978 |
[Group B streptococcus infections during the neonatal period (author's transl)].
Topics: Age Factors; Aminoglycosides; Ampicillin; Apnea; Humans; Infant, Newborn; Infant, Newborn, Diseases; | 1978 |
Sequelae of caffeine treatment in preterm infants with apnea.
Topics: Apnea; Caffeine; Child Development; Female; Follow-Up Studies; Humans; Infant, Low Birth Weight; Inf | 1979 |
Pharmacokinetic profile of caffeine in the premature newborn infant with apnea.
Topics: Administration, Oral; Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseas | 1979 |
Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies.
Topics: Aminophylline; Apnea; Drug Administration Schedule; Humans; Infant; Infant, Newborn; Infant, Prematu | 1979 |
Plasma xanthine levels in low birthweight infants treated or not treated with theophylline.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Metabolic Clearance Rate; Mil | 1979 |
Half life of theophylline in the preterm baby with apnoeic attacks.
Topics: Apnea; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1979 |
The effects of theophylline on renal function in the premature newborn.
Topics: Albumins; Aminophylline; Apnea; Creatinine; Glomerular Filtration Rate; Humans; Hyponatremia; Infant | 1979 |
Effect of aminophylline on respiratory center activity and metabolic rate in premature infants with idiopathic apnea.
Topics: Aminophylline; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Oxygen Consumption; Resp | 1979 |
[Recent knowledge on the regulation of breathing in newborn and premature infants].
Topics: Apnea; Chemoreceptor Cells; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; I | 1979 |
Effects of theophylline on serum and urine electrolytes in preterm infants with apnea.
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Theophylline; Water-Elect | 1979 |
Interconversion of theophylline and caffeine in newborn infants.
Topics: Age Factors; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Disease | 1979 |
Metabolism of theophylline to caffeine in premature newborn infants.
Topics: Adult; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; The | 1979 |
Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant.
Topics: Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophyl | 1979 |
[Treatment of apnea crisis in premature infants with a loading dose of theophylline].
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Injections, Intravenous; Male; | 1979 |
Apneic spells associated with timolol therapy in a neonate.
Topics: Acetazolamide; Apnea; Asphyxia Neonatorum; Cheyne-Stokes Respiration; Cryosurgery; Glaucoma; Humans; | 1979 |
Weaning very low birthweight infants from mechanical ventilation using intermittent mandatory ventilation and theophylline.
Topics: Aminophylline; Apnea; Bradycardia; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premat | 1979 |
Relationship of plasma and CSF concentrations of caffeine in neonates with apnea.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases | 1979 |
[Lesions of the nervous system in premature children with "conjugated" jaundices].
Topics: Apnea; Eye Manifestations; Face; Humans; Infant, Newborn; Infant, Premature, Diseases; Jaundice, Neo | 1979 |
Cutaneous stimulation and generation of breathing in the fetus.
Topics: Animals; Apnea; Electric Stimulation; Female; Fetus; Humans; Infant, Newborn; Infant, Premature, Dis | 1977 |
Development of a radioimmunoassay for theophylline. Application to studies in premature infants.
Topics: Aminophylline; Animals; Antibody Specificity; Apnea; Binding, Competitive; Cross Reactions; Goats; H | 1977 |
[Present status of retrolental fibroplasia in France].
Topics: Apnea; Body Weight; France; Humans; Infant, Newborn; Infant, Premature, Diseases; Oxygen; Retinopath | 1979 |
Waterbeds help reduce breathing cessations in premature infants.
Topics: Apnea; Beds; Humans; Infant, Newborn; Infant, Premature, Diseases; Water | 1977 |
Theophylline and apnoeas of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1977 |
Reduction of sleep apnea and bradycardia in preterm infants on oscillating water beds: a controlled polygraphic study.
Topics: Apnea; Beds; Bradycardia; Humans; Infant, Newborn; Infant, Premature, Diseases; Sleep; Sleep Stages; | 1978 |
Sleep and aminophylline treatment of apnea in preterm infants.
Topics: Aminophylline; Apnea; Bradycardia; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Prema | 1978 |
Kinetics and efficacy of theophylline in the treatment of apnea in the premature newborn.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline | 1978 |
Micro-method for the determination of caffeine and theophylline allowing direct application of biological fluids to thin-layer chromatography plates.
Topics: Apnea; Caffeine; Child; Child, Preschool; Chromatography, Thin Layer; Female; Humans; Infant; Infant | 1978 |
[Theophylline for prevention of apnea in premature infants (author's transl)].
Topics: Apnea; Birth Weight; Humans; Infant, Newborn; Infant, Premature, Diseases; Tachycardia; Theophylline | 1978 |
Alterations in state in apneic pre-term infants receiving theophylline.
Topics: Aminophylline; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Sleep; Sleep Stages; The | 1978 |
[Prevention of neonatal apnea with theophylline (author's transl)].
Topics: Apnea; Bradycardia; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Tachycardia; | 1978 |
Aminophylline therapy for idiopathic apnea in premature infants: effects on lung function.
Topics: Aminophylline; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Lung; Lung Compliance; O | 1978 |
Spontaneous neck flexion and airway obstruction during apneic spells in preterm infants.
Topics: Airway Obstruction; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Muscles; Neck | 1979 |
Relationship between plasma and whole blood theophylline concentration in neonates.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Plasma; Theophylline | 1979 |
Prolonged apnea of prematurity: Treatment with continuous airway distending pressure delivered by nasopharyngeal tube.
Topics: Apnea; Bradycardia; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intubat | 1976 |
[Management of neonatal hypoxia. Indication for oxygen therapy].
Topics: Apnea; Asphyxia Neonatorum; Biological Transport; Blood Circulation; Blood Gas Analysis; Heart Septa | 1975 |
[CPAP as therapy in apnea fits of premature infants].
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Positive-Pressure Respiration | 1976 |
Apnea associated with respiratory syncytial virus infection in young infants.
Topics: Apnea; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Respiratory Syncytial | 1977 |
The preterm baby.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases | 1977 |
Theophylline-induced diuresis in the neonate.
Topics: Apnea; Dehydration; Diuresis; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Polyuria; | 1977 |
[Factors causing apneas in otherwise healthy newborns: a neurophysiological Concept (author's transl)].
Topics: Apnea; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Respiration; | 1977 |
Effect of exchange transfusion on elimination of theophylline in premature neonates.
Topics: Aminophylline; Apnea; Birth Weight; Dose-Response Relationship, Drug; Exchange Transfusion, Whole Bl | 1977 |
[Apneas, changes in heart rate and transcutaneous PO2 changes in premature and newborn infants with respiration disorders].
Topics: Apnea; Bradycardia; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, | 1977 |
Cardiovascular effects of apnoea in preterm infants.
Topics: Apnea; Blood Pressure; Cardiovascular System; Chemoreceptor Cells; Female; Heart Rate; Humans; Infan | 1977 |
Microprocessor-controlled memory for cardiopulmonary monitoring of high-risk infants.
Topics: Apnea; Bradycardia; Electrocardiography; Electronics, Medical; Humans; Infant, Newborn; Infant, Prem | 1977 |
[Bradycardias and apneas in premature infants].
Topics: Apnea; Bradycardia; Electrocardiography; Electroencephalography; Eye Movements; Humans; Infant, Newb | 1976 |
Pharmacokinetic aspects of theophylline in premature newborns.
Topics: Adult; Apnea; Blood Proteins; Child; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, | 1976 |
Letter: Coffee, tea, and apnea.
Topics: Apnea; Coffee; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Maternal-Fetal Exchange | 1976 |
[Apnea in infants with low birth weights].
Topics: Apnea; Asphyxia Neonatorum; Birth Weight; Denmark; Humans; Infant, Newborn; Infant, Premature, Disea | 1976 |
[Apnea cases in children born with low birth weights].
Topics: Apnea; Asphyxia Neonatorum; Birth Weight; Humans; Infant, Newborn; Infant, Premature, Diseases; Resp | 1976 |
Treatment of apnea of prematurity with aminophylline.
Topics: Aminophylline; Apnea; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Rectum; Su | 1976 |
Letter: Questions on theophylline.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1976 |
[Prognostic score of newborn infants with low birth weight].
Topics: Apnea; Birth Weight; Body Temperature; Computers; Female; Humans; Infant, Newborn; Infant, Premature | 1976 |
Metabolic effect of theophylline in the premature neonate.
Topics: Apnea; Blood Glucose; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1976 |
Apnea in premature infants: recording by arterial catheter.
Topics: Aorta, Abdominal; Apnea; Catheterization; Humans; Infant, Newborn; Infant, Premature; Infant, Premat | 1976 |
Premature commercialism.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physiologic | 1976 |
[Longtime artificial respiration of newborn infants using the Bird respirator].
Topics: Apnea; Asphyxia Neonatorum; Birth Weight; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases | 1976 |
Early neonatal hypocalcaemia.
Topics: Apnea; Asphyxia Neonatorum; Birth Weight; Calcium; Ductus Arteriosus, Patent; Erythroblastosis, Feta | 1975 |
The xanthine treatment of apnea of prematurity.
Topics: Aminophylline; Apnea; Bradycardia; Caffeine; Humans; Hypoxia; Infant, Newborn; Infant, Premature, Di | 1975 |
Treatment of severe apnea in prematures with orally administered theophylline.
Topics: Administration, Oral; Apnea; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; Recur | 1975 |
Chemoreceptor reflexes in preterm infants: I. The effect of gestational and postnatal age on the ventilatory response to inhalation of 100% and 15% oxygen.
Topics: Age Factors; Apgar Score; Apnea; Female; Heart Rate; Humans; Hypoxia; Infant, Newborn; Infant, Prema | 1975 |
Chemoreceptor reflexes in preterm infants: II. The effect of gestational and postnatal age on the ventilatory response to inhaled carbon dioxide.
Topics: Age Factors; Apgar Score; Apnea; Carbon Dioxide; Chemoreceptor Cells; Female; Gestational Age; Heart | 1975 |
Letter: The use of xanthines in treating apnea of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Xanthines | 1975 |
[Infants of low birth weight after deliveries, morbidity and mortality (author's transl)].
Topics: Apgar Score; Apnea; Asphyxia Neonatorum; Birth Weight; Body Height; Breech Presentation; Cerebral He | 1975 |
Bradycardia preceding apneic attacks in low-birthweight infants. The relationship and management.
Topics: Animals; Apnea; Atropine; Bradycardia; Ephedrine; Female; Heart Rate; Humans; Infant; Infant, Newbor | 1976 |
Letter: The use of xanthines in treating apnea of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Xanthines | 1976 |
Urinary biogenic amines in idiopathic apnea of prematurity.
Topics: Apnea; Biogenic Amines; Humans; Infant, Newborn; Infant, Premature, Diseases | 1976 |
Neonatal complications and risk of intraventricular-periventricular hemorrhage.
Topics: Acid-Base Equilibrium; Apnea; Birth Weight; Cerebral Hemorrhage; Female; Gestational Age; Humans; In | 1992 |
Postoperative apnea syndrome in premature infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Postoperative Compli | 1992 |
Response to external obstruction in preterm infants with apnea.
Topics: Airway Obstruction; Apnea; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Prema | 1992 |
Episodic bradycardia in preterm infants.
Topics: Apnea; Bradycardia; Chi-Square Distribution; Electrocardiography; Female; Humans; Infant, Newborn; I | 1992 |
Reducing the hypoxemia, bradycardia, and apnea associated with suctioning in low birthweight infants.
Topics: Analysis of Variance; Apnea; Blood Pressure; Bradycardia; Female; Humans; Hypoxia; Infant, Low Birth | 1992 |
Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants.
Topics: Apnea; Blood Gas Monitoring, Transcutaneous; Blood Pressure; Caffeine; Humans; Infant, Newborn; Infa | 1992 |
Outpatient inguinal herniorrhaphy in premature infants: is it safe?
Topics: Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesthesia, General; Apnea; Bradycardia; | 1992 |
Response to tube breathing in preterm infants with apnea.
Topics: Apnea; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Masks; R | 1992 |
On sudden severe bradycardia secondary to hypoxemia.
Topics: Apnea; Bradycardia; Bronchopulmonary Dysplasia; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Pr | 1992 |
Compact apparatus for measurement of ventilatory response to carbon dioxide in newborns and infants.
Topics: Apnea; Carbon Dioxide; Equipment Design; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, | 1992 |
Doxapram for the initial treatment of idiopathic apnea of prematurity.
Topics: Apnea; Doxapram; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Respiration; To | 1992 |
Severe caffeine intoxication in a preterm neonate.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Male | 1992 |
Transfusion-induced changes in the breathing pattern of healthy preterm anemic infants.
Topics: Anemia; Apnea; Blood Transfusion; Hematocrit; Hemodynamics; Humans; Infant; Infant, Newborn; Infant, | 1992 |
Rectal aminophylline gel in treatment of apnoea in premature newborn babies.
Topics: Administration, Rectal; Aminophylline; Apnea; Gels; Humans; Infant, Newborn; Infant, Premature, Dise | 1991 |
Relationship between determinants of oxygen delivery and respiratory abnormalities in preterm infants with anemia.
Topics: Anemia; Apnea; Blood Transfusion; Cardiac Output; Hemoglobins; Humans; Infant, Newborn; Infant, Prem | 1992 |
Undetected apnea and bradycardia in infants.
Topics: Apnea; Bradycardia; Female; Humans; Incidence; Infant, Newborn; Infant, Premature, Diseases; Intensi | 1991 |
Site of upper airway obstruction in preterm infants with problematical apnoea.
Topics: Airway Obstruction; Apnea; Electrocardiography; Fiber Optic Technology; Heart; Humans; Infant, Newbo | 1991 |
The ventilatory response to endogenous CO2 in preterm infants.
Topics: Apnea; Carbon Dioxide; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Resp | 1991 |
Apnoea, bradycardia, and oxygen saturation in preterm infants.
Topics: Apnea; Bradycardia; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Longitudinal Studi | 1991 |
Spinal anaesthesia for inguinal hernia repair in high-risk neonates.
Topics: Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthesia, Spinal; Apnea; Female; Halothane; Herni | 1991 |
Respiratory outcome in extremely premature infants following ketamine anaesthesia.
Topics: Age Factors; Aminophylline; Anesthesia, Intravenous; Apnea; Birth Weight; Gestational Age; Humans; I | 1991 |
[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea].
Topics: Administration, Oral; Apnea; Drug Administration Schedule; Half-Life; Humans; Infant, Newborn; Infan | 1991 |
Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant, Ne | 1991 |
[Caffeine in the treatment of apnea in premature infants].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases | 1990 |
Apnea, transient episodes of bradycardia, and periodic breathing in preterm infants.
Topics: Apgar Score; Apnea; Birth Weight; Bradycardia; Cheyne-Stokes Respiration; Gestational Age; Heart Rat | 1990 |
Prospective pneumogram recordings in preterm infants with and without clinical apnea and bradycardia.
Topics: Apnea; Birth Weight; Bradycardia; Gestational Age; Humans; Infant, Low Birth Weight; Infant, Newborn | 1990 |
[Efficacy of percutaneous caffeine in the treatment of apnea in the premature infant].
Topics: Administration, Cutaneous; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Ma | 1990 |
Does the haemoglobin concentration predict post-op apnea in ex-preterm infants?
Topics: Apnea; Blood Transfusion; Bradycardia; Erythrocyte Transfusion; Hemoglobinometry; Humans; Infant, Ne | 1990 |
Postoperative apnoea in former preterm infants: does anaemia increase the risk?
Topics: Anemia; Apnea; Bradycardia; Hematocrit; Hernia, Inguinal; Humans; Infant, Newborn; Infant, Premature | 1990 |
Reflex induced apneas.
Topics: Apnea; Arousal; Deglutition; Humans; Infant, Newborn; Infant, Premature, Diseases; Laryngeal Muscles | 1990 |
The relationship of respiratory complications from gastroesophageal reflux to prematurity in infants.
Topics: Airway Obstruction; Apnea; Bronchopulmonary Dysplasia; Esophagus; Female; Gastroesophageal Reflux; H | 1990 |
Cardiovascular effects of caffeine therapy in preterm infants.
Topics: Apnea; Blood Pressure; Caffeine; Cardiac Output; Heart; Heart Rate; Humans; Infant, Newborn; Infant, | 1990 |
Does caffeine affect cerebral blood flow in the preterm infant?
Topics: Apnea; Blood Gas Monitoring, Transcutaneous; Caffeine; Cerebrovascular Circulation; Humans; Infant; | 1989 |
Caffeine citrate in the NICU.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases; | 1989 |
Characterization of prolonged apneic episodes associated with respiratory syncytial virus infection.
Topics: Apnea; Female; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Male; Respiration; Resp | 1989 |
Effect of blood transfusion on apnea frequency in growing premature infants.
Topics: Apnea; Blood Transfusion; Cheyne-Stokes Respiration; Humans; Infant; Infant, Newborn; Infant, Premat | 1989 |
Caffeine citrate. Pointers in practical pharmacology.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases | 1989 |
[Monitoring theophylline in premature newborn infants].
Topics: Apnea; Asphyxia Neonatorum; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physio | 1989 |
Wilson Mikity syndrome.
Topics: Apnea; Cyanosis; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Radiography; Respirator | 1989 |
Gastro-oesophageal reflux in preterm infants.
Topics: Apnea; Critical Care; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Infant Nutritiona | 1989 |
Postoperative apnea after caudal anesthesia in an ex-premature infant.
Topics: Anesthesia, Caudal; Anesthesia, Epidural; Apnea; Hernia, Inguinal; Humans; Infant; Infant, Newborn; | 1989 |
Apnea and bradycardia in a preterm neonate.
Topics: Antacids; Apnea; Bethanechol; Bethanechol Compounds; Bradycardia; Gastroesophageal Reflux; Humans; H | 1985 |
Risk factors for retrolental fibroplasia: experience with 3,025 premature infants. National Collaborative Study on Patent Ductus Arteriosus in Premature Infants.
Topics: Anemia; Apnea; Birth Weight; Bronchopulmonary Dysplasia; Female; Histamine H1 Antagonists; Humans; I | 1985 |
Prolonged expiratory apnoea and hypoxaemia.
Topics: Apnea; Humans; Hypoxia; Infant, Newborn; Infant, Premature, Diseases; Respiration; Respiratory Distr | 1985 |
Low-dose doxapram for apnoea of prematurity.
Topics: Apnea; Caffeine; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature, Di | 1986 |
Acetazolamide interferes with theophylline assay.
Topics: Acetazolamide; Aminophylline; Apnea; Drug Interactions; Humans; Infant, Newborn; Infant, Premature, | 1987 |
Home monitoring for infantile apnoea.
Topics: Apnea; Home Nursing; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physiologic; | 1987 |
Cardiorespiratory depression and plasma beta-endorphin levels in low-birth-weight infants during the first day of life.
Topics: Apnea; Asphyxia Neonatorum; beta-Endorphin; Endorphins; Humans; Hypotension; Infant, Low Birth Weigh | 1987 |
Oral versus intramuscular loading of caffeine in idiopathic apnoea of prematurity.
Topics: Administration, Oral; Apnea; Blood Glucose; Caffeine; Humans; Infant, Newborn; Infant, Premature, Di | 1988 |
Physiologic effects of doxapram in idiopathic apnea of prematurity.
Topics: Aminophylline; Apnea; Birth Weight; Blood Pressure; Carbon Dioxide; Doxapram; Gestational Age; Human | 1986 |
Ventilatory responses to carbon dioxide in infants at risk for sudden infant death syndrome.
Topics: Apnea; Carbon Dioxide; Cardiography, Impedance; Humans; Infant; Infant, Newborn; Infant, Premature, | 1986 |
Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity.
Topics: Apnea; Blood Pressure; Carbon Dioxide; Dose-Response Relationship, Drug; Doxapram; Half-Life; Heart | 1987 |
Upper GI examinations in older premature infants with persistent apnea: correlation with simultaneous cardiorespiratory monitoring.
Topics: Apnea; Bradycardia; Deglutition Disorders; Gastroesophageal Reflux; Heart; Humans; Infant, Newborn; | 1988 |
Developmental changes of caffeine elimination in infancy.
Topics: Aging; Apnea; Caffeine; Drug Administration Schedule; Gestational Age; Half-Life; Humans; Infant; In | 1988 |
Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data.
Topics: Apnea; Doxapram; Drug Administration Schedule; Humans; Infant, Newborn; Infant, Premature, Diseases | 1988 |
Respiratory control during nipple feeding in preterm infants.
Topics: Apnea; Bottle Feeding; Bradycardia; Humans; Hypoxia; Infant, Newborn; Infant, Premature, Diseases; M | 1988 |
Apnea in preterms.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases | 1988 |
The dose response of theophylline in the treatment of apnea of prematurity.
Topics: Apnea; Drug Administration Schedule; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Disease | 1988 |
Cerebral blood flow velocity variability in infants receiving assisted ventilation.
Topics: Age Factors; Apnea; Blood Flow Velocity; Cerebrovascular Circulation; Humans; Infant, Low Birth Weig | 1987 |
Prolonged apnea associated with upper airway protective reflexes in apnea of prematurity.
Topics: Apnea; Chemoreceptor Cells; Deglutition; Humans; Infant, Newborn; Infant, Premature, Diseases; Laryn | 1988 |
Phenobarbital increases aminophylline requirement in premature infants.
Topics: Aminophylline; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Phenobarbital; Seizures | 1988 |
Mothers of preterm and full-term infants on home apnea monitors.
Topics: Adult; Apnea; Female; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Phys | 1988 |
Magnesium therapy in premature neonates with apnea neonatorum.
Topics: Apnea; Birth Weight; Bradycardia; Drug Administration Schedule; Follow-Up Studies; Gestational Age; | 1988 |
Pharmacokinetics of doxapram in idiopathic apnea of prematurity.
Topics: Apnea; Doxapram; Female; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases | 1988 |
Respiratory pattern at hospital discharge in asymptomatic preterm infants.
Topics: Apnea; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Infant, Premature, Dise | 1988 |
Simultaneous administration of caffeine and phenobarbitone in infants with apnea.
Topics: Apnea; Caffeine; Drug Therapy, Combination; Half-Life; Humans; Infant; Infant, Newborn; Infant, Prem | 1987 |
Potential treatment of theophylline toxicity by high surface area activated charcoal.
Topics: Adsorption; Aminophylline; Apnea; Charcoal; Evaluation Studies as Topic; Humans; Infant; Infant, Low | 1987 |
Doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases | 1987 |
[Xanthines in apnea of premature infants. Influence on gastroesophageal reflux].
Topics: Apnea; Caffeine; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature, Diseases; Xant | 1987 |
Postanesthetic apnea and periodic breathing in infants.
Topics: Anesthesia, General; Apnea; Hernia, Inguinal; Humans; Infant; Infant, Newborn; Infant, Premature, Di | 1986 |
A developmental study on types and frequency distribution of short apneas (3 to 15 seconds) in term and preterm infants.
Topics: Apnea; Electroencephalography; Humans; Infant, Newborn; Infant, Premature, Diseases; Sleep Stages | 1987 |
Theophylline: a closer look.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1987 |
Infantile apnea and home monitoring devices.
Topics: Apnea; Home Nursing; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physiologic; | 1987 |
Infant apnea.
Topics: Airway Obstruction; Apnea; Bradycardia; Caffeine; Cardiography, Impedance; Home Nursing; Humans; Inf | 1986 |
Doxapram in the treatment of idiopathic apnea of prematurity: desirable dosage and serum concentrations.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, Parenteral | 1986 |
Doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases | 1986 |
Infantile apnea.
Topics: Apnea; Breast Feeding; Diagnosis, Differential; Gastroesophageal Reflux; Humans; Infant; Infant, New | 1986 |
[Apnea disclosing Chlamydia trachomatis infection in a premature infant].
Topics: Apnea; Bradycardia; Chlamydia Infections; Chlamydia trachomatis; Erythromycin; Female; Humans; Infan | 1986 |
Effect of caffeine on pneumogram and apnoea of infancy.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases; | 1986 |
[Peculiarities of drug therapy in childhood].
Topics: Apnea; Biological Availability; Biotransformation; Caffeine; Child; Child, Preschool; Dexamethasone; | 1986 |
Delay in caffeine elimination in breast-fed infants.
Topics: Apnea; Biological Availability; Bottle Feeding; Breast Feeding; Caffeine; Fatty Acids, Nonesterified | 1987 |
Relation between apnoea duration and type and neurological status of preterm infants.
Topics: Airway Obstruction; Apnea; Cerebral Hemorrhage; Female; Humans; Hydrocephalus; Infant, Newborn; Infa | 1985 |
Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants.
Topics: Apnea; Carbon Dioxide; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; Oxygen; Pos | 1985 |
Partitioning of heat losses and gains in premature newborn infants under radiant warmers.
Topics: Apnea; Body Temperature Regulation; Carbon Dioxide; Heating; Humans; Infant, Newborn; Infant, Premat | 1985 |
Respiratory airflow measurement in the neonate.
Topics: Apnea; Body Temperature; Carbon Dioxide; Heart Rate; Humans; Infant, Newborn; Infant, Newborn, Disea | 1985 |
Ventilatory control and carbon dioxide response in preterm infants with idiopathic apnea.
Topics: Apnea; Carbon Dioxide; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases | 1985 |
Effects of positive end expiratory pressure during ventilation of the preterm infant.
Topics: Apnea; Carbon Dioxide; Humans; Infant, Newborn; Infant, Premature, Diseases; Oxygen; Positive-Pressu | 1985 |
Rectal aminophylline in the management of apnoea of prematurity.
Topics: Aminophylline; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Recurrence; Suppositorie | 1985 |
Observations made on severe apneic spells in two infants at risk for sudden death.
Topics: Airway Resistance; Apnea; Bradycardia; Electrocardiography; Female; Humans; Infant, Newborn; Infant, | 1985 |
[Echovirus 11 outbreak among premature newborn infants in a neonatal intensive care unit].
Topics: Adult; Antibodies, Viral; Apnea; Cerebrospinal Fluid; Child, Preschool; Diarrhea; Disease Outbreaks; | 1985 |
Early childhood developmental follow-up of infants with GMH/IVH: effect of methylxanthine therapy.
Topics: Apnea; Cerebral Hemorrhage; Child Development; Female; Follow-Up Studies; Humans; Infant; Infant, Lo | 1985 |
[Recurrent apnea in the newborn infant. Study on 52 cases].
Topics: Aminophylline; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Recurrence; Sleep Apnea | 1985 |
Neonatal apnea associated with maternal clonazepam therapy: a case report.
Topics: Adult; Apnea; Benzodiazepinones; Clonazepam; Female; Humans; Infant, Newborn; Infant, Premature, Dis | 1985 |
Naloxone reversal of postoperative apnea in a premature infant.
Topics: Anesthesia, Inhalation; Apnea; Bradycardia; Endorphins; Humans; Infant, Newborn; Infant, Premature, | 1985 |
Episodes of apnea and bradycardia in the preterm newborn: impact on cerebral circulation.
Topics: Apnea; Blood Flow Velocity; Blood Pressure; Bradycardia; Brain; Cerebrovascular Circulation; Heart B | 1985 |
Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding.
Topics: Aging; Apnea; Breast Feeding; Caffeine; Cholestasis; Citrates; Drug Combinations; Gestational Age; H | 1985 |
Contactless apnoea detector based on radar.
Topics: Adult; Apnea; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Monit | 1971 |
Simple warning system for apnoea in premature infants.
Topics: Apnea; Electronics; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physiologic; T | 1967 |
An apnoea-alarm mattress.
Topics: Apnea; Beds; Electricity; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physiolo | 1969 |
Clinical assessment of apnoea-alarm mattress for newborn infants.
Topics: Animals; Apnea; Bedding and Linens; Female; Heart Rate; Humans; Infant Care; Infant, Newborn; Infant | 1970 |
[Electric current as stimulus in immature babies with recurrent apneic attacks? (author's transl)].
Topics: Anti-Bacterial Agents; Apnea; Birth Weight; Burns, Electric; Electric Stimulation; Electricity; Gest | 1974 |
[Experiences with the use of respiration monitors in an intensive care unit for premature and newborn infants].
Topics: Apnea; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Intensive Ca | 1973 |
Medical emergencies in the neonatal period.
Topics: Apnea; Emergencies; Humans; Hypoglycemia; Hypothermia; Infant, Newborn; Infant, Newborn, Diseases; I | 1974 |
Neonatal at risk factors.
Topics: Apgar Score; Apnea; Birth Weight; Child Development; Child, Preschool; Follow-Up Studies; Gestationa | 1972 |
Studies on pulmonary mechanics in infants.
Topics: Airway Resistance; Apnea; Asphyxia Neonatorum; Catheterization; Ductus Arteriosus, Patent; Heart Sep | 1974 |
Anaesthetic management of a very premature infant. Case report.
Topics: Acid-Base Equilibrium; Anesthesia, General; Apnea; Body Temperature; Ductus Arteriosus, Patent; Fema | 1972 |
Mechanical positive pressure ventilation of the newborn.
Topics: Apnea; Humans; Hypercapnia; Hypoxia; Infant, Newborn; Infant, Premature, Diseases; Positive-Pressure | 1972 |
Prevention of intraventricular haemorrhage in babies receiving artificial ventilation.
Topics: Apnea; Blood Coagulation Factors; Cerebral Hemorrhage; Cerebral Ventricles; Factor IX; Factor VII; F | 1973 |
[Apnea periods in the premature infant].
Topics: Apnea; Caffeine; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physi | 1974 |
Apnea and muscle weakness in two premature infants: descriptive case reports.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Muscle Tonus; Neostigmine; Positi | 1972 |
The association of hypocalcemia and recurrent apnea in premature infants.
Topics: Abruptio Placentae; Apgar Score; Apnea; Birth Weight; Blood Proteins; Calcium; Female; Gestational A | 1972 |
Polygraphic monitoring of apneic spells.
Topics: Apnea; Bradycardia; Brain; Electrocardiography; Electroencephalography; Electromyography; Electroocu | 1973 |
Apnoeic attacks in the newborn treated with aminophylline.
Topics: Aminophylline; Apnea; Carbon Dioxide; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseas | 1973 |
Transient cataracts in low-birth-weight infants.
Topics: Acidosis; Ampicillin; Apgar Score; Apnea; Bicarbonates; Birth Weight; Blood Pressure; Body Temperatu | 1973 |
Management of premature infants with patent ductus arteriosus.
Topics: Apnea; Digitalis; Diuretics; Ductus Arteriosus, Patent; Female; Heart Auscultation; Heart Defects, C | 1974 |
Intrauterine bronchiolitis obliterans. Report of an autopsy case and review of the literature.
Topics: Adult; Apnea; Autopsy; Bronchi; Bronchiolitis, Viral; Bronchitis; Cerebral Hemorrhage; Collagen; Con | 1974 |
[Problems of ventilation disorders in newborn and therapy possibilities].
Topics: Adolescent; Adult; Amniotic Fluid; Apnea; Buffers; Child; Child, Preschool; Humans; Infant; Infant, | 1974 |
Ventilator therapy in the newborn. Some mechanical considerations.
Topics: Apnea; Birth Weight; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Methods; | 1970 |
[Subacute prolonged pneumonia in the premature infant].
Topics: Acute Disease; Anti-Bacterial Agents; Apnea; Asthma; Cyanosis; Dyspnea; Female; Glucocorticoids; Hum | 1968 |
Periodic breathing and apnea in preterm infants. I. Evidence for hypoventilation possibly due to central respiratory depression.
Topics: Apnea; Birth Weight; Carbon Dioxide; Chemoreceptor Cells; Cheyne-Stokes Respiration; Female; Gestati | 1972 |
Periodic breathing and apnea in preterm infants. II. Hypoxia as a primary event.
Topics: Apnea; Birth Weight; Carbon Dioxide; Cheyne-Stokes Respiration; Female; Gestational Age; Heart Rate; | 1972 |
Contactless apnoea detector using low energy radar.
Topics: Adult; Apnea; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Radar | 1972 |
Ocular changes in premature babies receiving controlled oxygen therapy in the neonatal period.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Ophthalmoscopy; Oxygen; Oxygen Inhalati | 1971 |
The pre-term baby.
Topics: Anemia; Apnea; Birth Weight; Cerebral Hemorrhage; Enterocolitis, Pseudomembranous; Gestational Age; | 1971 |
[Indications for exchange transfusions in premature infants].
Topics: Acidosis, Respiratory; Apnea; Birth Weight; Exchange Transfusion, Whole Blood; Female; Humans; Hyper | 1969 |
[Apnea in mature and premature newborn infants].
Topics: Apnea; Asphyxia Neonatorum; Bradycardia; Cerebral Cortex; Electrocardiography; Electroencephalograph | 1969 |
Apnea in premature infants and incubator-air-temperature changes.
Topics: Air; Apnea; Birth Weight; Body Temperature; Body Temperature Regulation; Environmental Exposure; Fem | 1970 |
The premature baby who "forgets to breathe".
Topics: Apnea; Environmental Exposure; Humans; Infant Care; Infant, Newborn; Infant, Premature, Diseases; Te | 1970 |
[Cardiac arrhythmias in premature and full-term infants].
Topics: Apnea; Arrhythmias, Cardiac; Bradycardia; Electrocardiography; Female; Heart Block; Heart Conduction | 1970 |
Tracheotomy in premature infants.
Topics: Adult; Apnea; Esophageal Atresia; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Failur | 1971 |
Gastrostomy in the premature and newborn infant.
Topics: Apnea; Female; Gastrostomy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, D | 1968 |
Fatal laryngeal obstruction by iatrogenic subglottic cyst.
Topics: Apnea; Cysts; Humans; Iatrogenic Disease; Infant; Infant, Newborn; Infant, Premature, Diseases; Intu | 1968 |
Resuscitation of the newborn.
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Preg | 1968 |
Apnea in premature infants: monitoring, incidence, heart rate changes, and an effect of environmental temperature.
Topics: Apnea; Birth Weight; Bradycardia; Carbon Dioxide; Cyanosis; Heart Rate; Humans; Infant, Newborn; Inf | 1969 |
Respiratory arrest due to hypoglycemia: a complication of therapy in malnourished infants.
Topics: Apnea; Dehydration; Female; Glucose; Humans; Hypoglycemia; Infant; Infant Nutrition Disorders; Infan | 1965 |
Perinatal and environmental factors in late neurogenic sequelae. I. Infants having birth weights under 1,500 grams.
Topics: Apnea; Birth Weight; Child; Child, Preschool; Environment; Female; Follow-Up Studies; Humans; Infant | 1966 |